ESC Guidelines for the management of acute coronary swithout persistent ST-segment elevation: The Task Forceronary syndromes (ACS) in patients presenting without of the European Society of Cardiology (ESC)

European Heart Journal 32, 2999-3054

DOI: 10.1093/eurheartj/ehr236

Citation Report

#	Article	IF	CITATIONS
1	Nursing Challenges in the Care of Very Low Birth Weight Infants (<1,000 Grams). AACN Advanced Critical Care, 1994, 5, 231-241.	0.6	0
2	Sequential proteome alterations during genesis and progression of colon cancer. Cellular and Molecular Life Sciences, 2004, 61, 1246-1255.	2.4	71
3	The trefoil protein TFF1 is bound to MUC5AC in humangastric mucosa. Cellular and Molecular Life Sciences, 2004, 61, 1946-1954.	2.4	70
4	Ubiquitin-proteasome system. Cellular and Molecular Life Sciences, 2004, 61, 1562-78.	2.4	81
5	Ubiquitin-proteasome system. Cellular and Molecular Life Sciences, 2004, 61, 1589-95.	2.4	37
6	Developmental actions of natriuretic peptides in the brain and skeleton. Cellular and Molecular Life Sciences, 2004, 61, 2332-42.	2.4	17
7	Anti-glioma action of aloe emodin: the role of ERK inhibition. Cellular and Molecular Life Sciences, 2005, 62, 589-598.	2.4	85
8	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1	1 d:9 843	14 ² 2331 14 rgBT/Over
9	Le rapport bénéfice-risque des nouveaux agents antiagrégants plaquettaires. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 27-31.	0.0	4
10	High-sensitive Troponin, B-type natriuretic peptide and coronary angiogram findings in patients with non ST-segment elevation acute coronary syndrome. International Journal of Cardiology, 2011, 153, 335-337.	0.8	3
11	Female platelets are hard to control. Netherlands Heart Journal, 2011, 19, 449-450.	0.3	1
12	Medical groups, researchers fine-tune clopidogrel therapy. American Journal of Health-System Pharmacy, 2011, 68, 2318-2320.	0.5	O
13	Peri-operative myocardial infarction and high sensitive cardiac troponin: A start but by no means a finish. Heart, 2012, 98, 1402-1403.	1.2	1
14	The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovascular Disease, 2012, 1, 1-13.	0.4	27
15	Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years. European Heart Journal, 2012, 33, 2544-2550.	1.0	31
16	High-sensitivity cardiac troponin assays for risk stratification and for the diagnosis of acute myocardial infarction. Annals of Clinical Biochemistry, 2012, 49, 209-210.	0.8	7
17	Current antiplatelet options for NSTE-ACS patients. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 935-948.	0.2	5
19	Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. Heart, 2012, 98, 706-711.	1.2	54

#	ARTICLE	IF	CITATIONS
20	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	13.9	765
21	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
22	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 265-74.	3.8	386
23	MicroRNAs and myocardial infarction. Current Opinion in Cardiology, 2012, 27, 228-235.	0.8	34
24	Management of Non–ST-Segment Elevation Acute Coronary Syndrome. Critical Pathways in Cardiology, 2012, 11, 62-73.	0.2	1
25	Patients with circumflex occlusions miss out on reperfusion. Current Opinion in Cardiology, 2012, 27, 327-330.	0.8	14
26	Working together in cardiovascular prevention: the common mission of the <i>European Heart Journal</i> and the <i>European Journal of Preventive Cardiology</i> European Journal of Preventive Cardiology, 2012, 19, 1217-1226.	0.8	4
27	A Novel Approach to Cardiac Troponins to Improve the Diagnostic Work-up in Chest Pain Patients. Critical Pathways in Cardiology, 2012, 11, 199-205.	0.2	O
28	What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?. Current Opinion in Cardiology, 2012, 27, 361-367.	0.8	2
29	Lessons from platelet inhibition and patient outcomes. Current Opinion in Cardiology, 2012, 27, 355-360.	0.8	1
30	Point-of-Care Testing at the Disaster–Emergency–Critical Care Interface. Point of Care, 2012, 11, 180-183.	0.5	12
31	2012 Oman Heart Association Simplified Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Critical Pathways in Cardiology, 2012, 11, 139-146.	0.2	4
32	Microvascular Coronary Artery Spasm Presents Distinctive Clinical Features With Endothelial Dysfunction as Nonobstructive Coronary Artery Disease. Journal of the American Heart Association, 2012, 1, e002485.	1.6	74
33	Interpretation of acute myocardial infarction with persistent †hyperacute T waves' by cardiac magnetic resonance. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 344-348.	0.4	9
34	\hat{l}^2 -Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	3.8	377
41	The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: A Critical Appraisal. Methodist DeBakey Cardiovascular Journal, 2021, 8, 26.	0.5	17
47	Thromboâ€embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	2.9	71
48	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034

3

#	Article	IF	CITATIONS
49	Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart, 2012, 98, 558-565.	1.2	67
50	Pros and cons of high-sensitivity assays for cardiac troponin. Nature Reviews Cardiology, 2012, 9, 616-618.	6.1	12
51	Cardiac troponin determination in the diagnosis of acute myocardial infarction. Expert Review of Molecular Diagnostics, 2012, 12, 671-673.	1.5	0
52	Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22â€^740 patients. Heart, 2012, 98, 914-919.	1.2	72
53	CTA in the evaluation of acute chest pain syndromes. Should more widespread use be advocated?. Expert Opinion on Medical Diagnostics, 2012, 6, 275-280.	1.6	0
54	Glycoprotein IIb/IIIa Antagonists. Handbook of Experimental Pharmacology, 2012, , 199-223.	0.9	8
55	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets, 2012, 23, 537-551.	1.1	17
56	Heparin Disrupts the CXCR4/SDF-1 Axis and Impairs the Functional Capacity of Bone Marrow–Derived Mononuclear Cells Used for Cardiovascular Repair. Circulation Research, 2012, 111, 854-862.	2.0	91
57	The role of the interventional cardiologist in selecting antiplatelet agents in acute coronary syndromes: a 10-question strategy. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 170-176.	0.4	1
58	Açıklanamayan Troponin Yüksekliği. Haseki Tip Bulteni, 2012, 50, 153-155.	0.2	1
59	Copeptin for acute coronary syndrome: diamond or decoy?. Clinical Chemistry and Laboratory Medicine, 2012, 50, 191-2.	1.4	1
60	Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. European Heart Journal, 2012, 33, 1095-1104.	1.0	88
61	Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents. Circulation, 2012, 125, 1276-1287.	1.6	111
62	The impact of drug eluting stents availability on the treatment choice among medical therapy, percutaneous or surgical revascularisation and on 4-year clinical outcome in patients with coronary artery disease: a cohort study. BMJ Open, 2012, 2, e001926.	0.8	0
63	PERTINENT (a substudy of the EUROPA trial): a persistent legacy: EXPERTS' PERSPECTIVE. Cardiovascular Research, 2012, 96, 202-203.	1.8	0
64	Catheterization laboratories open 24 hours a day, every day: does stable non-ST-elevation acute coronary syndrome need the offer?. European Heart Journal, 2012, 33, 1992-1995.	1.0	5
65	Primary aortic sarcoma with multiple metastatic sites. European Heart Journal, 2012, 33, 1995-1995.	1.0	5
66	Long-term alcohol consumption in relation to all-cause and cardiovascular mortality among survivors of myocardial infarction: the Health Professionals Follow-up Study. European Heart Journal, 2012, 33, 1598-1605.	1.0	51

#	Article	IF	Citations
67	The best of the European Heart Journal: look back with pride. European Heart Journal, 2012, 33, 1161-1171.	1.0	10
68	Coronary microvascular dysfunction in the clinical setting: from mystery to reality. European Heart Journal, 2012, 33, 2771-2783.	1.0	191
69	Personalized antiplatelet therapy: state of the art. JRSM Cardiovascular Disease, 2012, 1, 1-10.	0.4	1
70	Clinical Use and Measurement of Cardiac Troponin (cTn). Proceedings of Singapore Healthcare, 2012, 21, 153-158.	0.2	1
71	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	0.9	35
72	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. Current Pharmaceutical Design, 2012, 18, 5344-5361.	0.9	59
73	Platelet Turnover in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5328-5343.	0.9	20
74	Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts. Current Cardiology Reviews, 2012, 8, 202-208.	0.6	5
75	Time trends in STEMIâ€"improved treatment and outcome but still a gender gap: a prospective observational cohort study from the SWEDEHEART register. BMJ Open, 2012, 2, e000726.	0.8	85
76	Welcome to the ESC journal family. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 5-8.	0.4	4
77	Challenges and opportunities in implementing pharmacogenomics testing in the clinics. Personalized Medicine, 2012, 9, 609-619.	0.8	0
80	Fondaparinux in Percutaneous Coronary Intervention for the Treatment of Acute Coronary Syndrome. Revista Brasileira De Cardiologia Invasiva (English Edition), 2012, 20, 155-160.	0.1	0
83	Role of the CHADS 2 Score in Acute Coronary Syndromes. Chest, 2012, 141, 1375-1376.	0.4	5
84	Management of diabetes and acute coronary syndromes. British Journal of Cardiac Nursing, 2012, 7, 370-375.	0.0	0
85	Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes. Circulation Journal, 2012, 76, 2673-2680.	0.7	20
86	Perioperative Management of Antiplatelet Agents in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 680-686.	0.6	7
87	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. American Heart Journal, 2012, 164, 706-714.	1.2	120
88	Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis, 2012, 108, 876-886.	1.8	155

#	Article	IF	Citations
89	Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 921.	3.8	11
90	Variation of Cardiac Troponin I and T Measured with Sensitive Assays in Emergency Department Patients with Noncardiac Chest Pain. Clinical Chemistry, 2012, 58, 1208-1214.	1.5	31
91	Cardiac troponin: a critical review of the case for point-of-care testing in the ED. American Journal of Emergency Medicine, 2012, 30, 1639-1649.	0.7	74
92	Thienopyridines and Other ADP-Receptor Antagonists. Handbook of Experimental Pharmacology, 2012, , 165-198.	0.9	24
93	Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!. Journal of the American College of Cardiology, 2012, 60, 951-956.	1.2	216
94	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012, 98, 1498-1503.	1.2	40
95	Diagnostic value of heart-type fatty acid binding protein determined by the rapid qualitative chromatographic immunoassay method for the detection of minor myocardial damage in patients presenting with non-ST elevation acute coronary syndrome. Anatolian Journal of Cardiology, 2012, 12, 584-90.	0.4	0
96	Intérêt des biomarqueurs devant une douleur thoracique. Références En Médecine D'urgence, 2012, , 187-196.	0.0	0
97	Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2012, 308, 2507.	3.8	175
98	Review of ticagrelor in the management of acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1315-1325.	1.5	1
99	Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clinical Research in Cardiology, 2012, 101, 573-584.	1.5	26
100	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet, The, 2012, 380, 1317-1324.	6.3	202
101	Improving long-term outcome after myocardial infarction. Lancet, The, 2012, 380, 1290-1291.	6.3	0
102	Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Molecular Medicine, 2012, 4, 1176-1185.	3.3	173
105	Biomarkers in acute coronary artery disease. Wiener Medizinische Wochenschrift, 2012, 162, 489-498.	0.5	9
106	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.4	414
107	Short-term (90 min) diagnostic performance for acute non-ST segment elevation myocardial infarction and 30-day prognostic evaluation of a novel third-generation high sensitivity troponin I assay. Clinical Biochemistry, 2012, 45, 1295-1301.	0.8	15
108	Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. Revista Espanola De Cardiologia (English Ed), 2012, 65, 205-207.	0.4	2

#	Article	IF	Citations
109	Comments on the ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 125-130.	0.4	0
110	Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor—a long continuing journey. Indian Heart Journal, 2012, 64, 54-59.	0.2	1
111	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1483-1493.	1.5	1
112	Modalités d'arrêt du traitement antiagrégant plaquettaire. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2012, 2012, 36-38.	0.0	1
113	Sencillo, obvio, olvidado. Revista Espanola De Cardiologia, 2012, 65, 867-868.	0.6	0
115	Interventional Management of ACS in Women: STEMI and NSTEMI. Interventional Cardiology Clinics, 2012, 1, 173-182.	0.2	1
120	Quelles indications pour le prasugrel et le ticagrelor dans les syndromes coronariens aigusÂ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2012, 2012, 31-35.	0.0	0
121	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention	1.0	5,247
122	Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis. Current Medical Research and Opinion, 2012, 28, 351-370.	0.9	20
123	Diagnosis and management of patients with acute cardiac symptoms, troponin elevation and culprit-free angiograms. Heart, 2012, 98, 974-981.	1.2	37
124	Emergency coronary angiography in comatose cardiac arrest patients: do real-life experiences support the guidelines?. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 291-301.	0.4	124
125	Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 222-231.	0.4	68
126	Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece. Applied Health Economics and Health Policy, 2012, 10, 261-271.	1.0	8
129	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
130	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Preventive Cardiology, 2012, 19, 585-667.	0.8	359
131	Valor de la determinación del genotipo de CYP2C19 *2 y *17 en la práctica clÃnica. Prometedor, aunque todavÃa no está listo. Revista Espanola De Cardiologia, 2012, 65, 205-207.	0.6	7
132	Comentarios a la guÃa de práctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de GuÃas de Práctica ClÃnica de la Sociedad Española de CardiologÃa. Revista Espanola De Cardiologia, 2012, 65, 125-130.	0.6	21
133	Release Kinetics of Cardiac Biomarkers in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Clinical Chemistry, 2012, 58, 1049-1054.	1.5	38

#	Article	IF	CITATIONS
134	Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 882.	3.8	48
135	Acute Coronary Syndrome in Patients With Atrial Fibrillation. Circulation, 2012, 126, 1176-1178.	1.6	3
136	Unstable Angina and Non–ST Elevation Myocardial Infarction. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 924-932.	2.5	66
137	Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: Necessary or too hazardous?. American Heart Journal, 2012, 163, 531-534.	1.2	3
138	Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. American Heart Journal, 2012, 163, 768-776.e2.	1.2	72
139	Effect of Glycemic Control on Response to Antiplatelet Therapy in Patients With Diabetes Mellitus and ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 110, 331-336.	0.7	13
141	Assay performance improved, but which "scorecard―designation for Vitros Troponin I?. Clinica Chimica Acta, 2012, 413, 826-828.	0.5	4
142	Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. Clinica Chimica Acta, 2012, 413, 933-937.	0.5	15
143	High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clinica Chimica Acta, 2012, 413, 1135-1140.	0.5	48
144	How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal, 2012, 33, 2252-2257.	1.0	666
145	Hyperinvasive approach to out-of hospital cardiac arrest using mechanical chest compression device, prehospital intraarrest cooling, extracorporeal life support and early invasive assessment compared to standard of care. A randomized parallel groups comparative study proposal. "Prague OHCA studyâ€. Journal of Translational Medicine, 2012, 10, 163.	1.8	99
146	A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. Trials, 2012, 13, 240.	0.7	10
147	Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 2470-2480.	1.9	27
148	Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. Clinical Pharmacokinetics, 2012, 51, 429-442.	1.6	66
149	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs, 2012, 72, 2087-2116.	4.9	106
150	New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2012, 5, 433-445.	1.4	61
151	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Review of Cardiovascular Therapy, 2012, 10, 489-503.	0.6	11
152	La copeptine. Références En Médecine D'urgence, 2012, , 115-120.	0.0	0

#	Article	IF	CITATIONS
153	Biomarqueurs chez le patient âgé aux urgences. Références En Médecine D'urgence, 2012, , 337-349.	0.0	1
154	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y ₁₂ receptor inhibitors. Expert Review of Cardiovascular Therapy, 2012, 10, 1011-1022.	0.6	O
155	Stent thrombosis: an overview. Expert Review of Cardiovascular Therapy, 2012, 10, 599-615.	0.6	16
156	Early triage of emergency department patients with acute coronary syndrome: Contribution of 64-slice computed tomography angiography. Archives of Cardiovascular Diseases, 2012, 105, 338-346.	0.7	7
157	Usefulness of high-sensitivity troponin T for the evaluation of patients with acute chest pain and no or minimal myocardial damage. American Heart Journal, 2012, 164, 194-200.e1.	1.2	31
158	Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department. American Heart Journal, 2012, 164, 698-705.e4.	1.2	62
159	Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patientsâ€"Results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal, 2012, 164, 728-734.	1.2	8
160	Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy. American Heart lournal, 2012, 164, 817-824,e13.	1.2	20
161	Ticagrelor: molecular discovery to clinical evidence. Indian Heart Journal, 2012, 64, 497-502.	0.2	8
162	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 59, 1413-1425.	1.2	257
163	Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Nonâé"ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2012, 60, 369-377.	1.2	40
164	Platelet Function Measurement in Elective Percutaneous Coronary Intervention Patients. JACC: Cardiovascular Interventions, 2012, 5, 290-292.	1.1	3
165	Use of Invasive Strategy in Non–ST-Segment Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival. JACC: Cardiovascular Interventions, 2012, 5, 893-902.	1.1	71
166	Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2012, 5, 1117-1125.	1.1	23
167	Non–ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 903-905.	1,1	8
168	Don't Forget the Intervention in Very Elderly Persons With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 917-918.	1.1	O
169	Clinical management of atrial fibrillation: early interventions, observation, and structured follow-up reduce hospitalizations. American Journal of Emergency Medicine, 2012, 30, 1962-1969.	0.7	26
170	Diagnostic sensitivity of high-sensitivity troponin T in acute myocardial infarction in patients with chest pain. Cor Et Vasa, 2012, 54, e227-e231.	0.1	1

#	ARTICLE	IF	Citations
171	Resistance to antiplatelet treatment: The clinical relevance of platelet function assays. Cor Et Vasa, 2012, 54, e305-e313.	0.1	3
172	The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart and Lung: Journal of Acute and Critical Care, 2012, 41, 456-462.	0.8	9
173	Shear-induced platelet aggregation in aspirin-treated patients: Initial experience with the novel PlaCor PRT® device. Thrombosis Research, 2012, 130, 753-758.	0.8	10
174	Drugs acting on the heart: heart failure and coronary insufficiency. Anaesthesia and Intensive Care Medicine, 2012, 13, 378-383.	0.1	1
175	Advances in monitoring of aspirin therapy. Platelets, 2012, 23, 526-536.	1.1	35
176	New anti-platelet agents: The end of resistance?. Thrombosis Research, 2012, 130, S53-S55.	0.8	7
181	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	0.8	224
182	GuÃa europea sobre prevención de la enfermedad cardiovascular en la práctica clÃnica (versión 2012). Revista Espanola De Cardiologia, 2012, 65, 937.e1-937.e66.	0.6	30
183	Simple, Obvious, Forgotten. Revista Espanola De Cardiologia (English Ed), 2012, 65, 867-868.	0.4	0
184	GuÃa de práctica clÃnica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
185	Antiagrégants plaquettaires. Actualites Pharmaceutiques, 2012, 51, 53-58.	0.0	1
187	Acetylsalicylic Acid/Esomeprazole Fixed-Dose Combination. Drugs and Aging, 2012, 29, 233-242.	1.3	7
190	Interventional management of acute coronary syndromes: applying the lessons of ST-elevation services to non-ST-elevation myocardial infarction. Heart, 2012, 98, 1407-1411.	1.2	7
191	Les biomarqueurs en médecine d'urgence. Références En Médecine D'urgence, 2012, , .	0.0	1
192	Serotonin Antagonism Improves Platelet Inhibition in Clopidogrel Low-Responders after Coronary Stent Placement: An In Vitro Pilot Study. PLoS ONE, 2012, 7, e32656.	1.1	10
193	Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers. PLoS ONE, 2012, 7, e38573.	1.1	9
194	Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals, 2012, 5, 279-296.	1.7	32
195	Sangramento em sÃndrome coronariana aguda sem supradesnivelamento de segmento ST. Revista Brasileira De Terapia Intensiva, 2012, 24, 284-293.	0.1	1

#	Article	IF	CITATIONS
196	Impedance Cardiography and Heart Rate Variability for Long-Term Cardiovascular Outcome Prediction After Myocardial Infarction. Medicina (Lithuania), 2012, 48, 52.	0.8	7
197	Oral antiplatelet therapy in acute coronary syndromes: update 2012. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 79-86.	0.4	8
198	ACETYLSALICYLIC ACID: DO WE KNOW EVERYTHING ABOUT IT AND ITS PROPER USE?. Rational Pharmacotherapy in Cardiology, 2012, 8, 708-716.	0.3	1
199	Antiplatelet therapy – ticagrelor. Hamostaseologie, 2012, 32, 177-185.	0.9	10
200	Vorapaxar expands antiplatelet options. Hamostaseologie, 2012, 32, 221-227.	0.9	8
202	High-risk non-ST elevation acute coronary syndromes (NSTEACS) for paramedics. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2012, 4, 448-456.	0.0	1
203	36 Antikoagulanzien. , 2012, , .		0
204	Utilização de terapêuticas comprovadamente úteis no tratamento da coronariopatia aguda: comparação entre diferentes regiões brasileiras. Análise do Registro Brasileiro de SÃndromes Coronarianas Agudas (BRACE - Brazilian Registry on Acute Coronary Syndromes). Arquivos Brasileiros De Cardiologia. 2012. 98. 282-289.	0.3	37
205	THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN. Rational Pharmacotherapy in Cardiology, 2012, 8, 405-414.	0.3	0
206	ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2012, 8, 531-537.	0.3	O
207	SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2012, 8, 788-797.	0.3	0
208	Acute coronary syndromes: an old age problem. Journal of Geriatric Cardiology, 2012, 9, 192-196.	0.2	31
209	Letter to the Editor Hepatocyte growth factor concentration during the first day of acute coronary syndrome. Archives of Medical Science, 2012, 2, 389-391.	0.4	1
210	Transulnar Sheathless Percutaneous Coronary Intervention during Bivalirudin Infusion in High-Risk Elderly Female with Non-ST Segment Elevation Myocardial Infarction. Heart International, 2012, 7, hi.2012.e10.	0.4	0
211	Acurácia dos escores GRACE e TIMI na predição da gravidade angiográfica da sÃndrome coronariana aguda. Arquivos Brasileiros De Cardiologia, 2012, 99, 818-824.	0.3	23
212	P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?. Thrombosis and Haemostasis, 2012, 108, 203-205.	1.8	3
213	Importance of potent P2Y12receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opinion on Pharmacotherapy, 2012, 13, 1771-1796.	0.9	9
214	A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy, 2012, 13, 175-191.	0.9	11

#	Article	IF	Citations
215	Coronary Revascularization in Women. Clinical Cardiology, 2012, 35, 156-159.	0.7	15
217	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. Herz, 2012, 37, 264-272.	0.4	2
221	Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2012, 34, 85-90.	1.0	60
222	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
223	Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. Current Cardiology Reports, 2012, 14, 486-492.	1.3	7
225	A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. Journal of Nuclear Cardiology, 2012, 19, 364-376.	1.4	72
226	Assessment of coronary heart disease by CT angiography: Current and evolving applications. Journal of Nuclear Cardiology, 2012, 19, 796-806.	1.4	21
228	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. Journal of Internal Medicine, 2012, 271, 521-536.	2.7	18
229	Improving Longâ€Term ACS Management: Is There a Role for the New Antiplatelets?. Journal of Interventional Cardiology, 2012, 25, 425-432.	0.5	4
230	Diabetes mellitus and the heart. International Journal of Clinical Practice, 2012, 66, 640-647.	0.8	29
231	Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. International Journal of Laboratory Hematology, 2012, 34, 484-494.	0.7	37
232	Routine Invasive Versus Conservative Management in Non-ST-elevation Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2012, 5, 22-29.	1.1	O
233	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research, 2012, 5, 41-51.	1.1	4
234	Risk Stratification in Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2012, 5, 1-10.	1.1	2
236	PCI ad hoc or PCI at an interval: a risk calculation. Clinical Research in Cardiology, 2012, 101, 155-157.	1.5	1
237	Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI): study protocol for a randomized controlled trial. Trials, 2013, 14, 110.	0.7	11
240	Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). European Journal of Clinical Pharmacology, 2013, 69, 309-317.	0.8	55
242	Infarto agudo de miocardio con elevación del segmento ST. SCACEST. Medicine, 2013, 11, 2248-2255.	0.0	0

#	Article	IF	CITATIONS
243	Protocolo terapéutico hospitalario del infarto de miocardio. Medicine, 2013, 11, 2275-2278.	0.0	0
245	Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thrombosis Research, 2013, 132, 240-247.	0.8	13
246	Emerging antithrombotic drugs for acute coronary syndrome. Expert Opinion on Emerging Drugs, 2013, 18, 307-318.	1.0	1
247	The combination of high sensitivity troponin T and copeptin facilitates early rule-out of ACS: a prospective observational study. BMC Cardiovascular Disorders, 2013, 13, 42.	0.7	29
248	Trends in hospital discharges, management and in-hospital mortality from acute myocardial infarction in Switzerland between 1998 and 2008. BMC Public Health, 2013, 13, 270.	1.2	18
249	Mitral Annular Displacement by Doppler Tissue Imaging May Identify Coronary Occlusion and Predict Mortality in Patients with Non–ST-Elevation Myocardial Infarction. Journal of the American Society of Echocardiography, 2013, 26, 875-884.	1.2	15
250	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. Journal of Cardiothoracic and Vascular Anesthesia, 2013, 27, 779-795.	0.6	12
251	Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2013, 132, e15-e18.	0.8	28
252	Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study. Journal of General Internal Medicine, 2013, 28, 216-222.	1.3	27
253	High-sensitivity cardiac troponins: no more †negatives'. Expert Review of Cardiovascular Therapy, 2013, 11, 1129-1139.	0.6	7
254	New oral anticoagulants after acute coronary syndrome. Best Practice and Research in Clinical Haematology, 2013, 26, 141-150.	0.7	2
255	New developments in parenteral anticoagulation for arterial and venous thromboembolism. Best Practice and Research in Clinical Haematology, 2013, 26, 203-213.	0.7	8
256	Platelet Function Testing and Tailored Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2013, 6, 316-328.	1.1	34
257	Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 346-354.	1.1	3
258	Platelet Function Testing in Patients with Acute Coronary Syndrome. Journal of Cardiovascular Translational Research, 2013, 6, 371-377.	1.1	6
259	Clinical Impact of Genetically Determined Platelet Reactivity. Journal of Cardiovascular Translational Research, 2013, 6, 398-403.	1.1	6
260	Evaluation of Crushed Ticagrelor Tablet Doses: Recovery Following Crushing and Naso-gastric Tube Passage Ex Vivo. Drugs in R and D, 2013, 13, 153-157.	1.1	19
261	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of Thrombosis and Thrombolysis, 2013, 36, 223-232.	1.0	31

#	Article	IF	CITATIONS
262	Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clinical Research in Cardiology, 2013, 102, 755-763.	1.5	33
263	Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clinical Research in Cardiology, 2013, 102, 495-503.	1.5	138
264	Evaluation of a novel portable capacitive ECG system in the clinical practice for a fast and simple ECG assessment in patients presenting with chest pain: FIDET (Fast Infarction Diagnosis ECG Trial). Clinical Research in Cardiology, 2013, 102, 179-184.	1.5	5
265	Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments. Cardiology and Therapy, 2013, 2, 47-56.	1.1	7
266	Thrombin Receptor Antagonism in Antiplatelet Therapy. Cardiology and Therapy, 2013, 2, 57-68.	1.1	10
267	Treatment of NSTEMI (Non-ST Elevation Myocardial Infarction). Current Emergency and Hospital Medicine Reports, 2013, 1, 18-28.	0.6	1
268	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 1115-1123.	13.9	871
269	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	6.3	286
270	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. Expert Review of Cardiovascular Therapy, 2013, 11, 975-984.	0.6	4
274	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interventional Cardiology Clinics, 2013, 2, 607-614.	0.2	1
275	Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2013, 111, 439-444.	0.7	9
276	Incremental value of cardiovascular magnetic resonance over echocardiography in the detection of acute and chronic myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 5.	1.6	15
278	Recent insights into the treatment of stable CAD. Herz, 2013, 38, 376-381.	0.4	3
279	Cardiac troponin level elevations not related to acute coronary syndromes. Nature Reviews Cardiology, 2013, 10, 623-634.	6.1	188
280	Role of central obesity in risk stratification after an acute coronary event: Does central obesity add prognostic value to the Global Registry of Acute Coronary Events (GRACE) risk score in patients with acute coronary syndrome?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 769-776.	0.2	7
281	Age-dependent care and long-term (20year) mortality of 14,434 myocardial infarction patients: Changes from 1985 to 2008. International Journal of Cardiology, 2013, 167, 693-697.	0.8	18
282	An evaluation of composite indicators of hospital acute myocardial infarction care: A study of 136,392 patients from the Myocardial Ischaemia National Audit Project. International Journal of Cardiology, 2013, 170, 81-87.	0.8	19
283	Prevenci $ ilde{A}^3$ n secundaria en el paciente coronario. EMC - Tratado De Medicina, 2013, 17, 1-8.	0.0	0

#	Article	IF	CITATIONS
284	Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: Meta-analysis and meta-regression. International Journal of Cardiology, 2013, 168, 1955-1964.	0.8	21
285	Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. American Heart Journal, 2013, 166, 662-668.e3.	1.2	11
286	ST-elevation and non-ST-elevation acute coronary syndromes: Should the guidelines be changed?. Journal of Electrocardiology, 2013, 46, 318-323.	0.4	35
287	Cardiac computed tomography guided treatment strategy in patients with recent acute-onset chest pain. International Journal of Cardiology, 2013, 168, 5257-5262.	0.8	59
288	Improving Outcomes After Acute Coronary Syndrome With Rehabilitation and Secondary Prevention. Clinical Therapeutics, 2013, 35, 1076-1081.	1.1	19
289	The German CPU Registry: Comparison of troponin positive to troponin negative patients. International Journal of Cardiology, 2013, 168, 1651-1653.	0.8	19
291	Role of central obesity in risk stratification after an acute coronary event: Does central obesity add prognostic value to the Global Registry of Acute Coronary Events (GRACE) risk score in patients with acute coronary syndrome?. Revista Portuguesa De Cardiologia, 2013, 32, 769-776.	0.2	8
292	Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1259-1266.e1.	0.4	44
293	Normal presenting levels of high-sensitivity troponin and myocardial infarction. Heart, 2013, 99, 1567-1572.	1.2	40
294	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International Journal of Cardiology, 2013, 168, 523-528.	0.8	21
295	Laboratory Medicine, 2013, 51, 1699-706.	1.4	19
296	Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience. International Journal of Cardiology, 2013, 168, 139-143.	0.8	12
297	Dual platelet inhibition in ACS - The Styrian consensus. Cor Et Vasa, 2013, 55, e131-e134.	0.1	0
298	Diagnostic value of magnetocardiography in coronary artery disease and cardiac arrhythmias: A review of clinical data. International Journal of Cardiology, 2013, 167, 1835-1842.	0.8	75
299	Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials. Atherosclerosis, 2013, 229, 482-488.	0.4	7
300	Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality. Heart, 2013, 99, 116-121.	1.2	35
301	Copeptin Improves the Diagnostic Performance of Sensitive Troponin I-Ultra but Cannot Rapidly Rule Out Nonâ€"ST-Elevation Myocardial Infarction at Presentation to an Emergency Department. Annals of Emergency Medicine, 2013, 61, 549-558.e1.	0.3	20
302	Glycoprotein IIb-IIIa inhibitors – Do we still need them?. Indian Heart Journal, 2013, 65, 260-263.	0.2	5

#	Article	IF	CITATIONS
303	The Effect of Ticagrelor on the Metabolism of Midazolam in Healthy Volunteers. Clinical Therapeutics, 2013, 35, 1025-1037.	1.1	15
304	Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, and Famotidine: A Prospective, Randomized, Crossover Study. Clinical Cardiology, 2013, 36, 342-346.	0.7	31
305	Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel. American Journal of Emergency Medicine, 2013, 31, 1287.	0.7	4
306	High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. International Journal of Cardiology, 2013, 167, 1877-1881.	0.8	28
307	Protocols of antithrombotic therapy in a University Cardiocenter. Cor Et Vasa, 2013, 55, e201-e206.	0.1	3
308	Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?. Internal and Emergency Medicine, 2013, 8, 673-680.	1.0	10
309	Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndromeâ€"Results from the countrywide TARGET study. International Journal of Cardiology, 2013, 168, 922-927.	0.8	30
310	Release Kinetics of Circulating Muscle-Enriched MicroRNAs in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Journal of the American College of Cardiology, 2013, 62, 992-998.	1.2	86
312	Handbook of Oral Anticoagulation. , 2013, , .		1
313	Novel oral anticoagulants in acute coronary syndrome. International Journal of Cardiology, 2013, 167, 2449-2455.	0.8	31
314	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. Vascular Pharmacology, 2013, 59, 53-62.	1.0	23
315	Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Archives of Cardiovascular Diseases, 2013, 106, 661-671.	0.7	19
317	Ticagrelor: the first novel reversible P2Y12inhibitor. Expert Opinion on Pharmacotherapy, 2013, 14, 237-245.	0.9	15
318	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal, 2013, 34, 1708-1713.	1.0	159
319	Impact of chronic total occlusion artery on 12 -month mortality in patients with non-ST-segment elevation myocardial infarction treated by percutaneous coronary intervention (From the PL-ACS) Tj ETQq $0\ 0\ 0$ r	gB ō/ Øverl	oc k 310 Tf 50
320	Pharmacogenetics and Cardiovascular Diseaseâ€"Implications for Personalized Medicine. Pharmacological Reviews, 2013, 65, 987-1009.	7.1	109
321	A critical overview on ticagrelor in acute coronary syndromes. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 105-115.	0.2	16
322	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	1.2	807

#	Article	IF	CITATIONS
323	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyâ€. European Heart Journal, 2013, 34, 1621-1629.	1.0	9
324	Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. Circulation, 2013, 128, 2785-2798.	1.6	91
325	Metabolomics in the Diagnosis of Acute Myocardial Ischemia. Journal of Cardiovascular Translational Research, 2013, 6, 808-815.	1.1	27
327	Early rule out of acute myocardial infarction in ED patients: value of combined high-sensitivity cardiac troponin T and ultrasensitive copeptin assays at admission. American Journal of Emergency Medicine, 2013, 31, 1302-1308.	0.7	43
328	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
329	Perioperative management of antiplatelet therapy. British Journal of Anaesthesia, 2013, 111, i3-i17.	1.5	81
330	Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. International Journal of Cardiology, 2013, 167, 1794-1797.	0.8	11
332	The impact of the HEART risk score in the early assessment of patients with acute chest pain: design of a stepped wedge, cluster randomised trial. BMC Cardiovascular Disorders, 2013, 13, 77.	0.7	52
333	Application of pattern recognition tools for classifying acute coronary syndrome: an integrated medical modeling. Theoretical Biology and Medical Modelling, 2013, 10, 57.	2.1	14
334	Clinical Outcomes, Health Resource Use, and Cost in Patients with Early versus Late Dual or Triple Anti-Platelet Treatment for Acute Coronary Syndrome. American Journal of Cardiovascular Drugs, 2013, 13, 273-283.	1.0	4
336	Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients. Trials, 2013, 14, 435.	0.7	16
337	Trialogue Plus. Acta Diabetologica, 2013, 50, 989-998.	1.2	2
338	Ethnic differences in the occurrence of acute coronary syndrome: results of the Malaysian National Cardiovascular Disease (NCVD) Database Registry (March 2006 - February 2010). BMC Cardiovascular Disorders, 2013, 13, 97.	0.7	37
339	Pharmacist care and the management of coronary heart disease: a systematic review of randomized controlled trials. BMC Health Services Research, 2013, 13, 461.	0.9	30
340	Ticagrelor: a review of its cost effectiveness in the management of acute coronary syndromes. Drugs and Therapy Perspectives, 2013, 29, 379-386.	0.3	3
341	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. Expert Review of Cardiovascular Therapy, 2013, 11, 817-828.	0.6	1
342	Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	13.9	539
343	The Metabolic Syndrome. , 2013, , .		11

#	Article	IF	CITATIONS
344	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	6.3	105
345	Management of cardiovascular disease in haemophilia. Thrombosis Research, 2013, 132, 8-14.	0.8	27
346	Efficacy of Shortâ€Term Highâ€Dose Atorvastatin Pretreatment in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Metaâ€analysis of Nine Randomized Controlled Trials. Clinical Cardiology, 2013, 36, E41-8.	0.7	16
347	The past, present and future of minimally invasive therapy in endovascular interventions: A review and speculative outlook. Minimally Invasive Therapy and Allied Technologies, 2013, 22, 242-253.	0.6	12
348	Supporting clinical guidelines using DL-temporal reasoning. , 2013, , .		0
349	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. Journal of Thrombosis and Haemostasis, 2013, 11, 1627-1639.	1.9	28
350	Secondary prevention of MI: current approaches to treatment. The Prescriber, 2013, 24, 23-29.	0.1	0
351	Clinical review: Bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. Critical Care, 2013, 17, 239.	2.5	11
352	Treatment costs of acute myocardial infarction in the Netherlands. Netherlands Heart Journal, 2013, 21, 230-235.	0.3	37
353	Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets, 2013, 24, 615-624.	1.1	35
354	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. Expert Review of Cardiovascular Therapy, 2013, 11, 1547-1556.	0.6	4
355	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients with Nonâ€STâ€Segment Elevation Acute Coronary Syndrome Initially Treated with Fondaparinux: Results from an International, Multicenter, Randomized Pilot Study (SWITCH III). Journal of Interventional Cardiology, 2013, 26, 107-113.	0.5	28
356	Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 19-26.	0.4	38
357	An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care, 2013, 2, 9-18.	0.4	31
358	Serum extracellular vesicle protein levels are associated with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 53-60.	0.4	71
359	Rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2013, 14, 917-927.	0.9	1
360	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. Expert Review of Cardiovascular Therapy, 2013, 11, 1557-1566.	0.6	1
361	Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2013, 66, 12-16.	0.4	2

#	Article	IF	CITATIONS
362	Mortality and Cardiovascular and Bleeding Outcomes in Patients With CKD Receiving Antiplatelet Therapy. American Journal of Kidney Diseases, 2013, 61, 18-21.	2.1	2
363	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. Platelets, 2013, 24, 549-553.	1.1	16
364	Update on acute coronary syndromes: the pathologists' view. European Heart Journal, 2013, 34, 719-728.	1.0	849
365	Laboratory diagnostics of myocardial infarction – troponins and beyond. Clinical Chemistry and Laboratory Medicine, 2013, 51, 83-89.	1.4	26
366	Release Kinetics of Copeptin in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Clinical Chemistry, 2013, 59, 566-569.	1.5	40
367	Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Thrombosis and Haemostasis, 2013, 109, 93-101.	1.8	45
368	Low-Dose Anticoagulation for Secondary Prevention in Acute Coronary Syndrome. American Journal of Cardiology, 2013, 111, 618-626.	0.7	12
369	Helio-geomagnetic influence in cardiological cases. Advances in Space Research, 2013, 51, 96-106.	1.2	13
370	Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 21-32.	0.4	0
371	Non–ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
372	Comment prendre en charge une femme enceinte atteinte d'une coronaropathie�. Praticien En Anesthesie Reanimation, 2013, 17, 174-179.	0.0	1
373	Epidemiology of Acute Coronary Syndromes in Spain: Estimation of the Number of Cases and Trends From 2005 to 2049. Revista Espanola De Cardiologia (English Ed), 2013, 66, 472-481.	0.4	58
374	High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thrombosis Research, 2013, 131, 313-319.	0.8	13
375	New predictors of mortality in the acute coronary syndromes. American Journal of Emergency Medicine, 2013, 31, 1286-1287.	0.7	0
376	Dose-dependent effect of aspirin on the level of sphingolipids in human blood. Advances in Medical Sciences, 2013, 58, 274-281.	0.9	19
377	Coronary-to-bronchial artery fistula in a patient with angina. Journal of Cardiology Cases, 2013, 7, e45-e47.	0.2	2
378	Platelet Function and Genetic Testing. Journal of the American College of Cardiology, 2013, 62, S21-S31.	1.2	28
379	Mucopolysaccharidosis type VI: A cardiologist's guide to diagnosis and treatment. International Journal of Cardiology, 2013, 167, 1-10.	0.8	13

#	Article	IF	CITATIONS
380	Czech contributions to European cardiology - The European Heart Journal's perspective. Cor Et Vasa, 2013, 55, e1-e5.	0.1	1
383	Algorithm for probable acute coronary syndrome using high-sensitivity troponin T assay vs fourth-generation troponin T assay. American Journal of Emergency Medicine, 2013, 31, 1226-1229.	0.7	8
384	The Optimal Duration of Dual Combination Antiplatelet Therapy After Stent Implantation and Perioperative Management Issues. Interventional Cardiology Clinics, 2013, 2, 585-594.	0.2	0
385	The feasibility of optical coherence tomography guided thrombus aspiration in patients with non-ST-elevation myocardial infarction after initial conservative therapy – A pilot study. International Journal of Cardiology, 2013, 168, 4981-4982.	0.8	4
386	High-sensitive troponin T levels and complex coronary lesions. American Journal of Emergency Medicine, 2013, 31, 1141.	0.7	6
388	Relationship between high-sensitive troponin T levels in patients with acute coronary syndrome with ST elevation and complex coronary lesions. American Journal of Emergency Medicine, 2013, 31, 1145-1146.	0.7	7
389	Challenges of serial troponin testing: A symphony in need for harmony. International Journal of Cardiology, 2013, 168, 4542.	0.8	5
390	Diagnosis performance of high sensitivity troponin assay in out-of-hospital cardiac arrest patients. International Journal of Cardiology, 2013, 169, 449-454.	0.8	31
392	Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. Clinical Biochemistry, 2013, 46, 1655-1659.	0.8	26
393	Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. International Journal of Cardiology, 2013, 167, 1134-1140.	0.8	51
394	Increasing specificity of high-sensitivity troponin: New approaches and perspectives in the diagnosis of acute coronary syndromes. Journal of Cardiology, 2013, 62, 205-209.	0.8	14
395	Acute coronary syndromes with ongoing myocardial ischemia (ACS with OMI) versus acute coronary syndromes without ongoing ischemia (ACS without OMI). The new classification of acute coronary syndromes should replace old classification based on ST segment elevation presence or absence-Expert consensus statement of the Czech Society of Cardiology. Cor Et Vasa, 2013, 55,	0.1	6
396	Prise en charge non invasive des NSTE-ACS : place des inhibiteurs des récepteurs P2Y12. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 35-39.	0.0	0
397	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2013, 166, 290-297.	1.2	20
399	Intercellular adhesion molecule 1 (ICAM-1) - A new substrate for the development of ventricular fibrillation?. International Journal of Cardiology, 2013, 168, 4917-4919.	0.8	0
400	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation. Interventional Cardiology Clinics, 2013, 2, 595-606.	0.2	0
401	The nuances of new antiplatelet drugs in acute coronary syndrome. Journal of Indian College of Cardiology, 2013, 3, 16-23.	0.1	1
402	Biological variability of hs-cardiac troponin T on the Roche Cobas 8000/e602 \hat{A}^{\otimes} immunoanalyzer. Clinica Chimica Acta, 2013, 425, 62-63.	0.5	10

#	Article	IF	CITATIONS
403	Atherosclerotic plaque burden in cocaine users with acute chest pain: Analysis by coronary computed tomography angiography. Atherosclerosis, 2013, 229, 443-448.	0.4	19
404	Calcium antagonists in the treatment of coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 301-308.	1.7	12
405	Long-term outcomes among older patients with non–ST-segment elevation myocardial infarction complicated by cardiogenic shock. American Heart Journal, 2013, 166, 298-305.	1.2	18
406	Troponin rise and poor outcome in patients presenting to the ED with short-duration atrial fibrillation. American Journal of Emergency Medicine, 2013, 31, 1147-1148.	0.7	0
407	Tratamiento antitromb \tilde{A}^3 tico y tipo de stent en pacientes con fibrilaci \tilde{A}^3 n auricular a los que se practica una intervenci \tilde{A}^3 n coronaria percut \tilde{A}_1 nea. Revista Espanola De Cardiologia, 2013, 66, 12-16.	0.6	9
408	Age, treatment, and outcomes in high-risk nonâ€ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. International Journal of Cardiology, 2013, 167, 2580-2587.	0.8	16
409	Bivalirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Should We Use It?. Heart Lung and Circulation, 2013, 22, 793-800.	0.2	1
410	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	0.7	721
411	Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Therapeutic Advances in Cardiovascular Disease, 2013, 7, 197-213.	1.0	50
412	COURAGE or FAME…? Who should have percutaneous coronary intervention in stable coronary artery disease?. Heart, 2013, 99, 442-444.	1.2	2
413	False Positive Troponin – A True Problem. Journal of Medical Biochemistry, 2013, 32, 197-206.	0.7	7
414	Coronary CT angiography outperforms calcium imaging in the triage of acute coronary syndrome. International Journal of Cardiology, 2013, 167, 1597-1602.	0.8	26
415	Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. Thrombosis Research, 2013, 132, e36-e41.	0.8	19
416	Difference vectors to describe dynamics of the ST segment and the ventricular gradient in acute ischemia. Journal of Electrocardiology, 2013, 46, 302-311.	0.4	22
417	Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. International Journal of Cardiology, 2013, 168, 1048-1055.	0.8	13
418	Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal, 2013, 166, 466-473.e1.	1.2	2
419	How Low Can We Go? The High-Sensitivity Cardiac Troponin Debate. Annals of Emergency Medicine, 2013, 62, 580-583.	0.3	7
420	Multislice Computed Tomographic Coronary Angiography for Quantitative Assessment of Culprit Lesions in Acute Coronary Syndromes. Canadian Journal of Cardiology, 2013, 29, 364-371.	0.8	52

#	Article	IF	CITATIONS
421	Continuity of maternity carer for all women. Lancet, The, 2013, 382, 1685-1687.	6.3	10
422	Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A report from the GReek AntiPlatelet rEgistry (GRAPE). International Journal of Cardiology, 2013, 168, 5329-5335.	0.8	27
425	Methylene blue for refractory anaphylaxisâ€"is it a magic bullet? The authors' response. American Journal of Emergency Medicine, 2013, 31, 1140-1141.	0.7	1
426	Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction. International Journal of Cardiology, 2013, 170, e23-e24.	0.8	18
427	The use of revascularization strategies in patients with acute coronary syndromes admitted to hospitals without catheterization facilities: Results from the ALERT-CZ registry. Cor Et Vasa, 2013, 55, e207-e211.	0.1	8
428	Abnormal troponin level as short-term predictor of poor outcome in acute atrial fibrillation. American Journal of Emergency Medicine, 2013, 31, 699-704.	0.7	25
429	Early Diagnosis of Myocardial Infarction Using Absolute and Relative Changes in Cardiac Troponin Concentrations. American Journal of Medicine, 2013, 126, 781-788.e2.	0.6	43
430	Sensitive troponin assays and N-terminal pro–B-type natriuretic peptide in acute coronary syndrome: Prediction of significant coronary lesions and long-term prognosis. American Heart Journal, 2013, 165, 716-724.	1.2	25
431	Prehospital ECG signs of acute coronary occlusion are associated with reduced one-year mortality. International Journal of Cardiology, 2013, 168, 3594-3598.	0.8	9
432	Comparison of Brachial Artery Wall Thickness Versus Endothelial Function to Predict Late Cardiovascular Events in Patients Undergoing Elective Coronary Angiography. American Journal of Cardiology, 2013, 111, 671-675.	0.7	20
433	Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. American Journal of Emergency Medicine, 2013, 31, 664-669.	0.7	2
434	Antiplatelet therapy after coronary stenting: for how long?. Lancet, The, 2013, 382, 1684-1685.	6.3	3
435	Cardiac rehabilitation after myocardial infarction: An invaluable intervention that is little used in Portugal. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 201-203.	0.2	0
436	Multivariate analysis of predictors of pre-hospital delay in acute coronary syndrome. International Journal of Cardiology, 2013, 168, 2706-2713.	0.8	74
437	Troponin rise and poor outcome in patients with acute atrial fibrillation: rationale and criteria of selection of patients. American Journal of Emergency Medicine, 2013, 31, 1148-1150.	0.7	0
439	Comparison of clinical outcomes between octogenarians and non-octogenarians with acute myocardial infarction in the drug-eluting stent era: Analysis of the Korean Acute Myocardial Infarction Registry. Journal of Cardiology, 2013, 62, 210-216.	0.8	21
440	Diagnostic Accuracy of Prehospital Clinical Prediction Models to Identify Short-term Outcomes in Patients with Acute Coronary Syndromes: A Systematic Review. Journal of Emergency Medicine, 2013, 44, 946-954.e6.	0.3	8
442	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non–ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. American Heart Journal, 2013, 165, 644-654.e1.	1.2	8

#	Article	IF	CITATIONS
443	Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel. American Journal of Emergency Medicine, 2013, 31, 1287-1288.	0.7	1
444	Panel multimarcador para pacientes conÂdolor torácico: ¿está todo dicho?. Revista Espanola De Cardiologia, 2013, 66, 523-525.	0.6	O
445	Diagnostic Performance of High-Sensitive Troponin T in Patients With Renal Insufficiency. American Journal of Cardiology, 2013, 112, 1968-1972.	0.7	51
446	Classification of myocardial infarction and unstable angina: A re-assessment. International Journal of Cardiology, 2013, 167, 2387-2390.	0.8	30
447	Old wine in new bottle: utility of contrast-enhanced point-of-care echocardiogram in the ED. American Journal of Emergency Medicine, 2013, 31, 1288-1289.	0.7	0
448	Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: Real world data from the Acute Coronary Syndrome Israeli Surveys: 2004–2010. International Journal of Cardiology, 2013, 168, 3971-3976.	0.8	5
449	AntiagregaciÃ ³ n oral en el intervencionismo coronario percutáneo: fármacos disponibles y duraciÃ ³ n de la terapia oral. Revista Espanola De Cardiologia Suplementos, 2013, 13, 16-23.	0.2	1
450	Creatinine-or cystatin C-based equations to estimate glomerular filtration rate in acute myocardial infarction: A disparity in estimating renal function and in mortality risk prediction. International Journal of Cardiology, 2013, 168, 4300-4301.	0.8	9
451	Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes. American Journal of Cardiology, 2013, 112, 737-745.	0.7	33
452	Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thrombosis Research, 2013, 131, 508-513.	0.8	95
453	Multimarker Panel for Patients With Chest Pain: Case Closed?. Revista Espanola De Cardiologia (English Ed), 2013, 66, 523-525.	0.4	0
454	Diagnostic Accuracy of 256-row Computed Tomographic Angiography for Detection of Obstructive Coronary Artery Disease Using Invasive Quantitative Coronary Angiography as Reference Standard. American Journal of Cardiology, 2013, 111, 510-515.	0.7	17
455	How to Manage Hyperglycemia in an Acute Coronary Syndrome Patient. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 93-103.	0.4	4
456	Antiplatelet Therapy After Coronary Stenting. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 1-10.	0.4	15
457	Cardiorenal Syndrome in Critical Care: The Acute Cardiorenal and Renocardiac Syndromes. Advances in Chronic Kidney Disease, 2013, 20, 56-66.	0.6	59
458	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	1.7	28
459	Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology. Cardiovascular Drugs and Therapy, 2013, 27, 239-245.	1.3	16
460	Medical emergencies: atrial fibrillation and myocardial infarction. Anaesthesia, 2013, 68, 84-101.	1.8	8

#	Article	IF	CITATIONS
461	Uric acid for diagnosis and risk stratification in suspected myocardial infarction. European Journal of Clinical Investigation, 2013, 43, 174-182.	1.7	7
462	Population Trends in Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 1222-1230.	1.2	144
463	Monitoring of Antiplatelet Therapy. , 2013, , 603-633.		2
464	Atherothrombosis and Coronary Artery Disease. , 2013, , 653-668.		0
465	Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty. CardioVascular and Interventional Radiology, 2013, 36, 1493-1499.	0.9	24
466	Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opinion on Emerging Drugs, 2013, 18, 9-23.	1.0	16
467	Imaging Strategies for Acute Chest Pain in the Emergency Department. American Journal of Roentgenology, 2013, 200, W26-W38.	1.0	15
468	Improving the use of direct oral anticoagulants in atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 288-294.	1.0	11
469	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy, 2013, 11, 307-317.	0.6	6
470	Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet) Tj ETQq1 1 0.784 American Journal of Cardiology, 2013, 112, 162-168.	1314 rgBT 0.7	/Qyerlock 10
471	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2013, 11, 447-462.	0.6	18
472	Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. Haemophilia, 2013, 19, 370-377.	1.0	27
473	Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Current Medical Research and Opinion, 2013, 29, 569-577.	0.9	18
474	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. European Journal of Clinical Pharmacology, 2013, 69, 1617-1633.	0.8	81
475	The Indication for Antithrombotic Primary Prophylaxis and Treatment in Case of Thromboembolic Complications in Patients with Metabolic Syndrome. , 2013 , , $155-164$.		0
476	Mimics of acute coronary syndrome on MDCT. Emergency Radiology, 2013, 20, 235-242.	1.0	3
477	Novel anti-thrombotic therapy in acute coronary syndromes. Cor Et Vasa, 2013, 55, e117-e125.	0.1	0
478	Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2013, 11, 437-445.	0.6	1

#	Article	IF	Citations
479	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. Future Cardiology, 2013, 9, 371-385.	0.5	0
480	Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score. Cardiology, 2013, 124, 97-104.	0.6	14
482	Will future troponin measurement overrule the ECG as the primary diagnostic tool in patients with acute coronary syndrome?. Journal of Electrocardiology, 2013, 46, 312-317.	0.4	10
483	Effectiveness of Percutaneous Coronary Intervention within 12 Hours to 28 Days of ST-Elevation Myocardial Infarction in a Real-World Chinese Population. PLoS ONE, 2013, 8, e58382.	1.1	8
484	Anaemia to predict outcome in patients with acute coronary syndromes. Archives of Cardiovascular Diseases, 2013, 106, 357-365.	0.7	29
485	Causes of Death in Patients ≥75 Years of Age With Non–ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2013, 112, 1-7.	0.7	34
486	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. Canadian Journal of Cardiology, 2013, 29, S60-S70.	0.8	11
487	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	0.8	113
488	Rosuvastatin calcium in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2013, 14, 1215-1227.	0.9	17
489	MicroRNAs as Biomarkers for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 458-470.	1.1	24
491	Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and Haemostasis, 2013, 110, 5-10.	1.8	15
492	EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome) Tj ETQq1	1 0.784314 1.2	rgBT /Overlo
494	Cystatin C– and Creatinine-Based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study. Clinical Chemistry, 2013, 59, 1369-1375.	1.5	19
495	Exactitud pronóstica de las escalas GRACE y TIMI en pacientes llevados a intervencionismo percutáneo por sÃndrome coronario agudo sin elevación del ST. Revista Colombiana De Cardiologia, 2013, 20, 130-135.	0.1	2
498	Factors Influencing the 99th Percentile of Cardiac Troponin I Evaluated in Community-Dwelling Individuals at 70 and 75 Years of Age. Clinical Chemistry, 2013, 59, 1068-1073.	1.5	51
499	Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis, 2013, 11, 316-329.	1.9	61
500	MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart, 2013, 99, 388-395.	1.2	40
501	The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism. Thrombosis Research, 2013, 132, 543-547.	0.8	9

#	Article	IF	CITATIONS
502	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. European Heart Journal, 2013, 34, 1630-1635.	1.0	47
503	Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction. European Heart Journal, 2013, 34, 3171-3172.	1.0	0
504	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
505	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes., 2013,, CD002130.		34
506	Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. European Heart Journal, 2013, 34, 345-353.	1.0	224
508	Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. Journal of Drug Assessment, 2013, 2, 30-39.	1.1	34
509	Nursing assessment of the causes of chest pain. British Journal of Cardiac Nursing, 2013, 8, 483-488.	0.0	4
510	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. European Heart Journal, 2013, 34, 872-874.	1.0	2
511	Optimal duration of clopidogrel therapy: the shorter the longer?. European Heart Journal, 2013, 34, 1705-1707.	1.0	2
512	Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries. European Heart Journal, 2013, 34, 1972-1981.	1.0	21
513	Is myocardial revascularization safe in trainees' hands?. European Heart Journal, 2013, 34, 2859-2861.	1.0	5
514	Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. European Heart Journal, 2013, 34, 3198-3205.	1.0	109
515	Adherence to dual antiplatelet therapy: can we do better?. Expert Review of Cardiovascular Therapy, 2013, 11, 1417-1424.	0.6	3
516	Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open, 2013, 3, e003044.	0.8	24
517	ESC Core Curriculum for the General Cardiologist (2013). European Heart Journal, 2013, 34, 2381-2411.	1.0	75
518	Dipyridamole coronary flow reserve stratifies prognosis in acute coronary syndrome patients without left anterior descending disease. European Heart Journal Cardiovascular Imaging, 2013, 14, 858-864.	0.5	12
520	International comparison of treatment and long-term outcomes for acute myocardial infarction in the elderly: Minneapolis/St. Paul, MN, USA and Goteborg, Sweden. European Heart Journal, 2013, 34, 3191-3197.	1.0	32
523	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. Future Cardiology, 2013, 9, 759-762.	0.5	0

#	Article	IF	Citations
524	Use of Antiplatelet Agents in Patients With Atherosclerotic Disease. Postgraduate Medicine, 2013, 125, 19-30.	0.9	2
525	Acute Aortic Syndromes. Hospital Practice (1995), 2013, 41, 34-44.	0.5	1
526	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of Medical Economics, 2013, 16, 510-521.	1.0	15
527	Cost–effectiveness of ticagrelor in acute coronary syndromes. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 9-18.	0.7	3
528	P2Y12 Inhibition in Patients with NSTEMI â€" Can Later Be Better?. New England Journal of Medicine, 2013, 369, 1056-1057.	13.9	2
529	Association between Angiotensin II Type 1 Receptor Polymorphism and Sudden Cardiac Death in Myocardial Infarction. Disease Markers, 2013, 35, 287-293.	0.6	7
530	The analgesic effect of oxygen during percutaneous coronary intervention (the OXYPAIN Trial). Acute Cardiac Care, 2013, 15, 63-68.	0.2	14
531	A 70 year old woman with chest pain after a stressful event. BMJ, The, 2013, 347, f5583-f5583.	3.0	2
532	Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?. Cardiology Research and Practice, 2013, 2013, 1-15.	0.5	6
533	Obstructive Sleep Apnea and Coronary Artery Disease: From Pathophysiology to Clinical Implications. Pulmonary Medicine, 2013, 2013, 1-9.	0.5	39
534	Troponin T elevation in amyotrophic lateral sclerosis without cardiac damage. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 75-77.	1.1	7
535	Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals?. BMJ, The, 2013, 346, f3197-f3197.	3.0	194
536	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. European Heart Journal, 2013, 34, 1670-1680.	1.0	175
537	Diagnostic performance of rising, falling, or rising and falling kinetic changes of high-sensitivity cardiac troponin T in an unselected emergency department population. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 314-322.	0.4	27
538	Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 359-370.	0.4	74
539	Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003–2009: National Institute for Cardiovascular Outcomes Research (NICOR). Heart, 2013, 99, 35-40.	1.2	66
540	Vasodilatory Capacity of the Coronary Microcirculation is Preserved in Selected Patients With Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 231-236.	1.4	103
541	Optimal In-Hospital and Discharge Medical Therapy in Acute Coronary Syndromes in Kerala. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 436-443.	0.9	41

#	ARTICLE	IF	CITATIONS
543	Long-term Prognostic Value of Dysglycemia and Ischemic Vascular Disease Beyond Abnormal Troponin Levels in Patients Presenting Acute Atrial Fibrillation. Critical Pathways in Cardiology, 2013, 12, 14-23.	0.2	1
544	Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes. Journal of Cardiovascular Medicine, 2013, 14, 807-814.	0.6	24
545	Use of high-sensitivity troponin for the diagnosis of acute myocardial infarction. Coronary Artery Disease, 2013, 24, 710-712.	0.3	5
546	Will high-sensitivity troponin assays lead to improved outcomes in patients with acute coronary syndrome?. Coronary Artery Disease, 2013, 24, 713-715.	0.3	3
547	Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 246-255.	0.4	9
548	Response to Letters Regarding Article, "High-Sensitivity Cardiac Troponin in the Distinction of Acute Myocardial Infarction From Acute Cardiac Noncoronary Artery Disease― Circulation, 2013, 127, e355-6.	1.6	2
549	Detection and management of asymptomatic myocardial injury after noncardiac surgery. European Journal of Preventive Cardiology, 2013, 20, 918-921.	0.8	3
550	Monocyte heterogeneity in myocardial infarction with and without ST elevation and its association with angiographic findings. Coronary Artery Disease, 2013, 24, 404-411.	0.3	7
551	The role of clopidogrel in the management of ischemic heart disease. Current Opinion in Cardiology, 2013, 28, 381-388.	0.8	0
552	Should \hat{l}^2 -blockers still be routine after myocardial infarction?. Current Opinion in Cardiology, 2013, 28, 399-404.	0.8	8
553	Coronary Wave Energy. Circulation: Cardiovascular Interventions, 2013, 6, 166-175.	1.4	27
554	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation, 2013, 128, 2192-2201.	1.6	268
555	Diagnosis and Management of Ischemic Heart Disease. Seminars in Thrombosis and Hemostasis, 2013, 39, 202-213.	1.5	59
556	High incidence of acute coronary occlusion in patients without protocol positive ST segment elevation referred to an open access primary angioplasty programme. Postgraduate Medical Journal, 2013, 89, 376-381.	0.9	6
557	Antithrombotic Therapy During and After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation. Circulation, 2013, 128, 2058-2061.	1.6	4
558	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. Postgraduate Medicine, 2013, 125, 91-102.	0.9	41
559	Additional diagnostic and prognostic value of copeptin ultra-sensitive for diagnosis of Clinical Chemistry and Laboratory Medicine, 2013, 51, 1307-19.	1.4	27
560	Acute chest pain and acute coronary syndromes. InnovAiT, 2013, 6, 362-370.	0.0	0

#	Article	IF	CITATIONS
561	Kongressbericht: POCT-Symposium der Arbeitsgruppe POCT der DGKL, 7. und 8. November 2012, Klinikum rechts der Isar der TU M \tilde{A}^1 /4nchen/Congress report: POCT-symposium of the working group POCT of the DGKL, 7 \hat{a} \in 8 November 2012, Klinikum rechts der Isar of the TU Munich. Laboratoriums Medizin, 2013, 37, .	0.1	0
562	Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1125-33.	1.4	16
563	Evaluating new diagnostic and prognostic biomarkers in cardiovascular disease. Heart, 2013, 99, 757-758.	1.2	7
564	The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiology Journal, 2013, 20, 577-582.	0.5	41
565	Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 299-308.	0.9	63
566	Bilateral internal mammary artery bypass grafting: long-term clinical benefits in a series of 1000 patients. Heart, 2013, 99, 854-859.	1.2	15
568	Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1727-37.	1.4	41
569	Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry®–GWTG™. Clinical Chemistry, 2013, 59, 1205-1214.	1.5	18
570	Evidenced-Based Antithrombotic Therapy for Acute Coronary Syndromes. Diabetes, 2013, 62, 709-710.	0.3	0
571	Genetic and nongenetic factors influencing the response to clopidogrel. Journal of Cardiovascular Medicine, 2013, 14, S1-S7.	0.6	19
572	Characteristics of new P2Y12 inhibitors. Journal of Cardiovascular Medicine, 2013, 14, S22-S30.	0.6	4
573	Impact of Chronic Kidney Disease in Early Invasive versus Early Conservative Revascularization Strategies in Non-ST-Segment Elevation Acute Coronary Syndromes: A Population-Based Study from NHIRD of Taiwan. Nephron Clinical Practice, 2013, 124, 38-46.	2.3	5
574	Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone. Circulation: Cardiovascular Interventions, 2013, 6, 567-574.	1.4	42
575	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation, 2013, 128, 823-833.	1.6	130
576	Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 289-294.	0.9	2
577	Novel Antiplatelet Agent Use for Acute Coronary Syndrome in the Emergency Department: A Review. Cardiology Research and Practice, 2013, 2013, 1-8.	0.5	5
578	Letter by Lippi and Cervellin Regarding Article, "High-sensitivity Cardiac Troponin in the Distinction of Acute Myocardial Infarction From Acute Cardiac Noncoronary Artery Disease†Circulation, 2013, 127, e353.	1.6	4
579	Guidelines-based treatment of anaemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 35-43.	0.4	11

#	Article	IF	CITATIONS
580	Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1217-1226.	1.4	48
581	The CYP2C19*1/*2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. Cardiology Research and Practice, 2013, 2013, 1-7.	0.5	11
582	Women's experiences of sexual health after firstâ€time myocardial infarction. Journal of Clinical Nursing, 2013, 22, 3532-3540.	1.4	20
583	Incremental Prognostic Value of Biomarkers beyond the GRACE (Global Registry of Acute Coronary) Tj ETQq1 1 0. Clinical Chemistry, 2013, 59, 1497-1505.	784314 rg 1.5	gBT /Overloo 50
584	Long-Term Effect of Dual Antiplatelet Treatment after Off-Pump Coronary Artery Bypass Grafting. Journal of Cardiac Surgery, 2013, 28, 366-372.	0.3	18
585	A cohort study of chest pain patients discharged from the emergency department for early outpatient treadmill exercise stress testing. EMA - Emergency Medicine Australasia, 2013, 25, n/a-n/a.	0.5	5
586	Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 708-715.	0.9	100
587	Timing of angiography in non-ST elevation myocardial infarction. Heart, 2013, 99, 1867-1873.	1.2	6
588	Cangrelor: a review on pharmacology and clinical trial development. Expert Review of Cardiovascular Therapy, 2013, 11, 1279-1291.	0.6	52
589	Nurses' role in the acute management of patients with non-ST-segment elevation acute coronary syndromes: an integrative review. European Journal of Cardiovascular Nursing, 2013, 12, 293-301.	0.4	20
590	Acute coronary syndrome: optimising management through risk assessment. Clinical Medicine, 2013, 13, 602-606.	0.8	8
591	Intensive-Dose Atorvastatin Regimen Halts Progression of Atherosclerotic Plaques in New-onset Unstable Angina With Borderline Vulnerable Plaque Lesions. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 119-125.	1.0	10
592	Advances in Myocardial Infarction Management. , 2013, , .		0
593	Cardiac MRI of acute coronary syndrome. Future Cardiology, 2013, 9, 351-370.	0.5	2
594	Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation Journal, 2013, 77, 2088-2096.	0.7	6
595	Is heparin sufficient in non-ST-elevation acute coronary syndrome percutaneous coronary intervention?. Interventional Cardiology, 2013, 5, 623-625.	0.0	O
596	Timing of Invasive Strategy in Diabetic and Non-Diabetic Patients with Non-St-Segment Elevation Acute Coronary Syndrome. Folia Medica, 2013, 55, 16-25.	0.2	3
597	Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. Thrombosis and Haemostasis, 2013, 110, 340-348.	1.8	7

#	Article	IF	CITATIONS
598	Reducing short-stay hospital admissions by ruling out non-ST elevation myocardial infarction and estimating coronary artery disease likelihood on an emergency department observation ward. BMJ Quality Improvement Reports, 2013, 2, u201080.w695.	0.8	3
599	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). Thrombosis and Haemostasis, 2013, 109, 769-786.	1.8	154
600	Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thrombosis and Haemostasis, 2013, 110, 11-13.	1.8	12
601	C-reactive protein and its role in coronary artery disease. British Journal of Cardiac Nursing, 2013, 8, 193-197.	0.0	0
602	Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Thrombosis and Haemostasis, 2013, 109, 846-853.	1.8	119
603	Clinical importance of antiplatelet drugs in cardiovascular diseases. Clinical Hemorheology and Microcirculation, 2013, 53, 81-96.	0.9	24
604	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. Critical Care, 2013, 17, R53.	2.5	62
605	The bivalirudin paradox. Journal of Cardiovascular Medicine, 2013, 14, 334-341.	0.6	9
606	Targeting Myocardial Metabolism for the Treatment of Stable Angina. Current Pharmaceutical Design, 2013, 19, 1587-1592.	0.9	3
607	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes., 2013,, CD002130.		12
608	Research Highlights: Highlights from the latest articles in antithrombotic and myocardial revascularization strategies in coronary artery disease. Interventional Cardiology, 2013, 5, 253-255.	0.0	0
609	Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection. Journal of Cardiovascular Pharmacology, 2013, 61, 250-257.	0.8	15
610	Correlation between serum high-mobility group box-1 levels and high-sensitivity C-reactive protein and troponin I in patients with coronary artery disease. Experimental and Therapeutic Medicine, 2013, 6, 121-124.	0.8	24
611	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and Haemostasis, 2013, 110, 1223-1231.	1.8	12
612	High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACSI. Thrombosis and Haemostasis, 2013, 109, 799-807.	1.8	5
613	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thrombosis and Haemostasis, 2013, 110, 1055-1064.	1.8	10
614	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Thrombosis and Haemostasis, 2013, 110, 777-784.	1.8	7
616	Cardiac Troponin T. Circulation Journal, 2013, 77, 1653-1661.	0.7	50

#	Article	IF	CITATIONS
617	State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Archives of Medical Science, 2013, 6, 1019-1027.	0.4	25
618	Percutaneous coronary intervention in treatment of multivessel coronary artery disease in patients with non-ST-segment elevation acute coronary syndrome. Postepy W Kardiologii Interwencyjnej, 2013, 2, 136-145.	0.1	9
620	THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY. Rational Pharmacotherapy in Cardiology, 2013, 9, 701-707.	0.3	8
621	s New oral anticoagulants – will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome?. Postepy W Kardiologii Interwencyjnej, 2013, 4, 348-352.	0.1	1
622	Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats. Thrombosis and Haemostasis, 2013, 109, 560-563.	1.8	7
623	Postoperative Care and Follow-Up After Coronary Stenting. Deutsches Ärzteblatt International, 2013, 110, 72-81; quiz 82.	0.6	14
624	Influence of the Timing of Percutaneous Coronary Intervention on Clinical Outcomes in Non-ST-Elevation Myocardial Infarction. Korean Circulation Journal, 2013, 43, 725.	0.7	21
625	New Horizons of Acute Myocardial Infarction: From the Korea Acute Myocardial Infarction Registry. Journal of Korean Medical Science, 2013, 28, 173.	1.1	18
627	The Impact of Vascular Access for In-Hospital Major Bleeding in Patients with Acute Coronary Syndrome at Moderate- to Very High-Bleeding Risk. Journal of Korean Medical Science, 2013, 28, 1307.	1.1	7
628	Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients. PLoS ONE, 2013, 8, e53860.	1.1	41
629	Basal and Ischemia-Induced Transcardiac Troponin Release into the Coronary Circulation in Patients with Suspected Coronary Artery Disease. PLoS ONE, 2013, 8, e60163.	1.1	11
630	Platelet function testing and prediction of procedural bleeding risk. Thrombosis and Haemostasis, 2013, 109, 817-824.	1.8	30
631	Effect of Early Statin Treatment in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction. Korean Circulation Journal, 2013, 43, 100.	0.7	26
632	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clinical Pharmacology: Advances and Applications, 2013, 5, 67.	0.8	4
633	CXCR4 positive and angiogenic monocytes in myocardial infarction. Thrombosis and Haemostasis, 2013, 109, 255-262.	1.8	21
635	How to Use High-Sensitivity Cardiac Troponins in Acute Cardiac Care?. Conference Papers in Medicine, 2013, 2013, 1-4.	0.6	1
636	Low-Dose Acetylsalicylic Acid Use and the Risk of Upper Gastrointestinal Bleeding: A Meta-Analysis of Randomized Clinical Trials and Observational Studies. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 159-167.	1.8	25
637	Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine. Conference Papers in Medicine, 2013, 2013, 1-4.	0.6	0

#	Article	IF	CITATIONS
638	The Perioperative Management of Treatment With Anticoagulants and Platelet Aggregation Inhibitors. Deutsches Ärzteblatt International, 2013, 110, 525-32.	0.6	58
639	Cardiovascular Biomarkers in ACS: State of the Art 2012. Conference Papers in Medicine, 2013, 2013, 1-5.	0.6	0
640	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thrombosis and Haemostasis, 2013, 109, 517-254.	1.8	12
641	Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Emergency Care Journal, 2013, 9, 14.	0.2	0
642	Ischemic heart disease in the emergency room: state of the art, innovation and research. Emergency Care Journal, 2013, 9, 7.	0.2	2
644	Is There Still a Role for Glycoprotein Ilb/IIIa Antagonists in Acute Coronary Syndromes?. Cardiology Research, 2013, 4, 1-7.	0.5	5
645	PHARMACOTHERAPY AND OUTCOMES OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION – GENDER DIFFERENCES IN REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 650-654.	0.3	0
646	THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 404-408.	0.3	3
647	Newer non-vitamin K-antagonist direct oral anticoagulants in acute coronary syndromes. Italian Journal of Medicine, 2013, 7, 22.	0.2	0
649	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular Health and Risk Management, 2014, 10, 101.	1.0	21
650	Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vascular Health and Risk Management, 2014, 10, 291.	1.0	1
651	Plaque Quantification by Coronary CT and Intravascular Ultrasound Identifies a Low CT Density Core as a Marker of Plaque Instability in Acute Coronary Syndromes. International Heart Journal, 2014, 55, 22-28.	0.5	35
652	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	1.1	28
654	Inpatient Coronary Angiography and Revascularisation following Non-ST-Elevation Acute Coronary Syndrome in Patients with Renal Impairment: A Cohort Study Using the Myocardial Ischaemia National Audit Project. PLoS ONE, 2014, 9, e99925.	1.1	14
655	Polymorphism of 9p21.3 Locus Is Associated with 5-Year Survival in High-Risk Patients with Myocardial Infarction. PLoS ONE, 2014, 9, e104635.	1.1	12
656	Likelihood and Predictors of ST-Elevation in Patients Hospitalized for Myocardial Infarction. PLoS ONE, 2014, 9, e108440.	1.1	5
657	Diagnosis of Non-ST-Elevation Acute Coronary Syndrome by the Measurement of Heart-Type Fatty Acid Binding Protein in Serum: A Prospective Case Control Study. Journal of Biomarkers, 2014, 2014, 1-9.	1.0	1
658	Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clinical Pharmacology: Advances and Applications, 2014, 6, 51.	0.8	56

#	Article	IF	CITATIONS
659	Lipoprotein-Associated Phospholipase A ₂ Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome. Yonsei Medical Journal, 2014, 55, 1507.	0.9	17
660	Thrombosis ââ,¬â€œ Besieged but Poorly Understood. Frontiers in Cardiovascular Medicine, 2014, 1, 4.	1.1	0
661	There's life in the old dog yet: Clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thrombosis and Haemostasis, 2014, 112, 10-11.	1.8	2
662	Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. Thrombosis and Haemostasis, 2014, 112, 12-14.	1.8	4
663	Southern Saskatchewan Ticagrelor Registry experience. Patient Preference and Adherence, 2014, 8, 1427.	0.8	10
664	Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention. Korean Circulation Journal, 2014, 44, 82.	0.7	10
665	Pigment Epithelial-Derived Factor and Acute Coronary Syndrome: A Novel Protective Biomarker but Not for Routine Clinical Use at Present. Cardiology, 2014, 127, 28-30.	0.6	1
666	Suboptimal use of gastroprotective medication in elderly antiplatelet users. Bratislava Medical Journal, 2014, 115, 643-648.	0.4	0
667	Prognostic Value of Peripheral Arterial Tonometry in Patients with Coronary Artery Disease and a High Cardiovascular Risk Profile. Journal of Atherosclerosis and Thrombosis, 2014, 21, 230-238.	0.9	8
668	Modern challenges in acute coronary syndrome. Medical Journal of Australia, 2014, 201, S86-7.	0.8	0
669	Optimising pharmacotherapy for secondary prevention of nonâ€invasively managed acute coronary syndrome. Medical Journal of Australia, 2014, 201, S100-5.	0.8	1
670	A pilot study on the application of the current European guidelines for the management of acute coronary syndrome without elevation of ST segment (NSTEMI) in the Emergency Department setting in the Italian region Lazio. Monaldi Archives for Chest Disease, 2014, 82, 175-82.	0.3	1
671	Decline in Serum Cholinesterase Activities Predicts 2-Year Major Adverse Cardiac Events. Molecular Medicine, 2014, 20, 38-45.	1.9	39
672	P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes. Hamostaseologie, 2014, 34, 20-28.	0.9	4
673	11.2 Koronare Herzkrankheit. , 2014, , .		0
674	The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study. Emergency Medicine Journal, 2014, 31, 286-291.	0.4	14
675	Acute Coronary Syndromes. Circulation Research, 2014, 114, 1847-1851.	2.0	35
676	Novel biomarkers in the diagnosis of acute coronary syndromes: the role of circulating miRNAs. Expert Review of Cardiovascular Therapy, 2014, 12, 1119-1124.	0.6	11

#	Article	IF	CITATIONS
678	Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 18-27.	0.4	98
680	Added value of H-FABP as a plasma biomarker for the early evaluation of suspected acute coronary syndrome. Clinical Lipidology, 2014, 9, 205-220.	0.4	19
681	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.0	2
682	Circulating chemokines in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and cardiovascular outcome. Biomarkers, 2014, 19, 611-619.	0.9	5
684	Relationship between coronary artery disease and C-reactive protein levels in NSTEMI patients with renal dysfunction: a retrospective study. BMC Nephrology, 2014, 15, 152.	0.8	12
685	Surgical revascularisation of the acute coronary artery syndrome. Expert Review of Cardiovascular Therapy, 2014, 12, 393-402.	0.6	5
686	The history of the cardiac emergency room, and the patient's history. Netherlands Heart Journal, 2014, 22, 550-551.	0.3	0
687	Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation. BMJ Open, 2014, 4, e004449.	0.8	11
688	Understanding factors that influence the use of risk scoring instruments in the management of patients with unstable angina or non-ST-elevation myocardial infarction in the Netherlands: a qualitative study of health care practitioners' perceptions. BMC Health Services Research, 2014, 14, 418.	0.9	12
689	The region makes the difference: disparities in management of acute myocardial infarction within Switzerland. European Journal of Preventive Cardiology, 2014, 21, 541-548.	0.8	16
692	Cardiac biomarkers for infarct diagnosis and early exclusion of acute coronary syndrome. Herz, 2014, 39, 668-671.	0.4	3
693	Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. European Heart Journal Cardiovascular Imaging, 2014, 15, 917-925.	0.5	15
694	Platelet RNA as a novel biomarker for the response to antiplatelet therapy. Future Cardiology, 2014, 10, 9-12.	0.5	5
695	Role of the ECG in initial acute coronary syndrome triage: primary PCI regardless presence of ST elevation. Netherlands Heart Journal, 2014, 22, 484-490.	0.3	21
696	An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research and Opinion, 2014, 30, 2193-2205.	0.9	7
697	Genetics of Response to Antiplatelet Therapy. Progress in Molecular Biology and Translational Science, 2014, 124, 123-153.	0.9	10
698	Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction. Anatolian Journal of Cardiology, 2014, 14, 515-518.	0.4	2
699	Mean platelet volume may not be related to clopidogrel resistance in patients with acute coronary syndrome. Anatolian Journal of Cardiology, 2014, 14, 405-407.	0.4	1

#	Article	IF	CITATIONS
700	The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. Platelets, 2014, 25, 268-273.	1.1	5
701	Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction. BioMed Research International, 2014, 2014, 1-8.	0.9	7
702	Perioperative Levels and Changes of High-Sensitivity Troponin T Are Associated With Cardiovascular Events in Vascular Surgery Patients*. Critical Care Medicine, 2014, 42, 1498-1506.	0.4	60
703	Stress hyperglycemia in acute myocardial infarction. Vojnosanitetski Pregled, 2014, 71, 858-869.	0.1	11
704	Direct oral anticoagulants: integration into clinical practice. Postgraduate Medical Journal, 2014, 90, 529-539.	0.9	15
705	Cardiac Regeneration and Cellular Therapy: Is there a Benefit of Exercise?. International Journal of Sports Medicine, 2014, 35, 181-190.	0.8	7
706	Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug. European Journal of Cardio-thoracic Surgery, 2014, 46, 198-205.	0.6	19
707	Clopidogrel responsiveness in chronic kidney disease patients with acute coronary syndrome. Dicle Medical Journal, 2014, 41, 34-40.	0.2	O
708	Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy. Platelets, 2014, 25, 439-446.	1.1	4
709	High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. European Heart Journal, 2014, 35, 1817-1824.	1.0	37
710	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. European Heart Journal, 2014, 35, 3250-3257.	1.0	81
711	Does a 'direct' transfer protocol reduce time to coronary angiography for patients with non-ST-elevation acute coronary syndromes? A prospective observational study. BMJ Open, 2014, 4, e005525-e005525.	0.8	6
712	Interaction between access choice and pharmacotherapy for coronary intervention: the results of a UK survey. Open Heart, 2014, 1, e000094.	0.9	6
713	Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?. Open Heart, 2014, 1, e000123.	0.9	8
714	New-onset atrial fibrillation during acute coronary syndromes: Predictors and prognosis. Revista Portuguesa De Cardiologia, 2014, 33, 281-287.	0.2	26
715	Management of heart failure complicating acute coronary syndromes in Montenegro and Serbia. European Heart Journal Supplements, 2014, 16, A61-A66.	0.0	1
720	Prognostic implications of non-culprit plaques in acute coronary syndrome: non-invasive assessment with coronary CT angiography. European Heart Journal Cardiovascular Imaging, 2014, 15, 1231-1237.	0.5	26
721	The use of reperfusion and revascularization procedures in acute coronary syndrome in Portugal: A systematic review. Revista Portuguesa De Cardiologia, 2014, 33, 707-715.	0.2	0

#	Article	IF	CITATIONS
725	Increased Content of Resistin in Epicardial Adipose Tissue of Patients with Advanced Coronary Atherosclerosis and History of Myocardial Infarction. Thoracic and Cardiovascular Surgeon, 2014, 62, 554-560.	0.4	17
726	Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovascular Research, 2014, 102, 429-435.	1.8	45
727	PK evaluation of fondaparinux sodium for the treatment of thrombosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 269-277.	1.5	2
728	The economic impact of acute coronary syndrome on length of stay: an analysis using the Healthcare Cost and Utilization Project (HCUP) databases. Journal of Medical Economics, 2014, 17, 191-197.	1.0	25
729	SÃndromes coronárias agudas sem supradesnivelamentoâ€ST nos octogenários: aplicabilidade dos scores GRACE e CRUSADE. Revista Portuguesa De Cardiologia, 2014, 33, 617-627.	0.2	22
730	Percutaneous coronary intervention in women: should management be different?. Interventional Cardiology, 2014, 6, 527-536.	0.0	1
731	Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. BMJ Open, 2014, 4, e004052.	0.8	19
732	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209-215.	1.0	224
733	Sex differences in the non-invasive risk stratification and prognosis after myocardial infarction. Journal of Electrocardiology, 2014, 47, 874-880.	0.4	11
734	Cochrane Corner: Qual é o impacto clÃnico da administração de oxigénio em doentes com enfarte agudo do miocárdio? Avaliação de uma revisão sistemática Cochrane. Revista Portuguesa De Cardiologia, 2014, 33, 641-643.	0.2	3
735	Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes) Tj ETQq	0 0.0 rgBT	Overlock 10
736	Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. European Heart Journal, 2014, 35, 365-375.	1.0	83
737	Bivalirudin Use and Oneâ€Month Outcome in the Context of Contemporary Antiplatelet Treatment: Insights from the Greek Antiplatelet Registry. Cardiovascular Therapeutics, 2014, 32, 120-126.	1.1	3
739	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current Medical Research and Opinion, 2014, 30, 813-828.	0.9	28
740	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ, The, 2014, 347, g6269-g6269.	3.0	75
741	The value of clinical and laboratory diagnostics for chest pain patients at the emergency department. Clinical Chemistry and Laboratory Medicine, 2014, 52, 259-66.	1.4	5
743	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
744	Prasugrel in NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2572-2574.	1.2	1

#	Article	IF	Citations
745	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2563-2571.	1.2	64
746	Update on the efficacy of statin treatment in acute coronary syndromes. European Journal of Clinical Investigation, 2014, 44, 501-515.	1.7	20
747	Rivaroxaban in acute coronary syndromes – is it prime time?. Expert Review of Cardiovascular Therapy, 2014, 12, 649-658.	0.6	1
748	Diagnosing myocardial ischaemia. Trends in Urology & Men's Health, 2014, 5, 21-25.	0.2	1
749	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	0.6	23
750	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	6.1	267
751	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert Review of Cardiovascular Therapy, 2014, 12, 963-976.	0.6	0
752	Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study. European Journal of Preventive Cardiology, 2014, 21, 1401-1408.	0.8	23
753	Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2014, 12, 463-474.	0.6	2
7 54	Switching Patients from Clopidogrel to Prasugrel in Acute Coronary Syndrome: Impact of the Clopidogrel Loading Dose on Platelet Reactivity. Journal of Interventional Cardiology, 2014, 27, 365-372.	0.5	10
755	Emergency Medical Equipment On Board German Airliners. Journal of Travel Medicine, 2014, 21, 318-323.	1.4	34
7 56	Rapid rule out of myocardial infarction with the use of copeptin as a biomarker for cardiac injury. Internal Medicine Journal, 2014, 44, 921-924.	0.5	9
757	Borderline trend towards longâ€ŧerm mortality benefit from drug eluting stents implantation in STâ€elevation myocardial infarction patients in Poland—data from NRDES registry. Catheterization and Cardiovascular Interventions, 2014, 83, 436-442.	0.7	13
758	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. Clinical Cardiology, 2014, 37, 178-187.	0.7	20
759	Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. Fundamental and Clinical Pharmacology, 2014, 28, 353-363.	1.0	11
760	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: Results from the ATHEROREMO-IVUS study. International Journal of Cardiology, 2014, 177, 847-853.	0.8	16
761	Right here waiting?. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 3099-3100.	0.4	0
762	Educational inequalities in 28 day and 1-year mortality after hospitalisation for incident acute myocardial infarction — A nationwide cohort study. International Journal of Cardiology, 2014, 177, 874-880.	0.8	21

#	ARTICLE	IF	CITATIONS
763	Early invasive versus selectively invasive strategy in patients with non Tâ€segment elevation acute coronary syndrome: Impact of age. Catheterization and Cardiovascular Interventions, 2014, 83, 686-701.	0.7	34
764	Heparin versus placebo for non-ST elevation acute coronary syndromes. The Cochrane Library, 2021, 2021, CD003462.	1.5	5
765	Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. Diabetes/Metabolism Research and Reviews, 2014, 30, 297-304.	1.7	6
767	Prospectively ECG-triggered high-pitch coronary angiography with third-generation dual-source CT at 70 kVp tube voltage: Feasibility, image quality, radiation dose, and effect of iterative reconstruction. Journal of Cardiovascular Computed Tomography, 2014, 8, 418-425.	0.7	81
768	The Impact of Modern Noninvasive Cardiac Imaging on Coronary Intervention Rates. Journal of Interventional Cardiology, 2014, 27, 50-57.	0.5	3
769	Pretreatment with P2Y ₁₂ Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. Circulation, 2014, 130, 1904-1914.	1.6	36
770	Pretreatment With P2Y ₁₂ Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Is Clinically Justified. Circulation, 2014, 130, 1891-1903.	1.6	39
771	Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelorâ€. European Journal of Cardio-thoracic Surgery, 2014, 46, 699-705.	0.6	41
772	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	1.0	1,253
773	Impact of Acute Hyperglycemia on Myocardial Infarct Size, Area at Risk, and Salvage in Patients With STEMI and the Association With Exenatide Treatment: Results From a Randomized Study. Diabetes, 2014, 63, 2474-2485.	0.3	59
774	Very early screening for sleep-disordered breathing in acute coronary syndrome in patients without acute heart failure. Sleep Medicine, 2014, 15, 1539-1546.	0.8	14
775	Duraci \tilde{A}^3 n del tratamiento antiagregante en el s \tilde{A} ndrome coronario agudo. Revista Espanola De Cardiologia Suplementos, 2014, 14, 32-37.	0.2	1
776	The use of reperfusion and revascularization procedures in acute coronary syndrome in Portugal: A systematic review. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 707-715.	0.2	0
780	Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome. Cardiology, 2014, 129, 224-232.	0.6	8
781	Routine thienopyridine pretreatment for acute coronary syndrome without ST elevation. BMJ, The, 2014, 347, g6282-g6282.	3.0	4
782	Improving risk stratification in non-ST-segment elevation myocardial infarction with combined assessment of GRACE and CRUSADE risk scores. Archives of Cardiovascular Diseases, 2014, 107, 681-689.	0.7	6
783	Near-Infrared Spectroscopy Predicts Cardiovascular Outcome in Patients WithÂCoronary Artery Disease. Journal of the American College of Cardiology, 2014, 64, 2510-2518.	1.2	162
784	Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction. Heart, 2014, 100, 652-657.	1.2	29

#	Article	IF	CITATIONS
786	Management of Patients With <scp>ST</scp> â€Segment Elevation or Non– <scp>ST</scp> â€Segment Elevation Acute Coronary Syndromes in Cardiac Rehabilitation Centers. Clinical Cardiology, 2014, 37, 213-221.	0.7	14
789	2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Circulation, 2014, 130, e344-426.	1.6	928
790	Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 268-274.	0.4	7
791	Impact of -455G/A Polymorphism of the \hat{l}^2 -Fibrinogen Gene on Platelet Aggregation in Patients With Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 238-243.	0.7	0
792	Serum Tryptase: A New Biomarker in Patients with Acute Coronary Syndrome?. International Archives of Allergy and Immunology, 2014, 164, 97-105.	0.9	21
793	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. Diabetes and Vascular Disease Research, 2014, 11, 395-409.	0.9	15
794	Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2014, 7, 104-112.	1.4	29
797	Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2078-2085.	1.1	115
798	Age-dependent improvements in survival after hospitalisation with acute myocardial infarction: an analysis of the Myocardial Ischemia National Audit Project (MINAP). Age and Ageing, 2014, 43, 779-785.	0.7	34
799	The value of signs, symptoms and plasma heart-type fatty acid-binding protein (H-FABP) in evaluating patients presenting with symptoms possibly matching acute coronary syndrome: background and methods of a diagnostic study in primary care. BMC Family Practice, 2014, 15, 203.	2.9	16
800	The effect of a regional care model on cardiac catheterization rates in patients with Acute Coronary Syndromes. BMC Health Services Research, 2014, 14, 550.	0.9	2
801	Repeat prescriptions of guideline-based secondary prevention medication in patients with type 2 diabetes and previous myocardial infarction in Dutch primary care. Family Practice, 2014, 31, 688-693.	0.8	15
802	Recent advances in antithrombotic treatment for acute coronary syndromes. Expert Review of Clinical Pharmacology, 2014, 7, 507-521.	1.3	5
803	Clinical Features and Prognosis of Patients With Coronary Spasm–Induced Non–STâ€Segment Elevation Acute Coronary Syndrome. Journal of the American Heart Association, 2014, 3, e000795.	1.6	49
804	Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?. Current Opinion in Cardiology, 2014, 29, 301-306.	0.8	1
805	Understanding beta-blockers. Nursing, 2014, 44, 55-59.	0.2	2
806	Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management. Journal of Cardiovascular Pharmacology, 2014, 63, 339-350.	0.8	64
807	Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open, 2014, 4, e004425.	0.8	273

#	Article	IF	CITATIONS
808	Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. Scandinavian Cardiovascular Journal, 2014, 48, 138-147.	0.4	4
809	Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. Journal of Cardiovascular Pharmacology, 2014, 64, 38-40.	0.8	0
810	High-sensitivity troponin T as a diagnostic tool for acute coronary syndrome in the real world. European Journal of Emergency Medicine, 2014, 21, 181-188.	0.5	9
811	2014 ESC/ESA Guidelines on non-cardiac surgery. European Journal of Anaesthesiology, 2014, 31, 517-573.	0.7	335
812	Ultrasound Molecular Imaging of Transient Acute Myocardial Ischemia With a Clinically Translatable P- and E-Selectin Targeted Contrast Agent. Investigative Radiology, 2014, 49, 224-235.	3.5	27
813	Large Animal Models for Left Ventricular Assist Device Research and Development. ASAIO Journal, 2014, 60, 2-8.	0.9	34
814	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 516-523.	0.7	4
815	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Current Opinion in Cardiology, 2014, 29, 553-563.	0.8	8
816	Inverse Correlation Between Cardiac Injury and Cardiac Anxiety. Journal of Cardiovascular Nursing, 2014, 29, 448-453.	0.6	9
817	Hypertension and Atrial Fibrillation. Critical Pathways in Cardiology, 2014, 13, 141-146.	0.2	3
818	The utility of copeptin in the emergency department for non-ST-elevation myocardial infarction rapid rule out. European Journal of Emergency Medicine, 2014, 21, 220-229.	0.5	20
819	The effects of CES1A2 A(â^'816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenetics and Genomics, 2014, 24, 204-210.	0.7	37
820	Aspirin and Proton Pump Inhibitor Combination Therapy for Prevention of Cardiovascular Disease and Barrett's Esophagus. Postgraduate Medicine, 2014, 126, 87-96.	0.9	6
821	Management of Acute Coronary Syndrome in the Hospital: A Focus on ACCF/AHA Guideline Updates to Oral Antiplatelet Therapy. Hospital Practice (1995), 2014, 42, 33-47.	0.5	5
822	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	0.9	173
823	The Incidence of Kidney Injury for Patients Treated With a Highâ€Potency Versus Moderateâ€Potency Statin Regimen After an Acute Coronary Syndrome. Journal of the American Heart Association, 2014, 3, e000784.	1.6	12
824	Anticoagulation during and after acute coronary syndrome. Hamostaseologie, 2014, 34, 72-77.	0.9	10
825	Spontaneous Coronary Artery Dissection. Circulation: Cardiovascular Interventions, 2014, 7, 777-786.	1.4	488

#	Article	IF	CITATIONS
826	2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 2014, 130, 2354-2394.	1.6	938
827	The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current Medical Research and Opinion, 2014, 30, 2151-2167.	0.9	2
828	Seeking actual benchmarks in acute coronary syndromes for European countries: insights from the EURHOBOP registry. Heart, 2014, 100, 1147-1148.	1.2	2
829	Type-II Myocardial Infarction – Patient Characteristics, Management and Outcomes. PLoS ONE, 2014, 9, e84285.	1.1	122
833	But he has no chest pain Oxford Medical Case Reports, 2014, 2014, 129-131.	0.2	0
834	Impact of D-Dimers on the Differential Diagnosis of Acute Chest Pain: Current Aspects besides the Widely Known. Clinical Medicine Insights: Cardiology, 2014, 8s2, CMC.S15948.	0.6	8
835	A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease. Avicenna, 2014, 2014, .	1.2	0
836	Evaluation of serum thiol levels in patients with non ST elevation acute coronary syndrome. Journal of Experimental and Clinical Medicine (Turkey), 2014, 30, 295-299.	0.1	3
837	Clinical Pathways for Non-ST Elevation Acute Coronary Syndrome in Oman: An Oman Heart Association Protocol for Hospital Quality Improvement Initiative. Oman Medical Journal, 2014, 29, 8-11.	0.3	0
838	Do we really need high-sensitive troponin immunoassays in the emergency department? Definitely, yes!. Clinical Chemistry and Laboratory Medicine, 2014, 52, 201-4.	1.4	8
839	Biomarkers in the prediction and management of acute coronary syndromes: current perspectives. Research Reports in Clinical Cardiology, 0, , 21.	0.2	3
840	Dipyridamole Stress Echocardiography Does Not Trigger Release of Highly-Sensitive Troponin I and T. Journal of Medical Biochemistry, 2014, 33, 376-383.	0.7	1
841	Antiplatelet effect of acetylsalicylic acid, metamizole and their combination - in vitro and in vivo comparisons. Clinical Hemorheology and Microcirculation, 2014, 56, 1-12.	0.9	10
842	Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes. Cardiology in Review, 2014, 22, 313-318.	0.6	6
843	Effects of a standard operating procedure on prehospital emergency care of patients presenting with symptoms of the acute coronary syndrome. European Journal of Emergency Medicine, 2014, 21, 236-239.	0.5	9
844	Atorvastatin preconditioning improves the forward blood flow in the noâ€reflow rats. Fundamental and Clinical Pharmacology, 2014, 28, 42-52.	1.0	5
845	Genetics of platelet inhibitor treatment. British Journal of Clinical Pharmacology, 2014, 77, 642-653.	1.1	37
846	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. Annales De Cardiologie Et D'Angeiologie, 2014, 63, 222-227.	0.3	7

#	ARTICLE	IF	CITATIONS
847	How to Avoid Inappropriate Interpretation and Reporting of Troponin Results Measured With High-Sensitivity Assays in the Emergency Department. American Journal of Cardiology, 2014, 113, 904-905.	0.7	1
848	We Have Compelling Indications forÂAntihypertensives, But Not for Parenteral Anticoagulants. Journal of Emergency Medicine, 2014, 46, e101-e102.	0.3	0
849	CHA2DS2-VASc scoring system as an initial method for screening high-risk patients in acute myocardial infarction. International Journal of Cardiology, 2014, 174, 777-780.	0.8	7
850	Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiographyâ€"The LURIC study. International Journal of Cardiology, 2014, 174, 96-105.	0.8	32
851	The severity of coronary artery disease and reversible ischemia revealed by N-terminal pro-brain natriuretic peptide in patients with unstable angina and preserved left ventricular function. Peptides, 2014, 52, 143-148.	1.2	2
852	¿Qué deben saber los cardiólogos sobre la copeptina?. Revista Espanola De Cardiologia, 2014, 67, 519-521.	0.6	7
854	Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thrombosis Research, 2014, 134, 105-110.	0.8	28
855	Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity. International Journal of Cardiology, 2014, 174, 874-876.	0.8	15
856	Acute coronary syndrome with a totally occluded culprit artery: relation of the ST injury vector with ST-elevation and non-ST elevation ECGs. Journal of Electrocardiology, 2014, 47, 183-190.	0.4	19
857	A Randomized Controlled Trial to Reduce Prehospital Delay Time inÂPatients With Acute Coronary Syndrome (ACS). Journal of Emergency Medicine, 2014, 46, 495-506.	0.3	55
858	Directionality and proportionality of the ST and ventricular gradient difference vectors during acute ischemia. Journal of Electrocardiology, 2014, 47, 500-504.	0.4	7
859	Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. International Journal of Cardiology, 2014, 174, 524-529.	0.8	9
860	Reply. American Journal of Cardiology, 2014, 113, 905.	0.7	0
861	Papel de los nuevos anticoagulantes orales en la cardiopatÃa isquémica. Cardiocore, 2014, 49, 95-98.	0.0	1
862	Association of hyperuricemia with cardiac events in patients with atrial fibrillation. International Journal of Cardiology, 2014, 172, 464-465.	0.8	9
863	Direct Oral Anticoagulants in Acute Coronary Syndrome. Seminars in Hematology, 2014, 51, 147-151.	1.8	4
864	Non–ST Segment Elevation Acute Coronary Syndrome. , 2014, , 124-134.		0
865	Predictors of highâ€risk angiographic findings in patients with nonâ€STâ€segment elevation acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2014, 83, 677-683.	0.7	20

#	Article	IF	CITATIONS
866	Coronary Microvascular Dysfunction. , 2014, , .		423
867	High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures. CardioVascular and Interventional Radiology, 2014, 37, 559-571.	0.9	6
868	Balancing Ischemic Efficacy and Bleeding Risk in the Upstream Management of Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 57-68.	0.6	0
869	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	0.6	1
870	Reported underuse of risk scores in patients with acute coronary syndromes without persistent ST elevations in clinical practice: results of a survey of the ALKK study group. Clinical Research in Cardiology, 2014, 103, 83-84.	1.5	4
871	Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. Clinical Research in Cardiology, 2014, 103, 11-19.	1.5	56
872	Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry. Clinical Research in Cardiology, 2014, 103, 29-40.	1.5	28
873	Current discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) study. Netherlands Heart Journal, 2014, 22, 20-27.	0.3	9
874	Hemoglobin A1c is a better predictor of prognosis following the non-ST elevation acute coronary syndrome than fasting and admission glucose. Wiener Klinische Wochenschrift, 2014, 126, 156-162.	1.0	6
875	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of Thrombosis and Thrombolysis, 2014, 38, 137-149.	1.0	25
876	Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. European Journal of Clinical Pharmacology, 2014, 70, 429-436.	0.8	36
877	Impact of Hypertension History on Short and Long-Term Prognosis in Patients with Acute Myocardial Infarction Treated with Percutaneous Angioplasty: Comparison Between STEMI and NSTEMI. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 37-43.	1.0	15
878	Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2014, 38, 65-72.	1.0	69
879	Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. Stroke, 2014, 45, 492-503.	1.0	63
880	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. Atherosclerosis, 2014, 233, 568-578.	0.4	21
881	"Troponin Elevation in Coronary Ischemia and Necrosis― Current Atherosclerosis Reports, 2014, 16, 396.	2.0	9
882	Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Internal and Emergency Medicine, 2014, 9, 225-235.	1.0	14
886	Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. Drugs, 2014, 74, 451-464.	4.9	9

#	Article	IF	CITATIONS
887	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. Journal of Cardiovascular Translational Research, 2014, 7, 64-71.	1.1	2
888	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. Journal of Cardiovascular Translational Research. 2014. 7, 91-100.	1.1	84
889	Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2014, 7, 19-28.	1.1	17
890	Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. Journal of Cardiovascular Translational Research, 2014, 7, 82-90.	1.1	5
891	Initial Experience With Ticagrelor in Patients With Critical Limb Ischemia and High On-Clopidogrel Platelet Reactivity Undergoing Complex Peripheral Endovascular Procedures. CardioVascular and Interventional Radiology, 2014, 37, 1450-1457.	0.9	16
892	A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Pharmacoeconomics, 2014, 32, 377-393.	1.7	5
894	Proton pump inhibitors and clopidogrel: an association to avoid?. Internal and Emergency Medicine, 2014, 9, 11-22.	1.0	13
895	Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Netherlands Heart Journal, 2014, 22, 55-61.	0.3	9
896	Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. British Journal of Anaesthesia, 2014, 112, 570-575.	1.5	64
897	Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. Journal of the American College of Cardiology, 2014, 63, 1061-1070.	1.2	81
898	Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100, ii1-ii67.	1.2	441
900	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. European Heart Journal, 2014, 35, 1760-1768.	1.0	25
901	Acute coronary syndrome management in older adults: guidelines, temporal changes and challenges. Age and Ageing, 2014, 43, 450-455.	0.7	49
902	Comparison of high sensitivity troponin T and I assays in the diagnosis of non-ST elevation acute myocardial infarction in emergency patients with chest pain. Clinical Biochemistry, 2014, 47, 321-326.	0.8	32
903	The use of platelet function testing in PCI and CABG patients. Blood Reviews, 2014, 28, 109-121.	2.8	17
904	Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome. American Journal of Cardiology, 2014, 113, 888-896.	0.7	9
905	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2014, 7, 113-124.	1.4	67
906	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. Circulation, 2014, 129, 293-303.	1.6	100

#	Article	IF	CITATIONS
907	Complementary, Alternative, and Putative Nontroponin Biomarkers of Acute Coronary Syndrome: New Resources for Future Risk Assessment Calculators. Revista Espanola De Cardiologia (English Ed), 2014, 67, 312-320.	0.4	1
908	Triple Antithrombotic Therapy: Risky but Sometimes Necessary. Revista Espanola De Cardiologia (English Ed), 2014, 67, 171-175.	0.4	3
909	Safety of a rapid diagnostic protocol with accelerated stress testing. American Journal of Emergency Medicine, 2014, 32, 124-128.	0.7	4
910	DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. American Heart Journal, 2014, 167, 322-328.	1.2	56
911	Prognostic performance of high-sensitivity cardiac troponin T kinetic changes adjusted for elevated admission values and the GRACE score in an unselected emergency department population. Clinica Chimica Acta, 2014, 435, 29-35.	0.5	4
912	Early diastolic strain rate in relation to systolic and diastolic function and prognosis in acute myocardial infarction: a two-dimensional speckle-tracking study. European Heart Journal, 2014, 35, 648-656.	1.0	102
913	GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	0.6	15
915	Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. European Heart Journal, 2014, 35, 2303-2311.	1.0	166
916	Multimarker approach in risk stratification of patients with acute coronary syndromes: Towards the ideal stratification. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 137-138.	0.2	0
917	Is it possible to separate ischemic and bleeding risk in patients with non-ST segment elevation acute coronary syndromes?. International Journal of Cardiology, 2014, 171, 448-450.	0.8	13
918	New antiplatelet agents in the treatment of acute coronary syndromes. Archives of Cardiovascular Diseases, 2014, 107, 178-187.	0.7	14
919	Impact of patient-related and treatment-related factors on in-hospital mortality of patients with ST-elevation myocardial infarction: Data of Russian Acute Coronary Syndrome Registry. Cor Et Vasa, 2014, 56, e217-e227.	0.1	4
920	Expression of leukocyte adhesion-related glycosyltransferase genes in acute coronary syndrome patients. Inflammation Research, 2014, 63, 629-636.	1.6	4
921	International differences in acute coronary syndrome patients' baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Heart, 2014, 100, 1201-1207.	1.2	56
922	Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 293-298.	0.7	32
923	The Current and Future Role of the Novel Oral Anticoagulantsâ€"Indications Beyond Atrial Fibrillation. Heart Lung and Circulation, 2014, 23, 2-9.	0.2	6
924	Causes of Early Stent Thrombosis in Patients Presenting With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 2510-2520.	1.2	102
925	Weekend compared with weekday presentation does not affect outcomes of patients presenting with non-ST elevation acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 99-104.	0.4	7

#	Article	IF	CITATIONS
926	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	1.0	171
928	Non-acute myocardial infarction-related causes of elevated high-sensitive troponin T in the emergency room: a cross-sectional analysis. Internal and Emergency Medicine, 2014, 9, 335-339.	1.0	55
929	Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary) Tj ETQq0 0 0 rgBT /0	Ovenlock 1	0∄f 50 657
930	Biomarkers and acute coronary syndromes: an update. European Heart Journal, 2014, 35, 552-556.	1.0	171
931	Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. European Heart Journal, 2014, 35, 969-978.	1.0	46
932	Evolving pattern of platelet P2Y $<$ sub $>$ 12 $<$ /sub $>$ inhibition in patients with acute coronary syndromes. Platelets, 2014, 25, 416-422.	1.1	13
933	Effect of an Optimized Treatment With Insulin on Platelet Reactivity After Discharge in Patients With an Acute Coronary Syndrome and Hyperglycemia. Revista Espanola De Cardiologia (English Ed), 2014, 67, 22-27.	0.4	1
934	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
935	Triple antithrombotic therapy in cardiac patients: more questions than answers. European Heart Journal, 2014, 35, 216-223.	1.0	32
936	Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. European Heart Journal, 2014, 35, 207-208.	1.0	1
937	Acute myocardial infarction associated with blood transfusion: Case report and literature review. Transfusion and Apheresis Science, 2014, 50, 260-262.	0.5	9
938	Presentation and Revascularization Patterns of Patients Admitted for Acute Coronary Syndromes in France Between 2004 and 2008 (from the National Observational Study of Diagnostic and) Tj ETQq1 1 0.784314	r gB 7T/Ove	erlook 10 Tf
939	First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. Platelets, 2014, 25, 636-638.	1.1	12
940	Role and timing of coronary intervention in non-ST-elevation myocardial infarction. Interventional Cardiology, 2014, 6, 183-198.	0.0	0
941	Cochrane Corner: What is the clinical impact of oxygen therapy for acute myocardial infarction? Evaluation of a Cochrane systematic review. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 641-643.	0.2	2
942	Non-ST-elevation acute coronary syndromes in octogenarians: Applicability of the GRACE and CRUSADE scores. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 617-627.	0.2	21
943	Increased risk and increased reward in coronary intervention in older patients with acute coronary syndrome. Heart, 2014, 100, 1483-1484.	1.2	2
944	Early systolic lengthening may identify minimal myocardial damage in patients with non-ST-elevation acute coronary syndrome. European Heart Journal Cardiovascular Imaging, 2014, 15, 1152-1160.	0.5	28

#	Article	IF	CITATIONS
945	Networks for improving care in patients with acute coronary syndrome: A framework. Acute Cardiac Care, 2014, 16, 41-48.	0.2	2
946	Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature. International Journal of Cardiology, 2014, 177, 461-466.	0.8	9
947	Accuracy of multidetector computed tomography for detection of coronary artery stenosis in acute coronary syndrome compared with stable coronary disease: A CORE64 multicenter trial substudy. International Journal of Cardiology, 2014, 177, 385-391.	0.8	14
948	Permanent polymer of drug eluting stents increases eosinophil cationic protein levels following percutaneous coronary intervention independently of C-reactive protein. Atherosclerosis, 2014, 237, 816-820.	0.4	3
949	Strategia di gestione delle sindromi coronariche acute. EMC - Urgenze, 2014, 18, 1-14.	0.0	0
950	Association Between Inflammatory Markers, Hemostatic Markers, and Traditional Risk Factors on Coronary Artery Spasm in Patients with Normal Coronary Angiography. Journal of Interventional Cardiology, 2014, 27, 29-35.	0.5	19
951	Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. Current Cardiology Reports, 2014, 16, 548.	1.3	2
952	Pharmacogenomics of oral antiplatelet drugs. Pharmacogenomics, 2014, 15, 509-528.	0.6	10
954	Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, 124, 689-699.	0.6	28
955	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American Heart Journal, 2014, 168, 622-631.e2.	1.2	16
956	Performance of the GRACE scores in a New Zealand acute coronary syndrome cohort. Heart, 2014, 100, 1960-1966.	1.2	20
957	Another Biomarker for Risk Assessment in Acute Myocardial Infarction?â^—. Journal of the American College of Cardiology, 2014, 64, 1708-1710.	1.2	1
958	Is Cocaine-associated Acute Myocardial Infarction the Same as Myocardial Infarction Associated With Recent Cocaine Consumption? Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 965-966.	0.4	0
959	Is Cocaine-associated Acute Myocardial Infarction the Same as Myocardial Infarction Associated With Recent Cocaine Consumption?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 964-965.	0.4	0
960	Temporal characteristics of decisions in hospital encounters: A threshold for shared decision making? A qualitative study. Patient Education and Counseling, 2014, 97, 216-222.	1.0	23
961	Le syndrome coronarien aigu des populations fragiles. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2014, 2014, 31-36.	0.0	0
962	High-sensitivity versus conventional troponin for management and prognosis assessment of patients with acute chest pain. Heart, 2014, 100, 1591-1596.	1.2	41
963	Dual antiplatelet treatment after stenting: is longer better?. Lancet, The, 2014, 384, 1553-1555.	6.3	7

#	Article	IF	CITATIONS
964	Introducing a chest pain pathway in the emergency department to improve quality of care for patients with possible cardiac chest pain. BMJ Quality Improvement Reports, 2014, 3, u204753.w2003.	0.8	4
965	Carotid intima media thickness and coronary atherosclerosis linkage in symptomatic intermediate risk patients evaluated by coronary computed tomography angiography. International Journal of Cardiology, 2014, 176, 988-993.	0.8	38
966	Managing Antithrombotic Therapy in Patients With Both Atrial Fibrillation and Coronary Heart Disease. Clinical Therapeutics, 2014, 36, 1176-1181.	1.1	8
968	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2014, 371, 1016-1027.	13.9	538
969	Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide?. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 237-245.	0.4	13
970	Excess mortality in women compared to men after PCI in STEMI: An analysis of 11,931 patients during 2000–2009. International Journal of Cardiology, 2014, 176, 456-463.	0.8	48
971	The "Dualâ€Pathway―Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2―TIMI 51 Trial. Cardiovascular Therapeutics, 2014, 32, 224-232.	1.1	10
972	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: Insights from the French FAST-MI program over 15 years. International Journal of Cardiology, 2014, 177, 281-286.	0.8	33
973	2014 AHA/ACC Guideline for theÂManagement of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Journal of the American College of Cardiology, 2014, 64, 2645-2687.	1.2	424
974	Update on Perioperative Myocardial Injury and Infarction. Advances in Anesthesia, 2014, 32, 23-36.	0.5	O
976	Relationship Between Red Cell Distribution Width and the GRACE Risk Score With In-Hospital Death in Patients With Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 577-582.	0.7	9
977	¿Los trastornos por cocaÃna asociados al infarto agudo de miocardio son lo mismo que el infarto de miocardio asociado al consumo reciente de cocaÃna?. Revista Espanola De Cardiologia, 2014, 67, 964-965.	0.6	0
978	Switching from ticagrelor to prasugrel: A warning. International Journal of Cardiology, 2014, 176, 1089-1090.	0.8	2
979	Type I collagen degradation during tissue repair: Comparison of mechanisms following fracture and acute coronary syndromes. Bone, 2014, 69, 1-5.	1.4	5
980	Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants. Journal of Clinical Pharmacology, 2014, 54, 843-849.	1.0	7
981	Effect of Aspiration Thrombectomy on Microvascular Obstruction in NSTEMI Patients. Journal of the American College of Cardiology, 2014, 64, 1117-1124.	1.2	75
982	Ischaemic heart disease: management of non-ST-elevation acute coronary syndrome. Medicine, 2014, 42, 505-511.	0.2	0
983	CT coronary angiography in the investigation of chest pain — Beyond coronary artery atherosclerosis; A pictorial review. International Journal of Cardiology, 2014, 176, 618-629.	0.8	10

#	Article	IF	CITATIONS
985	Reply. Journal of the American College of Cardiology, 2014, 64, 334.	1.2	0
986	The Importance of Genotype Variation Beyond Different Antiplatelet Therapy in Nonresponder Patients. Journal of the American College of Cardiology, 2014, 64, 333-334.	1.2	0
987	New-onset atrial fibrillation during acute coronary syndromes: Predictors and prognosis. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 281-287.	0.2	9
988	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2014, 3, 317-331.	0.2	O
989	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 246-256.	0.4	13
990	Validación del puntaje "crusade―en colombia: una cruzada para disminuir el riesgo de sangrado asociado con la intervención del sÃndrome coronario agudo sin elevación del st. Revista Colombiana De Cardiologia, 2014, 21, 24-26.	0.1	0
991	Re: Review article: Elevated troponin: Diagnostic gold or fool's gold?. EMA - Emergency Medicine Australasia, 2014, 26, 414-414.	0.5	0
992	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
993	Biochemical markers in the diagnosis of myocardial infarction. Cor Et Vasa, 2014, 56, e304-e310.	0.1	9
994	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. International Journal of Cardiology, 2014, 176, 300-302.	0.8	4
995	Post-resuscitation electrocardiograms, acute coronary findings and in-hospital prognosis of survivors of out-of-hospital cardiac arrest. Resuscitation, 2014, 85, 1245-1250.	1.3	46
996	Why some patients with acute coronary syndrome hospitalised in a university tertiary centre do not undergo coronary angiography? Results from the AHEAD ACS registry. Cor Et Vasa, 2014, 56, e369-e375.	0.1	1
997	Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 701-707.	0.9	28
998	The quality of laboratory aspects of troponin testing in clinical practice guidelines and consensus documents needs to be improved. Clinica Chimica Acta, 2014, 437, 58-61.	0.5	8
999	Detection of Myocardial Injury by CMR After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2014, 64, 349-357.	1.2	46
1000	Antiplatelet therapy for secondary prevention of coronary artery disease. Heart, 2014, 100, 1750-1756.	1.2	33
1001	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet, The, 2014, 384, 1577-1585.	6.3	269
1002	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart, 2014, 100, 1625-1635.	1.2	27

#	Article	IF	CITATIONS
1003	Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. Pharmacoeconomics, 2014, 32, 1063-1078.	1.7	1
1004	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European Heart Journal, 2014, 35, 1949-1956.	1.0	110
1005	Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?. European Heart Journal, 2014, 35, 2055-2057.	1.0	22
1006	Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (from the Milestone Registry). American Journal of Cardiology, 2014, 114, 979-987.	0.7	16
1008	Measuring hospital performance in the management of acute coronary syndromes. Netherlands Heart Journal, 2014, 22, 344-345.	0.3	1
1009	Monitoring guideline adherence in the management of acute coronary syndrome in hospitals: design of a multicentre study. Netherlands Heart Journal, 2014, 22, 346-353.	0.3	12
1010	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, The, 2014, 384, 1187-1195.	6.3	123
1013	Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 1208-1217.	13.9	905
1014	Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Journal of Thrombosis and Haemostasis, 2014, 12, 1850-1860.	1.9	9
1015	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. European Journal of Clinical Pharmacology, 2014, 70, 1049-1057.	0.8	9
1016	Impact of an invasive strategy on 5 years outcome in men and women with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2014, 168, 522-529.	1.2	16
1017	syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society	1.0	490
1018	(HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal. 2014, 35, 3155-3179. Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines?. Heart, 2014, 100, 1565-1566.	1.2	1
1019	2014 AHA/ACC Guideline for theÂManagement of Patients WithÂNon–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64, e139-e228.	1.2	2,746
1021	Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry. Clinical Research in Cardiology, 2014, 103, 655-64.	1.5	16
1022	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clinical Research in Cardiology, 2014, 103, 855-886.	1.5	19
1024	Anemia in the general population: prevalence, clinical correlates and prognostic impact. European Journal of Epidemiology, 2014, 29, 489-498.	2.5	69
1025	Effectiveness of a pilot intervention to reduce abciximab-related bleeding in patients with acute coronary syndromes. International Journal of Clinical Pharmacy, 2014, 36, 821-826.	1.0	3

#	Article	IF	Citations
1026	Coronary CT angiography for patients with suspected coronary artery disease. Heart, 2014, 100, 976-984.	1.2	9
1027	High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. Thrombosis Research, 2014, 133, 257-264.	0.8	10
1028	Classification and definition of acute coronary syndromes - A time for change?. Cor Et Vasa, 2014, 56, e279-e284.	0.1	1
1029	Utility of C-terminal Proendothelin in the Early Diagnosis and Risk Stratification of Patients With Suspected Acute Myocardial Infarction. Canadian Journal of Cardiology, 2014, 30, 195-203.	0.8	9
1030	Reperfusion Strategies in Acute Coronary Syndromes. Circulation Research, 2014, 114, 1918-1928.	2.0	82
1031	Clinical Outcomes with \hat{l}^2 -Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. American Journal of Medicine, 2014, 127, 939-953.	0.6	224
1032	In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 313-316.	0.4	30
1033	At-admission risk stratification for in-hospital life-threatening ventricular arrhythmias and death in non-ST elevation myocardial infarction patients. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 304-312.	0.4	11
1034	Aspirin Therapy in Primary Cardiovascular Disease Prevention. Journal of the American College of Cardiology, 2014, 64, 319-327.	1.2	150
1035	Monocyte subsets and monocyte-platelet aggregates in patients with unstable angina. Journal of Thrombosis and Thrombolysis, 2014, 38, 439-446.	1.0	28
1036	Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. Journal of Thrombosis and Thrombolysis, 2014, 38, 459-469.	1.0	18
1037	Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. International Journal of Hematology, 2014, 99, 263-271.	0.7	14
1038	Evaluating the Optimal Timing of Revascularisation in Patients with Transient ST-Segment Elevation Myocardial Infarction: Rationale and Design of the TRANSIENT Trial. Journal of Cardiovascular Translational Research, 2014, 7, 590-596.	1.1	10
1042	Prognosis of Troponin-Positive Patients with Non-Obstructive Coronary Artery Disease. Cardiology and Therapy, 2014, 3, 41-51.	1.1	2
1043	Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. Drugs, 2014, 74, 971-980.	4.9	46
1044	Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome. BMC Cardiovascular Disorders, 2014, 14, 21.	0.7	2
1045	Impact of impaired glomerular filtration rate and revascularization strategy on one-year cardiovascular events in acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. BMC Nephrology, 2014, 15, 66.	0.8	11
1046	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105

#	ARTICLE	IF	Citations
1047	Resistance to antiplatelet drugs: what progress has been made?. Expert Opinion on Pharmacotherapy, 2014, 15, 2553-2564.	0.9	30
1048	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	1.2	34
1051	Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects. Clinical Therapeutics, 2014, 36, 1217-1225.	1.1	7
1052	The need to identify new P2Y12 receptor inhibitors in the management and prevention of arterial thrombosis. Thrombosis Research, 2014, 134, 533-534.	0.8	2
1053	The incidence and outcomes of acute coronary syndromes in a central European country: Results of the CZECH-2 registry. International Journal of Cardiology, 2014, 173, 204-208.	0.8	29
1054	The ECG in the setting of myocardial infarction, characterized by cardiac magnetic resonance imaging. Journal of Electrocardiology, 2014, 47, 129-130.	0.4	2
1055	Tratamiento antiagregante plaquetario personalizado. Revista Espanola De Cardiologia, 2014, 67, 480-487.	0.6	10
1057	Abordagem multimarcadores na estratificação de risco dos doentes com sÃndrome coronária aguda: rumo à estratificação ideal. Revista Portuguesa De Cardiologia, 2014, 33, 137-138.	0.2	0
1058	Comparative effectiveness of upstream glycoprotein Ilb/Illa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal, 2014, 167, 43-50.	1.2	7
1059	Cardiac biomarkers in Takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 174, 798-801.	0.8	17
1061	Effects of Angiotensin-Converting Enzyme Inhibitors and Beta Blockers on Clinical Outcomes in Patients With and Without Coronary Artery Obstructions at Angiography (from a Register-Based) Tj ETQq0 0 0 r	gB ō./ Overl	oc#ko1.0 Tf 50
1062	Clinical impact of early intervention in octogenarians with non-ST-elevation myocardial infarction. International Journal of Cardiology, 2014, 172, 462-464.	0.8	7
1063	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. International Journal of Cardiology Heart & Vessels, 2014, 4, 188-192.	0.5	4
1065	Gestione delle sindromi coronariche acute nelle prime 48Âore. EMC - Anestesia-Rianimazione, 2014, 19, 1-13.	0.1	0
1066	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. American Heart Journal, 2014, 167, 840-845.	1.2	16
1067	How to manage prasugrel and ticagrelor in daily practice. European Journal of Internal Medicine, 2014, 25, 213-220.	1.0	11
1069	Biomarcadores no troponÃnicos, complementarios, alternativos y presuntos, para el sÃndrome coronario agudo: nuevos recursos para los futuros instrumentos de cálculo del riesgo. Revista Espanola De Cardiologia, 2014, 67, 312-320.	0.6	8
1070	Pretreatment with P2Y12 inhibitors in non–ST-segment elevation acute coronary syndrome: Time to revise the guidelines?. Archives of Cardiovascular Diseases, 2014, 107, 1-3.	0.7	1

#	Article	IF	CITATIONS
1072	Impact of Patients' Arrival Time on the Care and In-Hospital Mortality in Patients With Non-ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 262-269.	0.7	8
1073	Imaging QRS complex and ST segment in myocardial infarction. Journal of Electrocardiology, 2014, 47, 438-447.	0.4	7
1075	Early Assessment of Strain Echocardiography Can Accurately Exclude Significant Coronary Artery Stenosis in Suspected Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American Society of Echocardiography, 2014, 27, 512-519.	1.2	71
1076	Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglucémicos con sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2014, 67, 22-27.	0.6	11
1077	Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia. Cor Et Vasa, 2014, 56, e325-e332.	0.1	2
1078	Amsterdam Investigatora (Initiated Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of colonary lesions in consecutive all-comers: Rationale	1.2	41
1079	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). American Journal of Cardiology, 2014, 113, 936-944.	0.7	17
1080	Prevalence, clinical profile and 3-year survival of acute myocardial infarction patients with and without obstructive coronary lesions: The FAST-MI 2005 registry. International Journal of Cardiology, 2014, 172, e247-e249.	0.8	9
1081	Tratamiento antitromb \tilde{A}^3 tico combinado triple: arriesgado pero a \hat{A} veces necesario. Revista Espanola De Cardiologia, 2014, 67, 171-175.	0.6	8
1082	A Randomized Controlled Trial of Platelet Activity Before and After Cessation of Clopidogrel Therapy in Patients With Stable Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 63, 233-239.	1.2	16
1083	Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. Journal of the Formosan Medical Association, 2014, 113, 794-802.	0.8	49
1084	What Cardiologists Should Know About Copeptin. Revista Espanola De Cardiologia (English Ed), 2014, 67, 519-521.	0.4	6
1085	Personalized Antiplatelet Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 480-487.	0.4	1
1086	Risk of intracranial injury after minor head trauma in patients with pre-injury use of clopidogrel. American Journal of Emergency Medicine, 2014, 32, 71-74.	0.7	13
1087	The magnitude of percutaneous coronary intervention treatment in high and medium risk non-ST elevation acute coronary syndrome. Cor Et Vasa, 2014, 56, e333-e336.	0.1	0
1088	Dehydration and serum hyperosmolarity as new predictors of mortality after acute coronary syndrome. International Journal of Cardiology, 2014, 172, e472-e474.	0.8	9
1089	The WOEST study: Critical considerations and applicability. Cor Et Vasa, 2014, 56, e254-e258.	0.1	9
1090	Letter to the Editor. Journal of Electrocardiology, 2014, 47, 130.	0.4	O

#	Article	IF	CITATIONS
1091	Expeditious exclusion of acute coronary syndrome diagnosis by combined measurements of copeptin, high-sensitivity troponin, and GRACE score. American Journal of Emergency Medicine, 2014, 32, 293-296.	0.7	18
1092	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	2.0	79
1093	Nonantithrombotic Medical Options in Acute Coronary Syndromes. Circulation Research, 2014, 114, 1944-1958.	2.0	15
1094	The relationship between high-sensitive troponin T, neutrophil lymphocyte ratio and SYNTAX Score. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 108-115.	0.6	39
1095	Use of Observed Within-Person Variation of Cardiac Troponin in Emergency Department Patients for Determination of Biological Variation and Percentage and Absolute Reference Change Values. Clinical Chemistry, 2014, 60, 848-854.	1.5	30
1096	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 2014, 35, 1510-1514.	1.0	70
1097	The Year in Cardiology 2013: acute coronary syndromes. European Heart Journal, 2014, 35, 349-352.	1.0	1
1098	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	0.8	44
1099	Improving knowledge, attitudes and beliefs about acute coronary syndrome through an individualized educational intervention: A randomized controlled trial. Patient Education and Counseling, 2014, 96, 179-187.	1.0	34
1100	Antiplatelet therapy in patients after an acute coronary syndrome. Comparison of the Czech and Slovak Republics. Results of the ATHRO registry. Cor Et Vasa, 2014, 56, e320-e324.	0.1	1
1101	Predictors of long-term outcome of percutaneous coronary intervention in octogenarians with acute coronary syndrome. International Journal of Cardiology Heart & Vessels, 2014, 4, 138-144.	0.5	1
1102	Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300.	0.4	34
1103	Impact of Trimetazidine on Incidence of Myocardial Injury and Contrast-Induced Nephropathy in Diabetic Patients With Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 389-394.	0.7	30
1104	Dual antiplatelet therapy in patients with acute coronary syndrome treated by surgical revascularization. Cor Et Vasa, 2014, 56, e246-e253.	0.1	0
1105	Treatment of Acute Coronary Syndromes in the Elderly and in Patients With Comorbidities. Revista Espanola De Cardiologia (English Ed), 2014, 67, 564-573.	0.4	18
1106	Prognosis and disease progression in patients under 50 years old undergoing PCI: The CRAGS (Coronary aRtery diseAse in younG adultS) study. Atherosclerosis, 2014, 235, 483-487.	0.4	19
1107	Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention. American Heart Journal, 2014, 168, 346-353.e3.	1.2	5
1108	Does optical coherence tomography optimize results of stenting? Rationale and study design. American Heart Journal, 2014, 168, 175-181.e2.	1.2	26

#	Article	IF	CITATIONS
1109	Use of the CRUSADE Bleeding Risk Score in the Prediction of Major Bleeding for Patients with Acute Coronary Syndrome Receiving Enoxaparin in Thailand. Heart Lung and Circulation, 2014, 23, 1051-1058.	0.2	7
1112	Effect of Renin-Angiotensin System Inhibitors on Long-Term Survival in Patients Treated With Beta Blockers and Antiplatelet Agents After Acute Myocardial Infarction (from the MONICA/KORA) Tj ETQq1 1 0.7843	314orgBT /	Ovarsock 10 I
1113	A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs. Journal of Thrombosis and Thrombolysis, 2014, 37, 102-106.	1.0	5
1114	Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 111, 103-110.	1.8	7
1115	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	1.8	41
1116	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 112, 311-322.	1.8	7
1117	Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thrombosis and Haemostasis, 2014, 112, 266-272.	1.8	26
1118	A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 112, 290-299.	1.8	24
1119	Clinical disease registries in acute myocardial infarction. World Journal of Cardiology, 2014, 6, 415.	0.5	11
1120	Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World Journal of Cardiology, 2014, 6, 1140.	0.5	13
1121	New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) III: Endogenous Inhibition of Angiotensin Converting Enzyme (ACE) Provides Protection against Cardiovascular Diseases. PLoS ONE, 2014, 9, e93719.	1.1	15
1123	Reducing time to reperfusion for ST elevation myocardial infarction patients by a simple process change in the Emergency Department. BMJ Quality Improvement Reports, 2014, 3, u204753.w2063.	0.8	3
1124	The association between Point-of-Care testing of Troponin and the management of patients with chest pain suspected of acute coronary syndrome: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2014, 12, 99-112.	1.7	3
1129	Will cangrelor become the favored agent for acute coronary syndrome treatment?. Interventional Cardiology, 2014, 6, 537-545.	0.0	0
1130	Contraindications/Special Warnings and Precautions for Use of Contemporary Oral Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation Journal, 2014, 78, 180-187.	0.7	18
1131	Gender-specific Research for Emergency Diagnosis and Management of Ischemic Heart Disease: Proceedings from the 2014Academic Emergency MedicineConsensus Conference Cardiovascular Research Workgroup. Academic Emergency Medicine, 2014, 21, 1350-1360.	0.8	32
1132	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thrombosis and Haemostasis, 2014, 112, 924-931.	1.8	39
1133	Adaptation of Trustworthy Guidelines Developed Using the GRADE Methodology. Chest, 2014, 146, 727-734.	0.4	18

#	Article	IF	CITATIONS
1134	An observational study of co-morbidities in male Caucasian and South Asian sub-populations with acute coronary syndrome. IJC Metabolic & Endocrine, 2014, 5, 48-51.	0.5	0
1136	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 449-456.	0.2	3
1137	Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country. BMC Cardiovascular Disorders, 2015, 15, 136.	0.7	7
1138	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	1.2	5
1139	Acute Atherothrombotic Disease and Severe Bleeding: A Difficult Clinical Presentation in Medical Practice. Romanian Journal of Internal Medicine, 2015, 53, 349-354.	0.4	0
1142	Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 6.	1.6	125
1143	Relationship Between the Urine Flow Rate and Risk of Contrast-Induced Nephropathy After Emergent Percutaneous Coronary Intervention. Medicine (United States), 2015, 94, e2258.	0.4	6
1144	A Window on Geographic Variation in Health Care: Insights from EuroHOPE. Health Economics (United) Tj ETQq1	1 _{0.8} 78431	4ggBT/O∨
1145	Rationale, Design, and Baseline Characteristics of the <scp>EPICOR</scp> Asia Study (Longâ€≺scp>tErm followâ€≺scp>uP of antithrombotic management patterns In Acute) Tj ETQq0 0	Oorg/BT/Ov	erłock 10 T
1147	Carboxylesterase 1-Mediated Drug–Drug Interactions between Clopidogrel and Simvastatin. Biological and Pharmaceutical Bulletin, 2015, 38, 292-297.	0.6	22
1148	Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome – Randomized, Double-Blind, Phase III PHILO Study –. Circulation Journal, 2015, 79, 2452-2460.	0.7	218
1149	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Scientific Reports, 2015, 5, 13789.	1.6	19
1150	Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2). BMJ Open, 2015, 5, e007786.	0.8	21
1151	A cross-sectional multicentre study of cardiac risk score use in the management of unstable angina and non-ST-elevation myocardial infarction. BMJ Open, 2015, 5, e008523.	0.8	7
1152	Effectiveness of an Early Versus a Conservative Invasive Treatment Strategy in Acute Coronary Syndromes. Annals of Internal Medicine, 2015, 163, 737-746.	2.0	7
1153	Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Scientific Reports, 2015, 5, 13204.	1.6	17
1154	A look at phase-III cardiac rehabilitation and the complexity of patient care. British Journal of Cardiac Nursing, 2015, 10, 558-566.	0.0	O
1155	The effects of urgent percutaneous coronary intervention on right ventricular systolic functions in non-ST-elevation acute coronary syndromes. Interventional Medicine & Applied Science, 2015, 7, 69-77.	0.2	O

#	Article	IF	CITATIONS
1156	Should fee-for-service be for all guideline-advocated acute coronary syndrome (ACS) care? Observations from the Snapshot ACS study. Australian Health Review, 2015, 39, 379.	0.5	3
1157	Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Thrombosis and Haemostasis, 2015, 113, 577-584.	1.8	35
1158	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors $\hat{a} \in \hat{a}$ is an algorithm the answer? Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	43
1159	Coronary artery disease is associated with persistent lower quality of life in women. Open Heart, 2015, 2, e000305.	0.9	4
1160	Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Blood Coagulation and Fibrinolysis, 2015, 26, 874-881.	0.5	12
1161	Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. Journal of Cardiovascular Pharmacology, 2015, 66, 364-370.	0.8	25
1162	Quality markers in cardiology: measures of outcomes and clinical practice â€"a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery1. Cirugia Cardiovascular, 2015, 22, 315-324.	0.1	0
1165	Optimize the duration of DAPT following DES implantation: An updated system review and meta-analysis of 10 randomized trials. Clinical Trials and Regulatory Science in Cardiology, 2015, 6, 1-11.	1.0	4
1167	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
1169	Editorial on PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 217-219.	1.4	1
1170	An uncommon complication of atrial fibrillation. Oxford Medical Case Reports, 2015, 2015, 232-234.	0.2	3
1172	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. BMC Cardiovascular Disorders, 2015, 15, 117.	0.7	11
1173	Ticagrelor and bradycardia: a nested case–control study. Pharmacoepidemiology and Drug Safety, 2015, 24, 1281-1285.	0.9	6
1174	Impact of gender on use of revascularization in acute coronary syndromes: The national observational study of diagnostic and interventional cardiac catheterization (ONACI). Catheterization and Cardiovascular Interventions, 2015, 86, E58-65.	0.7	22
1175	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	0.7	8
1176	Preâ€treatment with dual antiplatelet therapy in patients with nonâ€ <scp>ST</scp> â€segment elevation acute coronary syndromes undergoing percutaneous coronary intervention. Internal Medicine Journal, 2015, 45, 1032-1037.	0.5	2
1177	The Appropriate Use of Percutaneous Coronary Intervention in Contemporary Clinical Practice. Proceedings of Singapore Healthcare, 2015, 24, 29-34.	0.2	1
1178	Early prediction of life-threatening arrhythmias in non-ST elevation myocardial infarction – does it change clinical practice?. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 37-40.	0.4	0

#	Article	IF	CITATIONS
1179	Fractional flow reserve of non-culprit vessel post-myocardial infarction: is it reliable?. BMC Cardiovascular Disorders, 2015, 15, 127.	0.7	1
1180	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation. 2015. 13. 19.	0.6	14
1181	Beyond FAMOUS-NSTEMI. Coronary Artery Disease, 2015, 26, e27-e34.	0.3	2
1182	Unveiling differences between patients with acute coronary syndrome with and without ST elevation through fingerprinting with CEâ€MS and HILICâ€MS targeted analysis. Electrophoresis, 2015, 36, 2303-2313.	1.3	19
1183	The STIB score: a simple clinical test to predict clopidogrel resistance. Acta Cardiologica, 2015, 70, 516-521.	0.3	14
1184	Review of point-of-care testing and biomarkers of cardiovascular diseases in emergency and prehospital medicine. Acta Cardiologica, 2015, 70, 510-515.	0.3	11
1185	Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. BMJ, The, 2015, 351, h3913.	3.0	94
1186	Education is critical for medication adherence in patients with coronary heart disease. Acta Cardiologica, 2015, 70, 197-204.	0.3	25
1187	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis, 2015, 114, 933-944.	1.8	11
1188	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	31
1189	Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 2015, 113, 221-230.	1.8	33
1190	Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 584-589.	0.7	7
1191	Heparins crossover in percutaneous coronary interventions. Journal of Cardiovascular Medicine, 2015, 16, 507-511.	0.6	0
1192	Role of masked coronary heart disease in patients with recent-onset atrial fibrillation and troponin elevations. European Journal of Emergency Medicine, 2015, 22, 162-169.	0.5	9
1193	Using beta-blockers with coronary artery disease. Nurs Crit Care (Ambler), 2015, 10, 6-10.	0.3	0
1194	Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome $\hat{a} \in \hat{a}$ a prospective audit. British Journal of Clinical Pharmacology, 2015, 80, 1176-1184.	1.1	0
1195	Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2015, 13, 2227-2232.	1.9	15
1196	<scp>DS</scp> 14 is more likely to measure depression rather than a personality disposition in patients with acute coronary syndrome. Scandinavian Journal of Psychology, 2015, 56, 685-692.	0.8	18

#	Article	IF	CITATIONS
1197	Chest pain and high-sensitivity troponin: What is the evidence?. SAGE Open Medicine, 2015, 3, 205031211557772.	0.7	2
1198	Choice of <scp>ICD</scp> â€10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundamental and Clinical Pharmacology, 2015, 29, 586-591.	1.0	50
1199	Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 349-352.	0.7	8
1200	Triple therapy for atrial fibrillation and percutaneous coronary intervention. Current Opinion in Cardiology, 2015, 30, 690-696.	0.8	1
1201	Quantitative Evaluation of Noncontrast Computed Tomography of the Head for Assessment of Anemia. Journal of Computer Assisted Tomography, 2015, 39, 842-848.	0.5	11
1202	Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease. European Journal of Clinical Investigation, 2015, 45, 1092-1097.	1.7	5
1203	Association of GRACE Risk Score with Angiographic Severity of Coronary Artery Disease in patients with ST Elevation Myocardial Infarction. Cardiovascular Journal, 2015, 8, 30-34.	0.0	9
1204	Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?. Postepy W Kardiologii Interwencyjnej, 2015, 3, 170-173.	0.1	8
1205	Men with Lower HDL Cholesterol Levels have Significant Increment of Soluble CD40 Ligand and High-sensitivity CRP Levels Following the Cessation of Long-term Clopidogrel Therapy. Journal of Atherosclerosis and Thrombosis, 2015, 22, 284-292.	0.9	10
1206	The Effect of Admission at Weekends on Clinical Outcomes in Patients with Non-ST-segment Elevation Acute Coronary Syndrome and Its Contributing Factors. Journal of Korean Medical Science, 2015, 30, 414.	1.1	7
1207	Clinical application of high-sensitivity cardiac troponin T test in acute myocardial infarction diagnosis. Genetics and Molecular Research, 2015, 14, 17959-17965.	0.3	6
1208	Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality. Clinical Interventions in Aging, 2015, 10, 1547.	1.3	16
1209	P2Y12 inhibitors for acute coronary syndromes: current perspectives. Research Reports in Clinical Cardiology, 2015, , 123.	0.2	0
1210	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Design, Development and Therapy, 2015, 9, 3801.	2.0	2
1211	Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Management and Research, 2015, 7, 133.	0.9	84
1212	Incremental Value of the CRUSADE, ACUITY, and HASâ€BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. Journal of the American Heart Association, 2015, 4, .	1.6	59
1213	CLINICAL ASPECTS OF PATIENT SELECTION FOR CORONARY ANGIOGRAPHY IN NON-ST ELEVATION ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology, 2015, 11, 272-282.	0.3	0
1214	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. Rational Pharmacotherapy in Cardiology, 2015, 11, 344-354.	0.3	0

#	Article	IF	CITATIONS
1215	The appropriate troponin T level associated with coronary occlusions in chronic kidney disease patients. Therapeutics and Clinical Risk Management, 2015, 11, 1143.	0.9	6
1216	Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. Therapeutics and Clinical Risk Management, 2015, 11, 263.	0.9	6
1217	The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. Thrombosis and Haemostasis, 2015, 114, 872-874.	1.8	0
1218	Use of medicines recommended for secondary prevention of acute coronary syndrome. Revista De Saude Publica, 2015, 49, .	0.7	4
1219	Does Treatment Impact Health Outcomes for Patients After Acute Coronary Syndrome?. International Journal of Environmental Research and Public Health, 2015, 12, 6136-6147.	1,2	3
1220	Borderline Values of Troponin-T and High Sensitivity C-Reactive Protein Did Not Predict 2-Year Mortality in TnT Positive Chest-Pain Patients, Whereas Brain Natriuretic Peptide Did. Frontiers in Cardiovascular Medicine, 2015, 2, 16.	1.1	3
1221	Non-ST elevation myocardial infarction related to total coronary artery occlusion – prevalenceÂand patient characteristics. Postepy W Kardiologii Interwencyjnej, 2015, 1, 9-13.	0.1	3
1222	Relationship of platelet indices with acute stent thrombosis in patients with acute coronary syndrome. Postepy W Kardiologii Interwencyjnej, 2015, 3, 224-229.	0.1	3
1223	Coronary stents and non-cardiac surgery: to bridge or not to bridge?. Thrombosis and Haemostasis, 2015, 114, 211-213.	1.8	0
1224	Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 40-49.	0.4	8
1225	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vascular Health and Risk Management, 2015, 11, 317.	1.0	11
1226	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. Thrombosis and Haemostasis, 2015, 114, 708-716.	1.8	3
1227	Recent advances in the diagnosis and treatment of acute myocardial infarction. World Journal of Cardiology, 2015, 7, 243.	0.5	138
1228	Periprocedural Anticoagulation of Patients Undergoing Pericardiocentesis for Cardiac Tamponade Complicating Catheter Ablation of Atrial Fibrillation. International Heart Journal, 2015, 56, 56-61.	0.5	7
1229	Combined Value of Red Blood Cell Distribution Width and Global Registry of Acute Coronary Events Risk Score for Predicting Cardiovascular Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. PLoS ONE, 2015, 10, e0140532.	1.1	20
1231	Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury. International Heart Journal, 2015, 56, 335-340.	0.5	12
1232	Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?. Disease Markers, 2015, 2015, 1-9.	0.6	22
1233	The Impact of Thrombocytopenia on Outcome in Patients with Acute Coronary Syndromes: A Single Center Retrospective Study. BioMed Research International, 2015, 2015, 1-7.	0.9	13

#	Article	IF	Citations
1234	A Silent Alarm at Occupational Evaluation Two Months after a Normal Painful ECG: A Case of Wellens' syndrome. Case Reports in Cardiology, 2015, 2015, 1-3.	0.1	3
1235	Different Plaque Composition and Progression in Patients with Stable and Unstable Coronary Syndromes Evaluated by Cardiac CT. BioMed Research International, 2015, 2015, 1-9.	0.9	14
1236	Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study. Journal of Analytical Methods in Chemistry, 2015, 2015, 1-12.	0.7	13
1238	The Interdisciplinary Management of Acute Chest Pain. Deutsches Ärzteblatt International, 2015, 112, 768-79; quiz 780.	0.6	24
1239	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. European Heart Journal, 2015, 36, 3155-3164.	1.0	58
1240	Impact of High Loading Dose of Atorvastatin in Diabetic Patients with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial. Cardiovascular Therapeutics, 2015, 33, 35-41.	1.1	23
1241	The proxy of renal function that most accurately predicts short- and long-term outcome after acute coronary syndrome. American Heart Journal, 2015, 169, 702-712.e3.	1.2	17
1242	Sex differences in mechanisms, presentation and management of ischaemic heart disease. Atherosclerosis, 2015, 241, 157-168.	0.4	113
1243	Impact of Leading Presenting Symptoms on the Diagnostic Performance of High-Sensitivity Cardiac Troponin T and on Outcomes in Patients with Suspected Acute Coronary Syndrome. Clinical Chemistry, 2015, 61, 744-751.	1.5	11
1244	Meta-Analysis of Relation Between Oral \hat{l}^2 -Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 115, 1529-1538.	0.7	68
1245	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace, 2015, 17, 840-854.	0.7	28
1246	Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal, 2015, 36, 2635-2642.	1.0	174
1247	Non-invasive prediction of hemodynamically significant coronary artery stenoses by contrast density difference in coronary CT angiography. European Journal of Radiology, 2015, 84, 1502-1508.	1.2	36
1248	Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1805-1814.	1.1	100
1249	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2015, 169, 899-905.e1.	1.2	91
1250	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. American Journal of Cardiology, 2015, 116, 660-668.	0.7	7
1251	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non–ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 809-817.	0.7	56
1252	Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical Pharmacokinetics, 2015, 54, 1125-1138.	1.6	102

#	Article	IF	Citations
1253	High sensitivity troponin: Does the 50% delta change alter clinical outcomes in chest pain presentations to the emergency room?. International Journal of Cardiology, 2015, 184, 170-174.	0.8	4
1254	Early rule-out and rule-in of myocardial infarction using sensitive cardiac Troponin I. International Journal of Cardiology, 2015, 195, 163-170.	0.8	31
1255	Surgical Versus Percutaneous Coronary Revascularization for Multivessel Disease in Diabetic Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	26
1256	Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction. Cardiovascular Medicine, 2015, , 461-504.	0.0	1
1257	Percutaneous Coronary Intervention and the Various Coronary Artery Disease Syndromes. Cardiovascular Medicine, 2015, , 597-620.	0.0	0
1258	Bioinformatics and Biomedical Engineering. Lecture Notes in Computer Science, 2015, , .	1.0	3
1260	Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Drug Safety, 2015, 38, 481-491.	1.4	6
1261	Comparison of model-based and expert-rule based electrocardiographic identification of the culprit artery in patients with acute coronary syndrome. Journal of Electrocardiology, 2015, 48, 483-489.	0.4	8
1262	Long-term mortality following interhospital transfer for acute myocardial infarction. Heart, 2015, 101, 1032-1040.	1.2	28
1263	Acute ischemic events are frequent after primary coronary stenting. Journal of Cardiovascular Medicine, 2015, 16, 178-188.	0.6	2
1264	Quantification of manual thrombus removal in patients with acute coronary syndromes. Journal of Cardiovascular Medicine, 2015, 16, 204-212.	0.6	6
1265	Association of bleeding, mortality and sex in acute coronary syndromes. Journal of Cardiovascular Medicine, 2015, 16, 347-354.	0.6	6
1266	Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Services Research, 2015, 15, 173.	0.9	47
1267	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. Circulation, 2015, 131, 2001-2009.	1.6	2
1268	Accelerated diagnostic protocol using high-sensitivity cardiac troponin T in acute chest pain patients. International Journal of Cardiology, 2015, 184, 208-215.	0.8	46
1269	Troponins and other biomarkers in the early diagnosis of acute myocardial infarction. Postgraduate Medical Journal, 2015, 91, 322-330.	0.9	11
1270	Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay. Annals of Clinical Biochemistry, 2015, 52, 543-549.	0.8	21
1271	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart, 2015, 101, 1219-1224.	1.2	15

#	Article	IF	CITATIONS
1272	The future of P2Y ₁₂ receptor antagonists. Platelets, 2015, 26, 392-398.	1.1	12
1273	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. International Journal of Cardiology, 2015, 201, S15-S23.	0.8	32
1274	The GRACE registry: how real-life evidence contributes to acute coronary syndrome guidelines. European Heart Journal Supplements, 2015, 17, D29-D31.	0.0	4
1275	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. Expert Review of Molecular Diagnostics, 2015, 15, 1577-1588.	1.5	46
1276	Temporal changes in the use and results of exercise echocardiography. European Heart Journal Cardiovascular Imaging, 2015, 16, 1207-1212.	0.5	21
1277	Fractional flow reserve in acute coronary syndromes. European Heart Journal, 2015, 36, 75-76.	1.0	10
1278	A conservative strategy in non-ST-segment elevation myocardial infarction – constraints and prognosis: The situation in Portugal. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 315-328.	0.2	7
1279	Management of high-risk non-ST elevation myocardial infarction in the UK: need for alternative models of care to reduce length of stay and admission to angiography times. Clinical Medicine, 2015, 15, 522-525.	0.8	8
1280	Clinical decision-making of cardiologists regarding admission and treatment of patients with suspected unstable angina or non-ST-elevation myocardial infarction: protocol of a clinical vignette study. BMJ Open, 2015, 5, e006441-e006441.	0.8	7
1281	Survival curves to support quality improvement in hospitals with excess 30-day mortality after acute myocardial infarction, cerebral stroke and hip fracture: a before-after study. BMJ Open, 2015, 5, e006741-e006741.	0.8	20
1282	Acute myocardial infarction or acute myocarditis? Discharge registry-based study of likelihood and associated features in hospitalised patients. BMJ Open, 2015, 5, e007555-e007555.	0.8	2
1283	Developments in the invasive diagnostic-therapeutic cascade of women and men with acute coronary syndromes from 2005 to 2011: a nationwide cohort study. BMJ Open, 2015, 5, e007785-e007785.	0.8	25
1284	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, 2015, 4, e001505.	1.6	62
1285	Monitoring the Efficacy of ADP Inhibitor Treatment in Patients With Acute STEMI Post-PCI by VASP-P Flow Cytometry Assay. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 334-338.	0.7	12
1286	Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute) Tj ETQq0 0 0 rgBT	/8verlock	10 Tf 50 18
	509-517.		
1287	Comparison of electric- and magnetic- cardiograms produced by myocardial ischemia in models of the human ventricle and torso., 2015,,.		3
1290	Prognostic impact of neutrophil gelatinase-associated lipocalin and B-type natriuretic in patients with ST-elevation myocardial infarction treated by primary PCI: a prospective observational cohort study. BMJ Open, 2015, 5, e006872.	0.8	29
1291	Recent advances in invasive coronary treatment strategies for out-of-hospital cardiac arrest: are they working?. Interventional Cardiology, 2015, 7, 395-402.	0.0	0

#	Article	IF	CITATIONS
1292	The impact of clinical pharmacist support on patients receiving multi-drug therapy for coronary heart disease in China: a long-term follow-up study. European Journal of Hospital Pharmacy, 2015, 22, 323-327.	0.5	4
1293	Valores de troponina elevados en pacientes sin sÃndrome coronario agudo: ¿cuál es el diagnóstico real?. Revista Espanola De Cardiologia, 2015, 68, 912-913.	0.6	3
1295	Bivalirudin in stable angina and acute coronary syndromes. , 2015, 152, 1-10.		6
1296	Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 403-410.	0.2	5
1297	Medical management: the dark side of acute coronary syndromes. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 179-181.	1.4	7
1298	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1 , 232-244.	1.4	13
1299	Age as a Prognostic Factor in Patients with Acute Coronary Syndrome undergoing Urgent/Emergency Cardiac Surgery. Heart Lung and Circulation, 2015, 24, 845-853.	0.2	4
1301	Personalization Based on Grouping Strategies for Short-Term Cardiovascular Event Risk Assessment. Cardiovascular Engineering and Technology, 2015, 6, 392-399.	0.7	3
1302	Tirofiban-induced acute profound thrombocytopenia: What is the optimal approach to treatment?. Platelets, 2015, 26, 197-198.	1.1	11
1303	Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Clinical Pharmacokinetics, 2015, 54, 147-166.	1.6	137
1304	Improved STEMI diagnosis by serial ECG analysis. Journal of Electrocardiology, 2015, 48, 99-100.	0.4	1
1305	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 499-508.	0.4	68
1306	Diagnostic performance of cardiac Troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. Clinical Biochemistry, 2015, 48, 254-259.	0.8	24
1307	Lights and (Some) Shadows in the Management of Acute Coronary Syndrome in Spain: the DIOCLES Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 85-86.	0.4	0
1308	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. European Journal of Internal Medicine, 2015, 26, 56-62.	1.0	37
1309	Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. Diabetes and Metabolism, 2015, 41, 304-311.	1.4	71
1310	Frailty Syndrome in cardiovascular disease: Clinical significance and research tools. European Journal of Cardiovascular Nursing, 2015, 14, 303-309.	0.4	25
1311	Updates to the ACCF/AHA and ESC STEMI and NSTEMI Guidelines: Putting Guidelines Into Clinical Practice. American Journal of Cardiology, 2015, 115, 23A-28A.	0.7	27

#	Article	IF	CITATIONS
1312	Acute Coronary Syndromes: Applying Practice Guidelines and Defining the Unmet Need in Clinical Practice. American Journal of Cardiology, 2015, 115, 1A-2A.	0.7	1
1314	New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology, 2015, 55, 373-397.	4.2	44
1315	Acute coronary syndromes and coronary intervention. European Heart Journal, 2015, 36, 323-324.	1.0	0
1316	Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2015, 15, 51-68.	1.0	28
1317	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. American Heart Journal, 2015, 169, 531-538.	1.2	9
1318	Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease. Expert Review of Molecular Diagnostics, 2015, 15, 547-556.	1.5	6
1319	Challenges and solutions in medically managed ACS in the Asia-Pacific region: Expert recommendations from the Asia-Pacific ACS Medical Management Working Group. International Journal of Cardiology, 2015, 183, 63-75.	0.8	15
1320	Guideline-adherence and perspectives in the acute management of unstable angina – Initial results from the German chest pain unit registry. Journal of Cardiology, 2015, 66, 108-113.	0.8	26
1321	Essential Service Standards for Equitable National Cardiovascular Care for Aboriginal and Torres Strait Islander People. Heart Lung and Circulation, 2015, 24, 126-141.	0.2	21
1322	¿En la era actual existe beneficio pronóstico del tratamiento con bloqueadores beta tras un sÃndrome coronario agudo con función sistólica conservada?. Revista Espanola De Cardiologia, 2015, 68, 585-591.	0.6	26
1323	Percutaneous Circulatory Assist Devices for High-Risk Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 229-244.	1.1	94
1324	Luces y (algunas) sombras en el manejo del sÃndrome coronario agudo en España: el estudio DIOCLES. Revista Espanola De Cardiologia, 2015, 68, 85-86.	0.6	1
1325	Infarto de miocardio en mayores de 75 a $\tilde{A}\pm$ os: una poblaci \tilde{A}^3 n en aumento. Estudio CASTUO. Revista Clinica Espanola, 2015, 215, 195-203.	0.2	11
1326	Prognostic Impact of Clopidogrel Pretreatment in Patients With Acute Coronary Syndrome Managed Invasively. American Journal of Cardiology, 2015, 115, 1019-1026.	0.7	17
1327	Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 585-591.	0.4	11
1328	Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 17-25.	0.2	0
1329	Heart failure: the cardiovascular epidemic of the 21st century. European Heart Journal, 2015, 36, 395-397.	1.0	33
1330	Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non–ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 707.	3.8	31

#	Article	IF	CITATIONS
1331	Meta-Analysis Appraising High Maintenance Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention With and Without High On-Clopidogrel Platelet Reactivity. American Journal of Cardiology, 2015, 115, 592-601.	0.7	8
1332	Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015, 26, 53-58.	1.1	22
1333	Early invasive strategy in high-risk acute coronary syndrome without ST-segment elevation. The Sisca randomized trial. International Journal of Cardiology, 2015, 182, 414-418.	0.8	31
1334	Myocardial infarction in older than 75 years: An increasing population. CASTUO study. Revista Clínica Espanõla, 2015, 215, 195-203.	0.3	3
1335	Effect of an Invasive Strategy on Outcome in Patients ≥75 Years of Age With Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 115, 576-580.	0.7	31
1336	Can Coronary Computed Tomography Angiography Replace Invasive Angiography?. Circulation, 2015, 131, 418-426.	1.6	39
1337	Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets, 2015, 26, 563-569.	1.1	22
1338	Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention. Journal of Clinical Pharmacology, 2015, 55, 123-131.	1.0	18
1339	Updates and Current Recommendations for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice. American Journal of Cardiology, 2015, 115, 10A-22A.	0.7	20
1340	Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 2015, 101, 119-125.	1.2	15
1341	Life-threatening complete atrioventricular block associated with ticagrelor therapy. International Journal of Cardiology, 2015, 182, 379-380.	0.8	28
1342	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.4	26
1343	Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. International Journal of Cardiology, 2015, 181, 443-445.	0.8	4
1344	Guideline-adherent therapy in patients with acute coronary syndromes. Herz, 2015, 40, 27-35.	0.4	16
1345	Cardiovascular magnetic resonance for the assessment of coronary artery disease. International Journal of Cardiology, 2015, 193, 84-92.	0.8	13
1346	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 441-452.	0.4	81
1347	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 168-178.	1.4	22
1348	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. Thrombosis Research, 2015, 135, 1140-1146.	0.8	3

#	Article	IF	CITATIONS
1349	Patients with atrial fibrillation complicated by coronary artery disease. Herzschrittmachertherapie Und Elektrophysiologie, 2015, 26, 39-44.	0.3	4
1350	Cardiac computed tomography in patients with acute chest pain. European Heart Journal, 2015, 36, 906-914.	1.0	24
1351	PronÃ ³ stico a largo plazo de pacientes con infarto agudo de miocardio sin elevaciÃ ³ n del segmento ST y arterias coronarias sin estenosis significativa. Revista Espanola De Cardiologia, 2015, 68, 777-784.	0.6	4
1352	The clinical and diagnostic performance characteristics of the high sensitivity Abbott cardiac troponin I assay. Clinical Biochemistry, 2015, 48, 275-281.	0.8	30
1353	Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 805.	3.8	115
1354	Revascularization in Patients with Diabetes: PCI or CABG or None at All. Current Cardiology Reports, 2015, 17, 565.	1.3	6
1355	Imaging Coronary Artery Disease and the Myocardial Ischemic Cascade. Radiologic Clinics of North America, 2015, 53, 261-269.	0.9	12
1356	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. Circulation: Cardiovascular Interventions, 2015, 8, e002301.	1.4	58
1357	Impact of Anticoagulation on Coronary Flow in Patients With Non-ST Elevation Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 48-57.	0.7	0
1358	Management of non-traumatic chest pain by the French Emergency Medical System: Insights from the DOLORES registry. Archives of Cardiovascular Diseases, 2015, 108, 181-188.	0.7	5
1359	The Effect of Different Doses and Different Routes of Acetylsalicylic Acid Administration on Platelet Aggregation in Healthy Volunteers and Ischemic Stroke Patients. Translational Stroke Research, 2015, 6, 160-165.	2.3	2
1360	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. Journal of Internal Medicine, 2015, 278, 1-18.	2.7	64
1361	High-sensitivity assays for cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2015, 53, 631-3.	1.4	8
1362	Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: Anex vivostudy. Platelets, 2015, 26, 324-330.	1.1	33
1363	The Effects of Oxygen Therapy on Myocardial Salvage in ST Elevation Myocardial Infarction Treated with Acute Percutaneous Coronary Intervention: The Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER) Study. Cardiology, 2015, 132, 16-21.	0.6	21
1364	Copeptin in acute coronary syndromes and heart failure management: State of the art and future directions. Archives of Cardiovascular Diseases, 2015, 108, 398-407.	0.7	25
1365	Risk stratification in non-ST elevation acute coronary syndromes: Risk scores, biomarkers and clinical judgment. IJC Heart and Vasculature, 2015, 8, 131-137.	0.6	21
1366	The Early Invasive Strategy in AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2015, 66, 521-523.	1.2	4

#	Article	IF	Citations
1367	Out-of-hospital cardiac arrest: contemporary management and future perspectives. Heart, 2015, 101, 1505-1516.	1.2	11
1368	Gender and survival after sudden cardiac arrest: A systematic review and meta-analysis. Resuscitation, 2015, 94, 55-60.	1.3	95
1369	Fast assessment and management of chest pain without ST-elevation in the pre-hospital gateway: Rationale and design. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 129-136.	0.4	22
1370	Nationwide trends in use and timeliness of diagnostic coronary angiography in acute coronary syndromes from 2005 to 2011: Does distance to invasive heart centres matter?. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 333-343.	0.4	6
1371	Usefulness of Early Rule-In and Rule-Out Biomarker Protocols to Estimate Ischemia-Induced Myocardial Injury in Early Chest Pain Presenters. American Journal of Cardiology, 2015, 115, 1667-1671.	0.7	8
1372	The role of alexithymia in predicting incident depression in patients at first acute coronary syndrome. Comprehensive Psychiatry, 2015, 62, 86-92.	1.5	7
1373	Importance of guideline adherence for unstable angina pectoris and prevention of serious cardiovascular events by conforming to guidelines. Journal of Cardiology, 2015, 66, 99-100.	0.8	0
1374	Cardiac CT in 2015: Clinical Role According to Current Multi-Societal Guidelines. Current Cardiovascular Imaging Reports, 2015, 8, 1.	0.4	0
1375	Mitral valve disease and acute coronary syndromes. European Heart Journal, 2015, 36, 1839-1841.	1.0	0
1376	A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 916-923.	1.1	5
1377	Criteria of the German Society of Cardiology for the establishment of chest pain units: update 2014. Clinical Research in Cardiology, 2015, 104, 918-928.	1.5	40
1379	10-Year Mortality Outcome of a RoutineÂlnvasive Strategy Versus a Selective Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2015, 66, 511-520.	1.2	54
1380	Prasugrel Versus Clopidogrel: AÂComparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy. Journal of Oral and Maxillofacial Surgery, 2015, 73, 1894-1900.	0.5	21
1381	Management of the patient with an acute coronary syndrome using oral anticoagulation. Netherlands Heart Journal, 2015, 23, 407-414.	0.3	4
1382	The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department. Clinical Biochemistry, 2015, 48, 1219-1224.	0.8	11
1383	Mortality and neurological outcome in the elderly after target temperature management for out-of-hospital cardiac arrest. Resuscitation, 2015, 91, 92-98.	1.3	50
1384	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. Thrombosis Research, 2015, 136, 613-619.	0.8	4
1385	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	1.4	16

#	Article	IF	CITATIONS
1386	Response to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary Syndromes. Cardiology, 2015, 132, 119-123.	0.6	5
1387	More transparency for a therapeutic window in platelet P2Y ₁₂ inhibition?. European Heart Journal, 2015, 36, 1714-1717.	1.0	5
1388	Coronary Angioscopy. , 2015, , .		4
1389	New oral anticoagulant and antiplatelet agents for neurosurgeons. British Journal of Neurosurgery, 2015, 29, 614-621.	0.4	4
1390	Disease complexity in acute coronary syndrome is related to the patient's immunological status. International Journal of Cardiology, 2015, 189, 115-123.	0.8	8
1391	Percutaneous coronary intervention in the elderly. International Journal of Cardiology, 2015, 199, 342-355.	0.8	23
1392	America vs Europe and the 2014 Non-ST Elevation Acute Coronary Syndrome Guidelines. Journal of Cardiovascular Translational Research, 2015, 8, 385-391.	1.1	1
1393	Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction. International Journal of Cardiology, 2015, 197, 48-55.	0.8	21
1394	Neutrophil-to-lymphocyte ratio predicts coronary artery lesion complexity and mortality after non-ST-segment elevation acute coronary syndrome. Revista Portuguesa De Cardiologia, 2015, 34, 465-471.	0.2	13
1395	Anemia in Intensive Cardiac Care Unit patients – An underestimated problem. Advances in Medical Sciences, 2015, 60, 307-314.	0.9	10
1396	A Risk Score for Predicting 1-Year Mortality in Patients ≥75 Years of Age Presenting With Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 208-213.	0.7	19
1398	A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. European Heart Journal Cardiovascular Imaging, 2015, 16, 441-448.	0.5	97
1399	Practical experience with ticagrelor: an Australian and New Zealand perspective. Current Medical Research and Opinion, 2015, 31, 1469-1477.	0.9	8
1400	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. Thrombosis Research, 2015, 136, 87-93.	0.8	27
1401	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	1.0	175
1402	Management Strategies for Clopidogrel Hypersensitivity. Drugs, 2015, 75, 999-1007.	4.9	5
1403	Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 686-693.	0.7	52
1405	Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy. Journal of the American Heart Association, 2015, 4, e002009.	1.6	2

#	Article	IF	CITATIONS
1406	Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. Atherosclerosis, 2015, 241, 579-587.	0.4	54
1407	Troponin I/ejection fraction ratio: A new index to differentiate Takotsubo cardiomyopathy from myocardial infarction. International Journal of Cardiology, 2015, 180, 255-257.	0.8	14
1408	OSACS score-a new simple tool for identifying high risk for Obstructive Sleep Apnea Syndrome based on clinical parameters. Anatolian Journal of Cardiology, 2015, 15, 50-55.	0.4	8
1409	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232.	2.9	74
1410	Presenting characteristics of patients undergoing cardiac troponin measurements in the emergency department. Canadian Journal of Emergency Medicine, 2015, 17, 62-66.	0.5	2
1411	Prasugrel Increases the Need for Platelet Transfusions and Surgical Reexploration Rates Compared with Clopidogrel in Coronary Artery Bypass Surgery. Thoracic and Cardiovascular Surgeon, 2015, 63, 028-035.	0.4	14
1412	Laboratory medicine as the science that underpins medicine: the "high-sensitivity―troponin paradigm. Clinical Chemistry and Laboratory Medicine, 2015, 53, 653-64.	1.4	15
1413	βâ€Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study. Journal of the American Heart Association, 2015, 4, .	1.6	46
1414	Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	17
1415	Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation. Current Cardiology Reports, 2015, 17, 41.	1.3	0
1416	Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome. Journal of Cardiology, 2015, 65, 203-207.	0.8	15
1418	Los bloqueadores β. Nursing (Ed Española), 2015, 32, 51-55.	0.0	0
1419	Fractional flow-guided management in patients with acute coronary syndromes: A systematic review and meta-analysis. International Journal of Cardiology, 2015, 187, 334-337.	0.8	6
1420	Analytical evaluation of point of care cTnT and clinical performances in an unselected population as compared with central laboratory highly sensitive cTnT. Clinical Biochemistry, 2015, 48, 334-339.	0.8	11
1421	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the) Tj ETQq0	0 0.r gBT /0	Owerlock 10
1422	Serum chemokine CCL17/thymus activation and regulated chemokine is correlated with coronary artery diseases. Atherosclerosis, 2015, 238, 365-369.	0.4	23
1423	Decreasing troponin turnaround time in the emergency department using the central laboratory: A process improvement study. Clinical Biochemistry, 2015, 48, 308-312.	0.8	17
1424	Chemopreventive effects of aspirin at a glance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 254-263.	3.3	26

#	Article	IF	Citations
1425	Impacto de la fibrilación ventricular que complica el curso de un sÃndrome coronario agudo en la incidencia a largo plazo de muerte súbita cardiaca. Revista Espanola De Cardiologia, 2015, 68, 878-884.	0.6	5
1426	Novel insights into an "old―phenomenon: the no reflow. International Journal of Cardiology, 2015, 187, 273-280.	0.8	100
1427	Physicians' adherence to acute coronary syndrome prescribing guidelines in <scp>V</scp> ietnamese hospital practice: a crossâ€sectional study. Tropical Medicine and International Health, 2015, 20, 627-637.	1.0	6
1428	Balancing the Risks and Benefits of Long†Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications. Journal of the American Heart Association, 2015, 4, e001897.	1.6	1
1429	Incremental value of copeptin to highly sensitive cardiac Troponin I for rapid rule-out of myocardial infarction. International Journal of Cardiology, 2015, 190, 170-176.	0.8	44
1430	Myocardial infarction: mechanisms, diagnosis, and complications. European Heart Journal, 2015, 36, 947-949.	1.0	13
1432	Outcomes of patients hospitalized for suspected acute coronary syndrome, in whom the diagnosis was not confirmed: Results from the CZECH-1 and CZECH-2 registries. Cor Et Vasa, 2015, 57, e1-e5.	0.1	0
1433	Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis. International Journal of Clinical Practice, 2015, 69, 1088-1111.	0.8	19
1434	Is the use of risk scores an indicator of guideline adherence for patients with acute coronary syndromes? Insights from the EYESHOT Registry. International Journal of Cardiology, 2015, 187, 80-83.	0.8	3
1435	Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel. Thrombosis Research, 2015, 135, 933-938.	0.8	6
1436	Multicenter trials, guidelines, and uncertainties $\hat{a} \in$ Do we know as much as we think we do?. International Journal of Cardiology, 2015, 187, 600-603.	0.8	8
1437	Criterios para realizar una transfusi \tilde{A}^3 n. FMC Formacion Medica Continuada En Atencion Primaria, 2015, 22, 208-213.	0.0	0
1438	The Clinical Care Standards in ACS: Towards an Integrated Approach to Evidence Translation in ACS Care. Heart Lung and Circulation, 2015, 24, 213-215.	0.2	7
1439	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International Journal of Cardiology, 2015, 186, 282-285.	0.8	6
1440	Effects of Rivaroxaban on Platelet Activation and Plateletâ€"Coagulation Pathway Interaction. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 554-562.	1.0	80
1441	Prevalencia y pron \tilde{A}^3 stico de la nefropat \tilde{A} a tras intervencionismo coronario percut \tilde{A}_1 neo de pacientes con s \tilde{A} ndrome coronario agudo y funci \tilde{A}^3 n renal normal. Revista Espanola De Cardiologia, 2015, 68, 310-316.	0.6	4
1442	Effects of hemolysis on the diagnostic accuracy of cardiac troponin I for the diagnosis of myocardial infarction. International Journal of Cardiology, 2015, 187, 313-315.	0.8	8
1443	High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease. Clinical Biochemistry, 2015, 48, 302-307.	0.8	67

#	Article	IF	CITATIONS
1444	Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: Optimal cut-off point, diagnostic value and future opportunities in primary care. European Journal of General Practice, 2015, 21, 156-163.	0.9	18
1446	Improvement in prehospital time in acute coronary syndrome between 1985 and 2013 in the south-eastern area of Hungary. Wiener Klinische Wochenschrift, 2015, 127, 218-221.	1.0	1
1447	Myocardial Infarction: Symptoms and Treatments. Cell Biochemistry and Biophysics, 2015, 72, 865-867.	0.9	273
1448	Adherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome: a multicentre study. Netherlands Heart Journal, 2015, 23, 214-221.	0.3	22
1449	STEMI or non-STEMI: that is the question. Netherlands Heart Journal, 2015, 23, 243-244.	0.3	2
1450	Guidance on guideline adherence. Netherlands Heart Journal, 2015, 23, 212-213.	0.3	0
1451	Significant narrowing of the circumflex artery leads to worse outcomes than right coronary artery narrowing in patients with anterior myocardial infarction treated invasively. Netherlands Heart Journal, 2015, 23, 258-262.	0.3	4
1452	NSAIDs Hypersensitivity: When and How to Desensitize?. Current Treatment Options in Allergy, 2015, 2, 124-140.	0.9	6
1453	National trends in hospital length of stay for acute myocardial infarction in China. BMC Cardiovascular Disorders, 2015, 15, 9.	0.7	27
1454	Validity of a 5-minute focused echocardiography with A-F mnemonic performed by non-echocardiographers in the management of patients with acute chest pain. Cardiovascular Ultrasound, 2015, 13, 16.	0.5	18
1455	Prevalence and Prognosis of Percutaneous Coronary Intervention-associated Nephropathy in Patients With Acute Coronary Syndrome and Normal Kidney Function. Revista Espanola De Cardiologia (English) Tj ETQq0	0 0 04rgBT /	Owerlock 10
1456	Recent Temporal Trends in the Presentation, Management, and Outcome of Women Hospitalized with Acute Coronary Syndromes. American Journal of Medicine, 2015, 128, 380-388.	0.6	21
1457	P2Y12receptor inhibitors for secondary prevention of ischemic stroke. Expert Opinion on Pharmacotherapy, 2015, 16, 1149-1165.	0.9	12
1458	Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry. International Journal of Cardiology, 2015, 187, 354-360.	0.8	9
1459	Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 977-993.	1.5	1
1460	Antiplatelet drug resistance: Molecular insights and clinical implications. Prostaglandins and Other Lipid Mediators, 2015, 120, 21-27.	1.0	32
1461	Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. Cmaj, 2015, 187, E243-E252.	0.9	195
1462	Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. American Journal of Cardiology, 2015, 116, 339-343.	0.7	30

#	Article	IF	CITATIONS
1463	Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ, The, 2015, 350, h15-h15.	3.0	157
1464	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. Postgraduate Medical Journal, 2015, 91, 284-290.	0.9	1
1465	Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials, 2015, 16, 198.	0.7	15
1466	Misdiagnosis of Myocardial Infarction Related to Limitations of the Current Regulatory Approach to Define Clinical Decision Values for Cardiac Troponin. Circulation, 2015, 131, 2032-2040.	1.6	111
1467	Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. Platelets, 2015, 26, 17-24.	1.1	10
1468	High-sensitivity cardiac troponin assays: Answers to frequently asked questions. Archives of Cardiovascular Diseases, 2015, 108, 132-149.	0.7	39
1469	Management of acute chest pain: A major role for coronary CT angiography. Diagnostic and Interventional Imaging, 2015, 96, 1105-1112.	1.8	5
1470	Early rule-out of acute coronary syndrome using undetectable levels of high sensitivity troponin T. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 403-409.	0.4	26
1471	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585
1472	Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 585-596.	0.9	4
1473	A multidisciplinary consensus document on followâ€up strategies for patients treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2015, 85, E129-39.	0.7	6
1474	Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction. Circulation, 2015, 131, 2041-2050.	1.6	174
1475	Mean Platelet Volume on Admission Improves Risk Prediction in Patients With Acute Coronary Syndromes. Angiology, 2015, 66, 456-463.	0.8	16
1476	Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a $\hat{a} \in \mathbb{R}$ Real World $\hat{a} \in \mathbb{R}$ registry. Thrombosis Research, 2015, 135, 1093-1099.	0.8	15
1477	Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Internal and Emergency Medicine, 2015, 10, 805-814.	1.0	6
1479	Timing of Percutaneous Coronary Intervention in Troponin-negative Patients With Acute Coronary Syndrome Without Persistent ST-segment Elevation. Critical Pathways in Cardiology, 2015, 14, 7-11.	0.2	9
1480	Prognostic power of lower pulse pressure on long-term all-cause mortality in octogenarians with acute coronary syndrome. Journal of Hypertension, 2015, 33, 279-286.	0.3	7
1481	Drugs acting on the heart: heart failure and coronary insufficiency. Anaesthesia and Intensive Care Medicine, 2015, 16, 237-242.	0.1	O

#	Article	IF	CITATIONS
1482	Prevention and treatment of atherosclerosis in haemophilia $\hat{a} \in \text{``how to balance risk of bleeding with risk of ischaemic events. European Journal of Haematology, 2015, 94, 23-29.}$	1.1	11
1483	Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 625-637.	1.5	7
1484	Impact of female sex on long-term acute coronary syndrome outcomes. Coronary Artery Disease, 2015, 26, 11-16.	0.3	12
1485	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 468-474.	0.4	18
1486	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart, 2015, 101, 854-863.	1.2	38
1487	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	6.3	59
1488	Outcomes after hypertensive crisis: Comparison between diabetics and nondiabetics. IJC Metabolic & Endocrine, 2015, 7, 25-30.	0.5	11
1489	Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. Journal of Cardiovascular Medicine, 2015, 16, 100-105.	0.6	5
1490	Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study Design and Rationale. Journal of Cardiovascular Medicine, 2015, 16, 253-258.	0.6	9
1491	Gastrointestinal Bleeding and Anticoagulant or Antiplatelet Drugs. Medicine (United States), 2015, 94, e377.	0.4	22
1492	Cardiac MR enables diagnosis in 90% of patients with acute chest pain, elevated biomarkers and unobstructed coronary arteries. British Journal of Radiology, 2015, 88, 20150025.	1.0	24
1493	A study of IgG antibodies to the ApoB protein in non-ST segment elevation acute coronary syndrome. Scandinavian Cardiovascular Journal, 2015, 49, 136-141.	0.4	2
1494	One-hour Rule-in and Rule-out of Acute Myocardial Infarction Using High-sensitivity Cardiac Troponin I. American Journal of Medicine, 2015, 128, 861-870.e4.	0.6	174
1495	Universal Definition of Myocardial Infarction: Clinical Insights. Cardiology, 2015, 131, 13-21.	0.6	1,946
1496	A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. Cardiology and Therapy, 2015, 4, 95-116.	1.1	13
1497	Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. Herz, 2015, 40, 1070-1083.	0.4	18
1498	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	1.0	293
1499	Investigational new drugs for the treatment of acute coronary syndrome. Expert Opinion on Investigational Drugs, 2015, 24, 1557-1570.	1.9	3

#	Article	IF	Citations
1501	Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015, 26, 498-500.	1.1	5
1502	Interventional cardiology: in search of the balance between ischaemia and bleeding. European Heart Journal, 2015, 36, 1197-1199.	1.0	3
1503	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores) Tj ETQq0 (Revista Espanola De Cardiologia (English Ed), 2015, 68, 976-995.e10.	0 rgBT /C)verlock 10°
1504	Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). American Heart Journal, 2015, 170, 566-572.e1.	1.2	26
1505	Optimizing outcomes after coronary artery bypass grafting: The argument for dual antiplatelet therapy. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 1555-1556.	0.4	0
1506	Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel. Drug Research, 2015, 65, 505-514.	0.7	8
1507	Dolor torácico en Urgencias. Medicine, 2015, 11, 5167-5174.	0.0	1
1508	Protocolo diagnóstico-terapéutico del sÃndrome coronario agudo sin elevación del segmento ST en Urgencias. Medicine, 2015, 11, 5209-5213.	0.0	1
1509	Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes, 2015, 13, 90.	1.0	27
1510	European Resuscitation Council Guidelines for Resuscitation 2015 Section 8. Initial management of acute coronary syndromes. Resuscitation, 2015, 95, 264-277.	1.3	114
1511	Post-Resuscitation ECG for Selection of Patients for Immediate Coronary Angiography in Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	56
1512	Dual Energy CT Imaging for the Assessment of Coronary Artery Stenosis., 2015, , 173-193.		0
1513	Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidenceâ€Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Journal of the American Heart Association, 2015, 4, .	1.6	79
1514	Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction. Cardiovascular Drugs and Therapy, 2015, 29, 495-495.	1.3	3
1515	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and olderâ€"rationale and design of the POPular AGE study. American Heart Journal, 2015, 170, 981-985.e1.	1.2	43
1516	Retrospective Evaluation of Two Fast-track Strategies to Rule Out Acute Coronary Syndrome in a Real-life Chest Pain Population. Journal of Emergency Medicine, 2015, 49, 833-842.	0.3	2
1517	Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome. Biomarkers in Medicine, 2015, 9, 209-216.	0.6	8
1518	Traitement médicamenteux du syndrome coronarien aigu du sujet âgé. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2015, 2015, 8-11.	0.0	O

#	ARTICLE	IF	CITATIONS
1519	Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study. BMC Cardiovascular Disorders, 2015, 15, 55.	0.7	4
1520	Apixaban Plus Mono Versus DualÂAntiplatelet Therapy in AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2015, 66, 777-787.	1.2	39
1521	Comparison of the management and inâ€hospital outcomes of acute coronary syndrome patients in <scp>A</scp> ustralia and <scp>N</scp> ew <scp>Z</scp> ealand: results from the binational <scp>SNAPSHOT</scp> acute coronary syndrome 2012 audit. Internal Medicine Journal, 2015, 45, 497-509.	0.5	7
1522	Dual antiplatelet therapy: optimal timing, management, and duration. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 198-204.	1.4	32
1523	Trends in 28â€day and 1â€year mortality rates in patients hospitalized for a first acute myocardial infarction in Norway during 2001–2009: a "Cardiovascular disease in Norway―(CVDNOR) project. Journal of Internal Medicine, 2015, 277, 353-361.	2.7	24
1524	Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress. Antioxidants and Redox Signaling, 2015, 23, 899-942.	2.5	130
1525	Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism. Clinica Chimica Acta, 2015, 451, 240-246.	0.5	22
1527	Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Revista Portuguesa De Cardiologia, 2015, 34, 403-410.	0.2	20
1528	European Resuscitation Council Guidelines for Resuscitation 2015. Resuscitation, 2015, 95, 1-80.	1.3	813
1529	Acute coronary syndromes. BMJ, The, 2015, 351, h5153.	3.0	46
1530	Dual antiplatelet therapy use by Canadian cardiac surgeons. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 1548-1554.e3.	0.4	27
1531	Dual-Energy CT in Cardiovascular Imaging. , 2015, , .		3
1532	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 2016, 37, ehv482.	1.0	70
1533	Renal dysfunction, coronary revascularization and mortality among elderly patients with non ST elevation acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 453-460.	0.4	18
1535	Clinical Utility of Ventricular Repolarization Dispersion for Realâ€Time Detection of Nonâ€ST Elevation	1.6	23
	Myocardial Infarction in Emergency Departments. Journal of the American Heart Association, 2015, 4, .		
1536	Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 2015, 4, 131-153.	1.1	6
1536 1537	Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes	1.1	7

#	Article	IF	CITATIONS
1539	Chest pain in the emergency department: risk stratification with Manchester triage system and HEART score. BMC Cardiovascular Disorders, 2015, 15, 48.	0.7	51
1540	Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay. BMC Medicine, 2015, 13, 169.	2.3	18
1541	Stress-echocardiography is underused in clinical practice: a nationwide survey in Austria. Wiener Klinische Wochenschrift, 2015, 127, 514-520.	1.0	1
1542	Long-term Prognosis of Patients With Non—ST-segment Elevation Acute Myocardial Infarction and Coronary Arteries Without Significant Stenosis. Revista Espanola De Cardiologia (English Ed), 2015, 68, 777-784.	0.4	3
1543	Neutrophil-to-lymphocyte ratio predicts coronary artery lesion complexity and mortality after non-ST-segment elevation acute coronary syndrome. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 r	gB Ti/2 verl	loc k 10 Tf 50
1545	Usefulness of the Logistic Clinical Syntax Score in Prediction of Saphenous Vein Graft Failure in Patients Undergoing Coronary Artery Bypass Grafting. Angiology, 2015, 66, 714-720.	0.8	5
1546	Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction — A pilot study. International Journal of Cardiology, 2015, 198, 26-30.	0.8	17
1547	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
1548	Coronary atherosclerosis and adverse outcomes in patients with recent-onset atrial fibrillation and troponin rise. American Journal of Emergency Medicine, 2015, 33, 1407-1413.	0.7	13
1549	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	0.9	30
1550	Assessment of Fractional Flow Reserve in Patients With Recent Nonâ∈"ST-Segmentâ∈"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e002207.	1.4	17
1551	A national survey of troponin testing and recommendations for improved practice. Annals of Clinical Biochemistry, 2015, 52, 527-542.	0.8	13
1552	Biomarkers in acute coronary syndrome. IJC Metabolic & Endocrine, 2015, 8, 20-23.	0.5	14
1553	CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 426-430.	1.3	30
1554	Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings. Cardiovascular Drugs and Therapy, 2015, 29, 461-467.	1.3	22
1555	Drug–drug interactions between clopidogrel and novel cardiovascular drugs. European Journal of Pharmacology, 2015, 765, 332-336.	1.7	10
1556	Temporal Release Pattern of Copeptin and Troponin T in Patients with Suspected Acute Coronary Syndrome and Spontaneous Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1273-1282.	1.5	46
1557	Optimizing Early Rule-Out Strategies for Acute Myocardial Infarction: Utility of 1-Hour Copeptin. Clinical Chemistry, 2015, 61, 1466-1474.	1.5	14

#	Article	IF	CITATIONS
1558	Controversies in Cardiology. , 2015, , .		0
1559	Microparticles: A Novel Player in Cardiovascular Diseases. Cardiology, 2015, 132, 249-251.	0.6	3
1560	Stroke: cardiac causes and their management. European Heart Journal, 2015, 36, 2339-2341.	1.0	1
1561	Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal. International Journal of Cardiology, 2015, 201, 494-496.	0.8	3
1562	In-hospital outcomes and long-term mortality according to sex and management strategy in acute myocardial infarction. Insights from the French ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2005 Registry. International Journal of Cardiology, 2015, 201, 265-270.	0.8	35
1563	Aspirin dosing in cardiovascular disease prevention and management: an update. Journal of Thrombosis and Thrombolysis, 2015, 40, 499-511.	1.0	7
1564	Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. International Journal of Cardiovascular Imaging, 2015, 31, 1281-1291.	0.7	12
1565	Incremental value of exercise echocardiography over exercise electrocardiography in a chest pain unit. European Journal of Internal Medicine, 2015, 26, 720-725.	1.0	11
1566	Imaging in coronary artery disease. Cardiac magnetic resonance Cor Et Vasa, 2015, 57, e453-e461.	0.1	2
1567	Monochromatic image reconstruction by dual energy imaging allows half iodine load computed tomography coronary angiography. European Journal of Radiology, 2015, 84, 1915-1920.	1.2	43
1569	Impact of Acute Coronary Syndrome Complicated by Ventricular Fibrillation on Long-term Incidence of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed), 2015, 68, 878-884.	0.4	3
1570	Elevated Troponin Levels in Patients Without Acute Coronary Syndrome: What is the Real Diagnosis? Response. Revista Espanola De Cardiologia (English Ed), 2015, 68, 913-914.	0.4	0
1571	A decisão de não revascularizar o enfarte agudo do miocárdio sem supradesnivelamento de ST – condicionantes e prognóstico. A realidade nacional. Revista Portuguesa De Cardiologia, 2015, 34, 315-328.	0.2	7
1572	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. Revista Portuguesa De Cardiologia, 2015, 34, 449-456.	0.2	4
1573	HAS-BLED score predicts risk of in-hospital major bleeding in patients with acute non-ST segment elevation myocardial infarction. Thrombosis Research, 2015, 136, 775-780.	0.8	11
1574	Elevated Troponin Levels in Patients Without Acute Coronary Syndrome: What is the Real Diagnosis?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 912-913.	0.4	0
1575	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). American Heart Journal, 2015, 170, 995-1004.e1.	1.2	23
1576	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. Circulation, 2015, 132, 1871-1879.	1.6	39

#	Article	IF	CITATIONS
1577	Early invasive treatment for acute coronary syndrome in patients with chronic kidney disease: do we know what we're doing?. Future Cardiology, 2015, 11, 5-8.	0.5	1
1578	Diagnostic accuracy of left ventricular longitudinal function by speckle tracking echocardiography to predict significant coronary artery stenosis. A systematicÂreview. BMC Medical Imaging, 2015, 15, 25.	1.4	42
1579	The coronary angiography - An old-timer in great shape. Cor Et Vasa, 2015, 57, e419-e424.	0.1	13
1580	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein Ilb/Illa Inhibitors in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 201-213.	1.1	69
1581	Identification of the major degradation pathways of ticagrelor. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 74-83.	1.4	18
1582	The German CPU Registry: Dyspnea independently predicts negative short-term outcome in patients admitted to German Chest Pain Units. International Journal of Cardiology, 2015, 181, 88-95.	0.8	19
1583	Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets, 2015, 26, 467-473.	1.1	25
1584	Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 226-231.	0.7	21
1585	Incidence and timing of serious arrhythmias after early revascularization in non ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 359-364.	0.4	5
1586	How acute changes in cardiac troponin concentrations help to handle the challenges posed by troponin elevations in non-ACS-patients. Clinical Biochemistry, 2015, 48, 218-222.	0.8	18
1587	Comparison of exercise electrocardiogram and exercise echocardiography in intermediate-risk chest pain patients. American Journal of Emergency Medicine, 2015, 33, 7-13.	0.7	4
1588	Prognostic value of IL6 in young adults presenting with acute coronary syndrome. Egyptian Heart Journal, 2015, 67, 151-158.	0.4	4
1589	Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. European Heart Journal, 2015, 36, 369-376.	1.0	182
1590	Elevated plasma dimethylglycine is a risk marker of mortality in patients with coronary heart disease. European Journal of Preventive Cardiology, 2015, 22, 743-752.	0.8	35
1591	Prognosis and Management of Acute Coronary Syndrome in Spain in 2012: The DIOCLES Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 98-106.	0.4	20
1592	Two-hour Algorithm for Triage Toward Rule-out and Rule-in of Acute Myocardial Infarction Using High-sensitivity Cardiac Troponin T. American Journal of Medicine, 2015, 128, 369-379.e4.	0.6	121
1593	Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. Herz, 2015, 40, 18-26.	0.4	26
1594	Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the †real world'. Journal of Thrombosis and Thrombolysis, 2015, 39, 499-507.	1.0	20

#	Article	IF	CITATIONS
1595	Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets, 2015, 26, 521-529.	1.1	13
1596	Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Reviews, 2015, 29, 179-189.	2.8	43
1597	An unusual case of a three coronary artery spasm. International Journal of Cardiology, 2015, 179, 29-30.	0.8	1
1598	Troponins in heart failure. Clinica Chimica Acta, 2015, 443, 78-84.	0.5	32
1600	The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. Clinica Chimica Acta, 2015, 438, 376-381.	0.5	80
1601	Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation) Tj ETQq1 1	0 .∄& 4314	rgBT /Overl
1602	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 555-560.	0.4	45
1603	The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury. Angiology, 2015, 66, 701-707.	0.8	15
1604	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 254-262.	0.4	14
1605	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 2015, 36, 100-111.	1.0	241
1606	Consensus recommendations for using the Multiplate $<$ sup $>$ $\hat{A}^{@}$ $<$ /sup $>$ for platelet function monitoring before cardiac surgery. International Journal of Laboratory Hematology, 2015, 37, 143-147.	0.7	35
1607	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386.	0.4	46
1608	Glycogen phosphorylase BB in myocardial infarction. Clinica Chimica Acta, 2015, 438, 107-111.	0.5	10
1609	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
1610	Risk assessment for obstructive sleep apnea and anxiety in a Pakistani population with coronary artery disease. Sleep and Breathing, 2015, 19, 291-296.	0.9	5
1611	GRACE score predicts heart failure admission following acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 165-171.	0.4	15
1612	MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel – the European MULTIPRAC Registry. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 220-229.	0.4	48
1613	HEART score and clinical gestalt have similar diagnostic accuracy for diagnosing ACS in an unselected population of patients with chest pain presenting in the ED. Emergency Medicine Journal, 2015, 32, 595-600.	0.4	49

#	Article	IF	CITATIONS
1614	Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians. Heart and Vessels, 2015, 30, 186-192.	0.5	11
1615	Coronary embolism causing acute myocardial infarction. Review of the literature. Studia Medyczne, 2016, 2, 131-135.	0.0	1
1616	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thrombosis and Haemostasis, 2016, 115 , $382-391$.	1.8	14
1617	Switching of Ticagrelor to Clopidogrel at 3 Months in Patients Treated for Acute Care Syndrome; Single Centre Experience. Cardiovascular Pharmacology: Open Access, 2016, 5, .	0.1	6
1618	Big data: a new look at old problems. European Heart Journal Quality of Care & Dinical Outcomes, 2016, 2, 144-146.	1.8	0
1619	Assistência ao paciente com sÃndrome coronariana aguda segundo indicadores de qualidade. Revista Brasileira De Enfermagem, 2016, 69, 757-764.	0.2	5
1620	Determinants of Mortality in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. CardioRenal Medicine, 2016, 6, 169-179.	0.7	5
1621	A Complex PCI Case with AF Suffering from VLST with NOAC Treatment. Journal of Clinical Case Reports, 2016, 06, .	0.0	0
1622	Impact of new health care policies on the quality of acute myocardial infarction treatment in Swiss hospitals: A before and after observational study. Journal of Hospital Administration, 2016, 5, 10.	0.0	2
1623	Which clinical scoring system should we use for the evaluation of chest pain in the Emergency Department? A review. Emergency Care Journal, 2016, 12, .	0.2	0
1624	How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE). Clinical Chemistry, 2016, 62, 1264-1271.	1.5	49
1625	Diurnal Rhythm of Cardiac Troponin: Consequences for the Diagnosis of Acute Myocardial Infarction. Clinical Chemistry, 2016, 62, 1602-1611.	1.5	71
1626	COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) Study: design and objectives. Postepy W Kardiologii Interwencyjnej, 2016, 4, 360-363.	0.1	2
1627	Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2016, 129, 2269-2274.	0.9	12
1628	Coronary artery disease (CAD) in chronic kidney disease patients. Giornale De Techniche Nefrologiche & Dialitiche, 2016, 28, 44-52.	0.1	1
1629	Percutaneous Coronary Intervention Is More Beneficial Than Optimal Medical Therapy in Elderly Patients with Angina Pectoris. Yonsei Medical Journal, 2016, 57, 382.	0.9	6
1630	Efficacy and safety outcomes of fractional flow reserve in guiding clinical therapy of non-ST-segment elevation myocardial infarction compared with angiography alone in elderly Chinese patients. Clinical Interventions in Aging, 2016, Volume 11, 1751-1754.	1.3	12
1631	Characteristics of and outcomes for elderly patients with acute myocardial infarction: differences between females and males. Clinical Interventions in Aging, 2016, Volume 11, 1309-1316.	1.3	6

#	Article	IF	CITATIONS
1632	Up-regulated Circulating T-cell Angiotensin Converting Enzyme Gene Expression and Activity in Acute Coronary Syndromes. Journal of Clinical & Cellular Immunology, 2016, 07, .	1.5	0
1633	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. Arquivos Brasileiros De Cardiologia, 2016, 106, 236-46.	0.3	4
1634	Focusing on spontaneous coronary artery dissection: actuality and future perspectives. Journal of Thoracic Disease, 2016, 8, E1784-E1786.	0.6	8
1635	The Modification Effect of Influenza Vaccine on Prognostic Indicators for Cardiovascular Events after Acute Coronary Syndrome: Observations from an Influenza Vaccination Trial. Cardiology Research and Practice, 2016, 2016, 1-9.	0.5	5
1636	Integration of medical therapy and mechanical circulatory support in the management of acute heart failure. Archives of Medical Science, 2016, 6, 1317-1323.	0.4	4
1637	Frailty and quality of life in elderly patients with acute coronary syndrome. Clinical Interventions in Aging, 2016, 11, 553.	1.3	18
1638	Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2016, 115, 7-24.	1.8	25
1640	Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis. PLoS ONE, 2016, 11, e0148756.	1.1	18
1641	STEMI Outcomes in Guangzhou and Hong Kong: Two-Centre Retrospective Interregional Study. PLoS ONE, 2016, 11, e0149981.	1.1	4
1642	Ventricular Dysfunction in Patients with Acute Coronary Syndrome Undergoing Coronary Surgical Revascularization: Prognostic Impact on Long-Term Outcomes. PLoS ONE, 2016, 11, e0168634.	1.1	3
1643	Efficacy and safety outcomes of ticagrelor compared with clopidogrel in Chinese elderly patients with acute coronary syndrome. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1101-1105.	0.9	41
1644	Acute chest pain and cardiac computed tomography. Sang Thrombose Vaisseaux, 2016, 28, 119-131.	0.1	0
1645	Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention – real life assessment. Postepy W Kardiologii Interwencyjnej, 2016, 4, 303-313.	0.1	9
1646	Manual Thrombus Aspiration and the Improved Survival of Patients With Unstable Angina Pectoris Treated With Percutaneous Coronary Intervention (30 Months Follow-Up). Medicine (United States), 2016, 95, e2919.	0.4	4
1647	Clopidogrel-Associated Neutropenia: Case Report and Review of the Literature. American Journal of Therapeutics, 2016, 23, e1197-e1201.	0.5	8
1648	Antiplatelet and Anticoagulation Treatment in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	0.6	2
1649	High levels of preoperative and postoperative N terminal B-type natriuretic propeptide influence mortality and cardiovascular complications after noncardiac surgery. European Journal of Anaesthesiology, 2016, 33, 444-449.	0.7	23
1650	Cardiac Computed Tomography in Certified German Chest Pain Units. Critical Pathways in Cardiology, 2016, 15, 11-15.	0.2	5

#	Article	IF	CITATIONS
1651	Trends in pharmacological therapy following an acute coronary syndrome in Portugal. Journal of Cardiovascular Medicine, 2016, 17, 639-646.	0.6	3
1652	BleeMACS. Journal of Cardiovascular Medicine, 2016, 17, 744-749.	0.6	27
1653	Association between comorbidities and absence of chest pain in acute coronary syndrome with in-hospital outcome. International Journal of Cardiology, 2016, 217, S37-S43.	0.8	20
1654	Management of Patients With NSTE-ACS. Journal of the American College of Cardiology, 2016, 68, 313-321.	1.2	62
1655	External validation of the ProACS score for risk stratification of patients with acute coronary syndromes. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 323-328.	0.2	7
1656	Discriminative Power of the HEART Score for Obstructive Coronary Artery Disease in Acute Chest Pain Patients Referred for CCTA. Critical Pathways in Cardiology, 2016, 15, 6-10.	0.2	3
1657	Association of Early Stress Testing with Outcomes for Emergency Department Evaluation of Suspected Acute Coronary Syndrome. Critical Pathways in Cardiology, 2016, 15, 60-68.	0.2	6
1658	Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. Journal of Thrombosis and Haemostasis, 2016, 14, 273-281.	1.9	37
1659	Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Internal Medicine Journal, 2016, 46, 559-565.	0.5	30
1660	Acute myocardial infarction in the elderly: Treatment strategies and 28â€dayâ€case fatality from the <scp>MONICA/KORA</scp> myocardial infarction registry. Catheterization and Cardiovascular Interventions, 2016, 87, 680-688.	0.7	10
1661	Impact of anticoagulation regimen prior to revascularization in patients with nonâ€ <scp>ST</scp> â€segment elevation acute coronary syndromes: The <scp>ACUITY</scp> trial. Catheterization and Cardiovascular Interventions, 2016, 88, 174-181.	0.7	4
1662	Sustained increase in platelet aggregation after the cessation of clopidogrel. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 161-165.	0.9	2
1663	Relationship between metabolites of arachidonic acid and prognosis in patients with acute coronary syndrome. Thrombosis Research, 2016, 144, 192-201.	0.8	37
1664	Predictive factors for perioperative blood transfusion in neck dissection. Laryngoscope, 2016, 126, 851-857.	1.1	8
1665	Myocardial perfusion 320-row multidetector computed tomography–guided treatment strategy for the clinical management of patients with recent acute-onset chest pain. American Heart Journal, 2016, 179, 127-135.	1.2	5
1666	Analgesia by telemedically supported paramedics compared with physicianâ€administered analgesia: A prospective, interventional, multicentre trial. European Journal of Pain, 2016, 20, 1176-1184.	1.4	45
1667	PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 379-381.	0.9	3
1668	Defining Characteristics and Related Factors of Decreased Cardiac Tissue Perfusion: Proposal of a New Nursing Diagnosis. International Journal of Nursing Knowledge, 2016, 27, 175-180.	0.4	4

#	Article	IF	CITATIONS
1669	Type <scp>D</scp> personality is related to severity of acute coronary syndrome in patients with recurrent cardiovascular disease. British Journal of Health Psychology, 2016, 21, 694-711.	1.9	13
1670	Effect of thrombus aspiration on postprocedural outcomes in elderly patients with acute <scp>ST</scp> â€elevation myocardial ınfarction. Geriatrics and Gerontology International, 2016, 16, 722-728.	0.7	O
1671	Women's experiences during myocardial infarction: systematic review and metaâ€ethnography. Journal of Clinical Nursing, 2016, 25, 599-609.	1.4	6
1672	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. Heart, 2016, 102, 1648-1654.	1.2	21
1673	Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study. BMJ Open, 2016, 6, e011600.	0.8	18
1674	Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart, 2016, 3, e000384.	0.9	9
1675	Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ Open, 2016, 6, e010880.	0.8	30
1679	Reducing time to angiography and hospital stay for patients with high-risk non-ST-elevation acute coronary syndrome: retrospective analysis of a paramedic-activated direct access pathway. BMJ Open, 2016, 6, e010428.	0.8	3
1680	Systematic review and meta-analysis of optimal P2Y ₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart, 2016, 3, e000296.	0.9	13
1681	Prasugrel Use in Real Life: A Report From the Outpatient Setting in France. Clinical Cardiology, 2016, 39, 378-384.	0.7	1
1682	Validation of NICE diagnostic guidance for rule out of myocardial infarction using high-sensitivity troponin tests. Heart, 2016, 102, 1279-1286.	1.2	26
1683	Degree of dyspnoea in patients with non-ST-elevation acute coronary syndrome: A report from Japanese multicenter registry. International Journal of Clinical Practice, 2016, 70, 978-987.	0.8	1
1684	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally? Sometimes earlier may not be better Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3316-3323.	1.0	26
1685	Comparison of Risk Prediction With the <scp>CKDâ€EPI</scp> and <scp>MDRD</scp> Equations in Non– <scp>ST</scp> â€Segment Elevation Acute Coronary Syndrome. Clinical Cardiology, 2016, 39, 507-515.	0.7	17
1686	Health utility indexes in patients with acute coronary syndromes. Open Heart, 2016, 3, e000419.	0.9	14
1687	Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. Open Heart, 2016, 3, e000347.	0.9	4
1688	Predictors of non-invasive therapy and 28-day-case fatality in elderly compared to younger patients with acute myocardial infarction: an observational study from the MONICA/KORA Myocardial Infarction Registry. BMC Cardiovascular Disorders, 2016, 16, 151.	0.7	4
1689	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart, 2016, 102, 1221-1229.	1.2	3

#	Article	IF	CITATIONS
1690	Individualized antithrombotic therapy. Hamostaseologie, 2016, 36, 26-32.	0.9	8
1691	Combined measurements of plasma copeptin and troponin-I levels for early exclusion of acute myocardial infarction. Egyptian Journal of Critical Care Medicine, 2016, 4, 127-132.	0.2	0
1692	Does anemia affect the predictive ability of bleeding risk scores in patients with acute coronary syndromes?. Revista Portuguesa De Cardiologia, 2016, 35, 637-644.	0.2	0
1693	Hypersensitivity to aspirin and urgent percutaneous coronary intervention: A therapeutic challenge. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 619.e1-619.e5.	0.2	1
1694	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 645-653.	0.2	5
1695	Does anemia affect the predictive ability of bleeding risk scores in patients with acute coronary syndromes?. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 637-644.	0.2	0
1696	Study to Improve Cardiovascular Outcomes in high-risk older patieNts (ICON1) with acute coronary syndrome: study design and protocol of a prospective observational study. BMJ Open, 2016, 6, e012091.	0.8	25
1697	Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. BMJ Open, 2016, 6, e012604.	0.8	26
1698	Unfractioned heparin versus bivalirudin in patients undergoing percutaneous coronary intervention for acute coronary syndrome. The Cochrane Library, 0, , .	1.5	0
1699	2016 ACC/AHA Guideline FocusedÂUpdate on Duration of DualÂAntiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	1.2	1,232
1700	Life-threatening ventricular tachyarrhythmias in the cardiology department: Implications for appropriate prescription of telemetry monitoring. Resuscitation, 2016, 101, 6-11.	1.3	6
1701	The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get With the Guidelines (GWTG) Medicare-linked database. American Heart Journal, 2016. 178. 65-73.	1.2	54
1702	Serum IgE levels are associated with coronary artery disease severity. Atherosclerosis, 2016, 251, 355-360.	0.4	36
1703	Platelet function testing after acute myocardial infarction: The correlation among various assays is insufficient. Cor Et Vasa, 2016, 58, e411-e418.	0.1	0
1704	Modified revisiting of old balloon inflation technique during PCI for dealing with thrombus laden lesion in non-ST-segment elevation myocardial infarction. Indian Heart Journal, 2016, 68, 202-204.	0.2	1
1705	Reply to the Letter to the Editor entitled "Bleeding risk assessment and comorbidities in elderly patients with acute coronary syndromes― Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 249-250.	0.2	0
1706	Myocardial Infarction in the "Young― Risk Factors, Presentation, Management and Prognosis. Heart Lung and Circulation, 2016, 25, 955-960.	0.2	94
1707	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. American Heart Journal, 2016, 178, 37-44.	1.2	20

#	Article	IF	CITATIONS
1708	Gender differences in the prognostic role of uric acid and confounding factors. Journal of Cardiology, 2016, 67, 483.	0.8	0
1709	Reply to the Letter to the Editor entitled "Bleeding risk assessment and comorbidities in elderly patients with acute coronary syndromes― Revista Portuguesa De Cardiologia, 2016, 35, 249-250.	0.2	0
1710	Validity of the updated GRACE risk predictor (version 2.0) in patients with non-ST-elevation acute coronary syndrome. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 25-31.	0.2	4
1711	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	0.8	8
1712	Editorial Commentary: Striking a balance: Individualizing antithrombotic therapy after myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 335-336.	2.3	1
1713	Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction $\hat{a} \in \mathbb{C}$ a systematic review. Expert Opinion on Pharmacotherapy, 2016, 17, 1387-1394.	0.9	8
1714	Renin–angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 172-177.	1.0	5
1715	Telomere length, antioxidant status and incidence of ischaemic heart disease in type 2 diabetes. International Journal of Cardiology, 2016, 216, 159-164.	0.8	27
1716	Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: atherogenic index of plasma, neutrophil–lymphocyte ratio. BMC Cardiovascular Disorders, 2016, 16, 96.	0.7	30
1717	Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. American Journal of Therapeutics, 2016, 23, e1876-e1889.	0.5	12
1718	High-frequency QRS analysis superior to conventional ST-segment analysis of women with chest pain. American Journal of Emergency Medicine, 2016, 34, 437-442.	0.7	5
1719	Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss–of function polymorphisms (*2/*3). International Journal of Cardiology, 2016, 212, 148-150.	0.8	5
1720	Scores de risco cardiovascular: utilidade e limitações. Revista Portuguesa De Cardiologia, 2016, 35, 15-18.	0.2	5
1721	Timing of intervention in high-risk non-ST-elevation acute coronary syndromes in PCI versus non-PCI centres. Netherlands Heart Journal, 2016, 24, 181-187.	0.3	9
1722	Prise en charge des douleurs thoraciques aiguësÂ: l'apport majeur du coroscanner. Diagnostic and Interventional Imaging, 2016, 97, 34-41.	0.0	0
1723	Time to shift from contemporary to high-sensitivity cardiac troponin in diagnosis of acute coronary syndromes. Indian Heart Journal, 2016, 68, 851-855.	0.2	5
1724	Clinical relevance of high sensitivity C-reactive protein in cardiology. Medicina (Lithuania), 2016, 52, 1-10.	0.8	57
1725	Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study. Platelets, 2016, 27, 452-458.	1.1	33

#	Article	IF	CITATIONS
1726	High-sensitivity troponin measurements: challenges and opportunities for the laboratory and the clinician. Annals of Clinical Biochemistry, 2016, 53, 191-195.	0.8	2
1727	Facilitating or getting in the way? The effect of clinicians' knowledge, values and beliefs on referral and participation. European Journal of Preventive Cardiology, 2016, 23, 1141-1150.	0.8	27
1728	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 5-12.	1.4	40
1729	Clinical impact of the 2010–2012 low-end shift of high-sensitivity cardiac troponin T. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 399-408.	0.4	20
1730	Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients. Renal Failure, 2016, 38, 728-737.	0.8	8
1731	Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 2016, 18, 48.	1.3	4
1732	Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. Heart Lung and Circulation, 2016, 25, 1077-1086.	0.2	127
1733	eComment. Rise of Ticagrelor and the vital necessity for specific reversal agents. Interactive Cardiovascular and Thoracic Surgery, 2016, 22, 410-410.	0.5	O
1734	Effect of Beta Blockers and Renin–Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Medicine (United States), 2016, 95, e2971.	0.4	11
1735	The presence of remodeled and mixed atherosclerotic plaques at coronary ct angiography predicts major cardiac adverse events â€" The CAFÉ-PIE Study. International Journal of Cardiology, 2016, 215, 325-331.	0.8	16
1736	Increased homocysteine and lipoprotein(a) levels highlight systemic atherosclerotic burden in patients with a history of acute coronary syndromes. Journal of Vascular Surgery, 2016, 64, 163-170.	0.6	16
1737	Platelet-Mediated Thrombosis. Circulation Research, 2016, 118, 1380-1391.	2.0	56
1738	A clinical score to obviate the need for cardiac stress testing in patients with acute chest pain and negative troponins. American Journal of Emergency Medicine, 2016, 34, 1421-1426.	0.7	4
1739	Transatlantic Editorial: A Comparison Between European and North American Guidelines on Myocardial Revascularization. Annals of Thoracic Surgery, 2016, 101, 2031-2044.	0.7	4
1740	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal, 2016, 37, 1967-1976.	1.0	433
1741	Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2016, 42, 360-368.	1.0	10
1742	Transatlantic Editorial: a comparison between European and North American guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2016, 49, 1307-1317.	0.6	8
1744	Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. European Heart Journal, 2016, 37, 2406-2413.	1.0	270

#	Article	IF	CITATIONS
1745	Transatlantic editorial: A comparison between European and North American guidelines on myocardial revascularization. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 304-316.	0.4	14
1746	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2016, 177, 1-8.	1.2	23
1747	Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). Canadian Journal of Cardiology, 2016, 32, 1246.e13-1246.e19.	0.8	4
1748	Deconvoluting the Dual Antiplatelet Activity of a Plant Extract. Journal of Agricultural and Food Chemistry, 2016, 64, 4511-4521.	2.4	13
1749	Prasugrel 5Âmg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. Journal of Thrombosis and Thrombolysis, 2016, 42, 369-375.	1.0	4
1750	Primary percutaneous coronary intervention network in Bosnia and Herzegovina: Where are we now and how to improve PCI network. International Journal of Cardiology, 2016, 217, S49-S51.	0.8	1
1751	Do elderly females have a higher risk of acute myocardial infarction? A retrospective analysis of 329 cases at an emergency department. Taiwanese Journal of Obstetrics and Gynecology, 2016, 55, 563-567.	0.5	7
1752	Long-Term Prognosis of Deferred AcuteÂCoronary Syndrome Lesions Based on Nonischemic FractionalÂFlowÂReserve. Journal of the American College of Cardiology, 2016, 68, 1181-1191.	1.2	72
1753	Chronic Stable Angina Pectoris: History and Epidemiology. , 2016, , 1-13.		1
1754	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart, 2016, 102, 1396-1402.	1.2	13
1755	Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. American Heart Journal, 2016, 181 , $16-25$.	1.2	63
1756	Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON study. Hellenic Journal of Cardiology, 2016, 57, 157-166.	0.4	33
1757	Routine invasive strategy in acute coronary syndrome patients with renal dysfunction. Results of the ARIAM-SEMICYUC registry. Medicina Intensiva (English Edition), 2016, 40, 280-288.	0.1	3
1759	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 319-321.	0.2	0
1760	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Thrombosis Research, 2016, 147, 108-114.	0.8	10
1761	Administration of Coagulation-Altering Therapy in the Patient Presenting for Oral Health and Maxillofacial Surgery. Oral and Maxillofacial Surgery Clinics of North America, 2016, 28, 443-460.	0.4	2
1762	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.4	249
1763	Validação externa do score de risco ProACS para estratificação de risco de doentes com sÃndrome coronária aguda. Revista Portuguesa De Cardiologia, 2016, 35, 323-328.	0.2	6

#	Article	IF	CITATIONS
1764	Hipersensibilidade à aspirina e coronariografia urgente: desafio terapêutico. Revista Portuguesa De Cardiologia, 2016, 35, 619.e1-619.e5.	0.2	0
1765	Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2016, 147, 52-57.	0.8	20
1766	Octogenarians died mainly of cardiovascular diseases five years after acute coronary syndrome. Scandinavian Cardiovascular Journal, 2016, 50, 300-304.	0.4	5
1767	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. International Journal of Cardiology, 2016, 221, 682-687.	0.8	1
1768	Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031665648.	1.0	5
1769	Is hemoglobin variation a linear predictor of mortality in acute coronary syndrome?. Clinical Trials and Regulatory Science in Cardiology, 2016, 19, 9-12.	1.0	3
1770	Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). Atherosclerosis, 2016, 254, 20-27.	0.4	10
1771	Validation of presentation and 3 h high-sensitivity troponin to rule-in and rule-out acute myocardial infarction. Heart, 2016, 102, 1270-1278.	1.2	82
1772	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. International Journal of Cardiology, 2016, 222, 1079-1083.	0.8	10
1773	Influence of the coronary calcium score on the ability to rule out coronary artery stenoses by coronary CT angiography in patients with suspected coronary artery disease. Journal of Cardiovascular Computed Tomography, 2016, 10, 343-350.	0.7	19
1774	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). American Heart Journal, 2016, 181, 26-34.	1.2	16
1775	Long-term major adverse cardiovascular events and quality of life after coronary angiography in elderly patients with acute coronary syndrome. International Journal of Cardiology, 2016, 222, 481-485.	0.8	3
1776	Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. Journal of Clinical Anesthesia, 2016, 34, 586-599.	0.7	19
1777	Percutaneous management of patients with acute coronary syndromes from unprotected left main disease: A comprehensive review and presentation of a treatment algorithm. Catheterization and Cardiovascular Interventions, 2016, 87, 90-100.	0.7	2
1778	"Realâ€World―Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheterization and Cardiovascular Interventions, 2016, 88, 535-544.	0.7	55
1779	Cardiac <scp>CT</scp> for the Interventional Cardiologist. Continuing Cardiology Education, 2016, 2, 13-24.	0.4	0
1780	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 8-27.	2.9	835
1782	Pre-test probability of obstructive coronary stenosis in patients undergoing coronary CT angiography: Comparative performance of the modified diamond-Forrester algorithm versus methods incorporating cardiovascular risk factors. International Journal of Cardiology, 2016, 222, 346-351.	0.8	15

#	Article	IF	CITATIONS
1783	Assessment of Patient's Peak Skin Dose Using Gafchromic Films During Interventional Cardiology Procedures: Routine Experience Feedback. Radiation Protection Dosimetry, 2017, 174, 395-405.	0.4	9
1784	Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. International Journal of Cardiology, 2016, 219, 387-393.	0.8	19
1785	Correction of prasugrelâ€related bleeding by prophylactic transfusion of human platelets in a rabbit model. Transfusion, 2016, 56, 2618-2626.	0.8	2
1786	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia, 2016, 35, 645-653.	0.2	12
1787	Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease. International Journal of Angiology, 2016, 25, 210-218.	0.2	1
1788	Relationship Between Anemia and Mortality Outcomes in a National Acute Coronary Syndrome Cohort: Insights From the UK Myocardial Ischemia National Audit Project Registry. Journal of the American Heart Association, 2016, 5, .	1.6	57
1789	The Leipzig Prospective Drug-Eluting Balloon-Registry – Outcome of 484 Consecutive Patients Treated for Coronary In-Stent Restenosis and De Novo Lesions Using Paclitaxel-Coated Balloons –. Circulation Journal, 2016, 80, 379-386.	0.7	11
1790	A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circulation Journal, 2016, 80, 1113-1122.	0.7	54
1791	Virtual Monochromatic Imaging in Patients with Intermediate to High Likelihood of Coronary Artery Disease. Academic Radiology, 2016, 23, 1490-1497.	1.3	3
1792	Cytomegalovirusâ€Productive Infection Is Associated With Acute Coronary Syndrome. Journal of the American Heart Association, 2016, 5, .	1.6	50
1793	Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. BMC Cardiovascular Disorders, 2016, 16, 164.	0.7	9
1794	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization. Wiener Klinische Wochenschrift, 2016, 128, 906-915.	1.0	1
1795	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and AcuteACoronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1905-1913.	1.1	38
1796	Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. Platelets, 2016, 27, 650-657.	1.1	7
1797	Effects of \hat{I}^2 -blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. International Journal of Cardiology, 2016, 221, 765-769.	0.8	9
1798	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomarkers in Medicine, 2016, 10, 903-918.	0.6	8
1799	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. European Heart Journal, 2016, 37, 3335-3342.	1.0	138
1800	Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non–ST Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	4

#	Article	IF	CITATIONS
1802	Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways. Journal of Ethnopharmacology, 2016, 192, 10-19.	2.0	10
1803	Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: Insights from the BleeMACS registry. International Journal of Cardiology, 2016, 221, 364-370.	0.8	13
1804	A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. American Journal of Cardiovascular Drugs, 2016, 16, 285-295.	1.0	1
1805	Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. Journal of the Chinese Medical Association, 2016, 79, 521-530.	0.6	38
1806	A novel troponin I rule-out value below the upper reference limit for acute myocardial infarction. Heart, 2016, 102, 1721-1727.	1.2	11
1807	Secondary preventive medication use in a prevalent populationâ€based cohort of acute coronary syndrome survivors. Cardiovascular Therapeutics, 2016, 34, 423-430.	1.1	7
1808	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. European Heart Journal, 2017, 38, ehw525.	1.0	164
1809	Myocardial infarction in intensive care units: A systematic review of diagnosis and treatment. Journal of the Intensive Care Society, 2016, 17, 314-325.	1.1	7
1810	Anesthesia for Patients with Concomitant Cardiac and Renal Dysfunction. Anesthesiology Clinics, 2016, 34, 697-710.	0.6	5
1811	Acute coronary syndromesâ€"the role of the CCU nurse. Part I: Initial management. British Journal of Cardiac Nursing, 2016, 11, 453-458.	0.0	1
1812	Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries: a subset analysis of results from the observational, longitudinal cohort study EPICOR. Acta Cardiologica, 2016, 71, 15-24.	0.3	4
1813	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2016, 24, .	0.0	6
1814	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 2016, 3, e000371.	0.9	7
1816	ST-segment elevation in lead aVR in the setting of acute coronary syndrome. Acta Cardiologica, 2016, 71, 47-54.	0.3	8
1817	Non-ST-segment Elevation Myocardial Infarction Associated with Multiple Comorbidities in a Patient with a Ventriculoperitoneal Shunt for Obstructive Hydrocephalus Following Traumatic Brain Injury. Journal of Cardiovascular Emergencies, 2016, 2, 85-90.	0.1	О
1818	Prehospital diagnosis of patients with acute myocardial infarction. Diagnosis, 2016, 3, 155-166.	1.2	26
1819	Assessment of diastolic dysfunction in patients with acute coronary syndrome and preserved systolic function: comparison between Doppler transthoracic echocardiography and velocity-encoded cardiac magnetic resonance. Acta Cardiologica, 2016, 71, 425-434.	0.3	1
1820	Association between plasma ADAMTS-7 levels and severity of disease in patients with stable obstructive coronary artery disease. Medicine (United States), 2016, 95, e5523.	0.4	8

#	Article	IF	CITATIONS
1821	Medical consumption compared for TIMI and HEART score in chest pain patients at the emergency department: a retrospective cost analysis. BMJ Open, 2016, 6, e010694.	0.8	22
1822	Predicting mortality after acute coronary syndromes in people with chronic obstructive pulmonary disease. Heart, 2016, 102, 1442-1448.	1.2	10
1823	A rare case of large intracoronary thrombosis in advanced breast cancer patient treated with epirubicin and cisplatin. Journal of Cardiovascular Medicine, 2016, 17, e241-e243.	0.6	6
1824	Use of diagnostic coronary angiography in women and men presenting with acute myocardial infarction: a matched cohort study. BMC Cardiovascular Disorders, 2016, 16, 120.	0.7	6
1825	Symptoms and delay times during myocardial infarction in 694 patients with and without diabetes; an explorative cross-sectional study. BMC Cardiovascular Disorders, 2016, 16, 108.	0.7	22
1826	Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. BMC Cardiovascular Disorders, 2016, 16, 115.	0.7	45
1827	The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model. Medicine (United States), 2016, 95, e4145.	0.4	2
1828	The value of 3-dimensional longitudinal strain in the evaluation of complex coronary lesions in non-ST-segment elevation acute coronary syndrome patient. Medicine (United States), 2016, 95, e4667.	0.4	6
1829	Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. The Cochrane Library, 2016, 2016, CD004815.	1.5	42
1830	The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Catheterization and Cardiovascular Interventions, 2016, 87, 608-615.	0.7	10
1831	Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1â€year outcomes from the GReek AntiPlatElet (GRAPE) Registry. Journal of Thrombosis and Haemostasis, 2016, 14, 1146-1154.	1.9	58
1832	Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of	1.6	1,069
1833	Patients' goals, resources, and barriers to future change: A qualitative study of patient reflections at hospital discharge after myocardial infarction. European Journal of Cardiovascular Nursing, 2016, 15, 495-503.	0.4	23
1834	Validity of the updated GRACE risk predictor (version 2.0) in patients with non-ST-elevation acute coronary syndrome. Revista Portuguesa De Cardiologia, 2016, 35, 25-31.	0.2	11
1835	On- versus off-hour care for patients with non-ST-segment elevation myocardial infarction in Germany. Herz, 2016, 41, 725-731.	0.4	5
1836	Early vascular healing after titanium–nitride–oxide-coated stent versus platinum–chromium everolimus-eluting stent implantation in patients with acute coronary syndrome. International Journal of Cardiovascular Imaging, 2016, 32, 1031-1039.	0.7	14
1837	Delay in Revascularization and Prognosis After Myocardial Infarction. Angiology, 2016, 67, 300-300.	0.8	0
1838	Point-of-care haemostasis and coagulation monitoring in cardiac surgery at IRCCS Policlinico San Donato. European Heart Journal Supplements, 2016, 18, E42-E48.	0.0	7

#	Article	IF	CITATIONS
1839	Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. European Heart Journal Supplements, 2016, 18, F19-F26.	0.0	15
1840	Educational Case: A 57-year-old man with chest pain. Oxford Medical Case Reports, 2016, 2016, 62-65.	0.2	0
1841	Early versus delayed percutaneous coronary intervention in patients with non-ST elevation acute coronary syndromes. Coronary Artery Disease, 2016, 27, 344-349.	0.3	7
1842	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. American Journal of Cardiology, 2016, 118, 700-707.	0.7	22
1843	Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. Platelets, 2016, 27, 812-820.	1.1	3
1844	Impact of low hemoglobin on the development of contrast-induced nephropathy: A retrospective cohort study. Experimental and Therapeutic Medicine, 2016, 12, 603-610.	0.8	13
1845	Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The †wait a day†approach might be safer. Netherlands Heart Journal, 2016, 24, 173-180.	0.3	16
1846	Immediate percutaneous coronary intervention in NSTE-ACS: the sun is not hurried by early risers. Netherlands Heart Journal, 2016, 24, 171-172.	0.3	0
1848	Treatment variation in stent choice in patients with stable or unstable coronary artery disease. Netherlands Heart Journal, 2016, 24, 110-119.	0.3	4
1849	Preoperative diagnosis and postoperative prognosis in patients undergoing coronary artery bypass graft surgery. American Heart Journal, 2016, 171, e9.	1.2	0
1850	The effects of bivalirudin vs heparin on short-term outcomes in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2016, 214, 270-274.	0.8	1
1851	Ischemic heart disease and early diagnosis. Study on the predictive value of 2D strain. International Journal of Cardiology, 2016, 215, 150-156.	0.8	33
1852	Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. Resuscitation, 2016, 105, 16-21.	1.3	10
1853	Antithrombotic Therapy and Direct Medical Costs in Patients with Acute Coronary Syndrome in Shanghai, China. Value in Health Regional Issues, 2016, 9, 93-98.	0.5	3
1854	Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiology, 2016, 1, 397.	3.0	186
1855	The effect of activated clotting time values for patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Thrombosis Research, 2016, 144, 202-209.	0.8	5
1856	Predictive role of high sensitivity troponin T within four hours from presentation of acute coronary syndrome in elderly patients. BMC Emergency Medicine, 2016, 16, 1.	0.7	17
1857	Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study. Cardiovascular Diabetology, 2016, 15, 60.	2.7	26

#	ARTICLE	IF	CITATIONS
1858	How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities. European Journal of Medical Research, 2016, 21, 11.	0.9	1
1859	Analysis of extracellular vesicles using magnetic nanoparticles in blood of patients with acute coronary syndrome. Biochemistry (Moscow), 2016, 81, 382-391.	0.7	10
1860	Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. Wiener Klinische Wochenschrift, 2016, 128, 467-479.	1.0	45
1861	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. Revista Portuguesa De Cardiologia, 2016, 35, 319-321.	0.2	1
1862	Women's helpâ€seeking behaviour during a first acute myocardial infarction. Scandinavian Journal of Caring Sciences, 2016, 30, 670-677.	1.0	10
1863	Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes. Journal of Pharmacy Practice, 2016, 29, 239-249.	0.5	10
1864	The current status of multi-arterial off-pump coronary artery bypass grafting. Surgery Today, 2016, 46, 1-12.	0.7	7
1865	Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. Heart and Vessels, 2016, 31, 275-287.	0.5	3
1866	Incremental value of heart-type fatty acid-binding protein in suspected acute myocardial infarction early after symptom onset. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 185-192.	0.4	17
1867	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 3-12.	0.4	41
1868	Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis, 2016, 41, 464-474.	1.0	18
1869	Clinical effectiveness of the systematic use of the GRACE scoring system (in addition to clinical) Tj ETQq1 1 0.784 compared with clinical assessment alone: a prospective study. Heart and Vessels, 2016, 31, 897-906.	1314 rgBT 0.5	/Overlock 1 6
1870	Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial) Tj ETQqC	0.4rgBT	/Overlock 10
1871	Care, 2016, 5, 364-374. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 177-184.	0.4	9
1872	Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis. Cardiology, 2016, 133, 163-172.	0.6	15
1873	Quality markers in cardiology: measures of outcomes and clinical practice—a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. European Heart Journal, 2016, 37, 12-23.	1.0	14
1874	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. Circulation, 2016, 133, 248-255.	1.6	26
1876	Ethnic differences in clinical outcome of patients presenting to the emergency department with chest pain. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 32-40.	0.4	7

#	Article	IF	CITATIONS
1877	Immunosensors for human cardiac troponins and CRP, in particular amperometric cTnI immunosensor. Biocybernetics and Biomedical Engineering, 2016, 36, 29-41.	3.3	3
1878	Newer antiplatelet agents in acute coronary syndrome. BMJ, The, 2016, 352, h7025.	3.0	1
1879	Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet, The, 2016, 387, 1057-1065.	6.3	342
1880	Management of acute coronary syndrome in the very elderly. Lancet, The, 2016, 387, 1029-1030.	6. 3	12
1881	Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. Heart and Vessels, 2016, 31, 1740-1751.	0.5	69
1882	Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0 h/1 h-algorithm for the early diagnosis of acute myocardial infarction. International Journal of Cardiology, 2016, 207, 238-245.	0.8	85
1883	Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients. Journal of the American College of Cardiology, 2016, 67, 264-272.	1,2	121
1884	Reliability of a new method for coronary artery calcium or metal subtraction by 320-row cardiac CT. European Radiology, 2016, 26, 3208-3214.	2.3	17
1885	Myocardial injury associated with transcatheter aortic valve implantation (TAVI). Clinical Research in Cardiology, 2016, 105, 379-387.	1.5	23
1886	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. American Journal of Hypertension, 2016, 29, 509-518.	1.0	23
1887	The use of transthoracic echocardiography for the assessment of left ventricular systolic and diastolic function in patients with suspected or ascertained chronic heart failure. Expert Review of Cardiovascular Therapy, 2016, 14, 37-50.	0.6	4
1888	Dual pathway therapy in acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2016, 42, 254-260.	1.0	11
1889	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 214-222.	0.4	11
1890	Long-term survival in octogenarians and older patients with ST-elevation myocardial infarction in the era of primary angioplasty: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 243-252.	0.4	32
1891	Effects on length of stay and costs with same-day retransfer to the referring hospitals for patients with acute coronary syndrome after angiography and/or percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 375-380.	0.4	6
1892	Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. Scandinavian Cardiovascular Journal, 2016, 50, 99-107.	0.4	33
1893	Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. Heart Failure Reviews, 2016, 21, 25-47.	1.7	18
1894	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. Vascular Pharmacology, 2016, 81, 1-14.	1.0	8

#	Article	IF	CITATIONS
1896	Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. European Heart Journal Quality of Care & Dinical Outcomes, 2016, 2, 81-90.	1.8	18
1897	Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials. American Heart Journal, 2016, 176, 36-43.	1.2	8
1898	Diagnosis of acute coronary occlusion in patients with non–STEMI by point-of-care echocardiography with speckle tracking. American Journal of Emergency Medicine, 2016, 34, 1914.e3-1914.e6.	0.7	9
1899	Estrategia invasiva de rutina en el sÃndrome coronario agudo sin elevación del segmento ST con disfunción renal. Resultados del registro ARIAM-SEMICYUC. Medicina Intensiva, 2016, 40, 280-288.	0.4	9
1900	Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 172-183.	1.8	88
1901	Coronary Artery Calcium as an Independent Surrogate Marker in the Risk Assessment of Patients With Atrial Fibrillation and an Intermediate Pretest Likelihood for Coronary Artery Disease Admitted to a German Chest Pain Unit. Clinical Cardiology, 2016, 39, 157-164.	0.7	6
1902	Does RIDDLE-NSTEMI Provide an Answer to the Timing of ACS Therapy?. JACC: Cardiovascular Interventions, 2016, 9, 550-552.	1.1	1
1903	Optimizing the management of acute coronary syndromes in sub-Saharan Africa: A statement from the AFRICARDIO 2015 Consensus Team. Archives of Cardiovascular Diseases, 2016, 109, 376-383.	0.7	45
1904	CT Angiography for the Prediction of Hemodynamic Significance in Intermediate and Severe Lesions. JACC: Cardiovascular Imaging, 2016, 9, 559-564.	2.3	53
1905	Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. Cardiovascular Drugs and Therapy, 2016, 30, 189-198.	1.3	19
1906	Current status of data on cangrelor., 2016, 159, 102-109.		39
1907	Gender Differences in Presentation, Coronary Intervention, and Outcomes of 28,985 Acute Coronary Syndrome Patients in Victoria, Australia. Women's Health Issues, 2016, 26, 14-20.	0.9	57
1908	Indicaciones y duraci \tilde{A}^3 n de las combinaciones de antiagregantes. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 29-34.	0.0	0
1909	Nocturnal oxygen therapy in patients with chronic heart failure and sleep apnea: a systematic review. Sleep Medicine, 2016, 17, 149-157.	0.8	34
1910	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Thrombosis Research, 2016, 139, 114-120.	0.8	11
1911	Acute Coronary Syndrome: Focus on Antiplatelet Therapy. Critical Care Nurse, 2016, 36, 15-27.	0.5	12
1912	The Prognostic Impact of In-Hospital Change in Mean Platelet Volume in Patients With Non–ST-Segment Elevation Myocardial Infarction. Angiology, 2016, 67, 690-696.	0.8	11
1913	Do stable non–ST-segment elevation acute coronary syndromes require admission to coronary care units?. American Heart Journal, 2016, 175, 184-192.	1.2	31

#	Article	IF	CITATIONS
1914	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC: Cardiovascular Interventions, 2016, 9, 207-215.	1.1	43
1915	Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. Aids, 2016, 30, 1413-1421.	1.0	12
1916	Noninvasive cardiac imaging in suspected acute coronary syndrome. Nature Reviews Cardiology, 2016, 13, 266-275.	6.1	14
1917	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction—a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). American Heart Journal, 2016, 175, 36-46.	1.2	31
1918	Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 249-255.	0.6	11
1919	Guideline-conforming timing of invasive management in troponin-positive or high-risk ACS without persistent ST-segment elevation in German chest pain units. Herz, 2016, 41, 151-158.	0.4	7
1920	The Predictive Factors on Extended Hospital Length of Stay in Patients with AMI: Laboratory and Administrative Data. Journal of Medical Systems, 2016, 40, 2.	2.2	11
1921	Endothelial immunomediated reactivity in acute cardiac ischaemia: Role of endothelin 1, interleukin 8 and NT-proBNP in patients affected by unstable angina pectoris. International Journal of Immunopathology and Pharmacology, 2016, 29, 516-522.	1.0	5
1922	Prevalence of metabolic syndrome and association with burden of atherosclerotic disease in patients with stable coronary artery disease. Current Medical Research and Opinion, 2016, 32, 1175-1181.	0.9	11
1923	Étude prospective de l'évolution des consommations alimentaires après sevrage tabagique brutal de patients hospitalisés en unité de soins intensifs de cardiologie. Cahiers De Nutrition Et De Dietetique, 2016, 51, 33-39.	0.2	0
1924	Management and Long-Term Outcome of Acute Coronary Syndrome Patients Presenting with Heart Failure in a Contemporary New Zealand Cohort (ANZACS-QI 4). Heart Lung and Circulation, 2016, 25, 837-846.	0.2	6
1925	The Use of Echocardiography in Certified Chest Pain Units: Results from the German Chest Pain Unit Registry. Cardiology, 2016, 134, 75-83.	0.6	10
1926	B-type natriuretic peptide signal peptide (BNPsp) in patients presenting with chest pain. Clinical Biochemistry, 2016, 49, 645-650.	0.8	6
1927	Cardiovascular risk scores: Usefulness and limitations. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.	784314 rg 0.2	gBT4/Overloc
1928	Present and Future of Cardiac Troponin in Clinical Practice: A Paradigm Shift to High-Sensitivity Assays. American Journal of Medicine, 2016, 129, 354-365.	0.6	74
1929	MRI in the assessment of ischaemic heart disease. Heart, 2016, 102, 239-252.	1,2	23
1930	Echocardiographic assessment of left ventricular systolic function: from ejection fraction to torsion. Heart Failure Reviews, 2016, 21, 77-94.	1.7	75
1931	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. International Journal of Cardiology, 2016, 203, 697-701.	0.8	24

#	Article	IF	CITATIONS
1932	Coronary CT Angiography for SuspectedÂACS in the Era of High-Sensitivity Troponins. Journal of the American College of Cardiology, 2016, 67, 16-26.	1.2	134
1933	Prognostic Value of Coronary Computed Tomography Imaging in Patients at High Risk Without Symptoms of Coronary Artery Disease. American Journal of Cardiology, 2016, 117, 768-774.	0.7	21
1934	Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 34, 463-477.	1.7	2
1935	The prognostic value of CT coronary angiography in patients attending hospital with troponin-negative acute chest pain and inconclusive exercise treadmill tests. European Heart Journal Cardiovascular Imaging, 2016, 17, 542-549.	0.5	4
1936	Coronary revascularisation in older patients with non-ST elevation acute coronary syndromes. Heart, 2016, 102, 416-424.	1,2	14
1937	Heart-type fatty acid-binding protein detects more patients with non-ST segment elevation myocardial infarction compared to troponin-T. Egyptian Heart Journal, 2016, 68, 11-16.	0.4	1
1938	Longitudinal modelling of theory-based depressive vulnerabilities, depression trajectories and poor outcomes post-ACS. Journal of Affective Disorders, 2016, 191, 41-48.	2.0	8
1939	Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2016, 17, 1146-1152.	0.5	102
1940	Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 41-50.	0.4	11
1941	Effectiveness, safety and feasibility of an evidence-based insulin infusion protocol targeting moderate glycaemic control in intensive cardiac care units. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 117-124.	0.4	5
1942	The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation. Clinical Chemistry and Laboratory Medicine, 2016, 54, 339-44.	1.4	16
1943	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	2.3	3
1944	Troponin levels within the normal range and probability of inducible myocardial ischemia and coronary events in patients with acute chest pain. European Journal of Internal Medicine, 2016, 28, 59-64.	1.0	6
1945	Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. American Journal of Medicine, 2016, 129, 274-282.e2.	0.6	31
1946	Preoperative Ticagrelor administration leads to a higher risk of bleeding during and after coronary bypass surgery in a case-matched analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 22, 136-140.	0.5	8
1947	Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome. Clinical Research in Cardiology, 2016, 105, 356-363.	1.5	6
1948	The incremental value of stress testing in patients with acute chest pain beyond serial cardiac troponin testing. Emergency Medicine Journal, 2016, 33, 319-324.	0.4	15
1949	Usefulness of SYNTAX score II in complex percutaneous coronary interventions in the setting of acute coronary syndrome. Journal of the Saudi Heart Association, 2016, 28, 63-72.	0.2	14

#	ARTICLE	IF	CITATIONS
1950	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. International Journal of Cardiology, 2016, 202, 305-310.	0.8	20
1951	One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. American Heart Journal, 2016, 171, 92-102.e5.	1.2	102
1952	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
1953	Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. Value in Health Regional Issues, 2016, 9, 22-27.	0.5	11
1955	Usefulness of traditional echocardiographic parameters in assessment of left ventricular function in patients with normal ejection fraction early after acute myocardial infarction: results from a large consecutive cohort. European Heart Journal Cardiovascular Imaging, 2016, 17, 413-420.	0.5	14
1956	Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. European Heart Journal: Acute Cardiovascular Care, 2016. 5. 13-22.	0.4	17
1957	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 282-288.	0.4	3
1958	How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?. Platelets, 2016, 27, 59-65.	1.1	16
1959	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromesâ€"The COPACS Study. American Journal of Medicine, 2016, 129, 105-114.	0.6	8
1960	Mehran contrast nephropathy risk score: Is it still useful 10 years later?. Journal of Cardiology, 2016, 67, 262-267.	0.8	41
1961	Transradial Coronary Intervention Versus Coronary Artery Bypass Grafting for Unprotected Left Main and/or Multivessel Disease in Patients With Acute Coronary Syndrome. Angiology, 2016, 67, 83-88.	0.8	5
1962	THE STORM (acute coronary Syndrome in paTients end Of life and Risk assesMent) study. Emergency Medicine Journal, 2016, 33, 10-16.	0.4	18
1963	Acute coronary syndrome in the Asia-Pacific region. International Journal of Cardiology, 2016, 202, 861-869.	0.8	85
1964	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 231-242.	0.4	110
1965	Estimating glomerular filtration rate in acute coronary syndromes: Different equations, different mortality risk prediction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 223-230.	0.4	14
1966	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	0.4	53
1967	Predictive performance of HAS-BLED risk score for long-term survival in patients with non-ST elevated myocardial infarction without atrial fibrillation. Journal of Cardiology, 2017, 69, 136-143.	0.8	12
1968	Editor's Choice-Medically managed patients with non–ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 262-271.	0.4	18

#	Article	IF	CITATIONS
1969	Characteristics of patients who are acutely admitted to hospital under surgical care and do not have a surgical procedure – Is there an alternative to admission?. Journal of the Royal College of Surgeons of Edinburgh, 2017, 15, 259-266.	0.8	3
1970	Thrombus aspiration in non-ST-elevation myocardial infarction – 12-month clinical outcome of the randomised TATORT-NSTEMI trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 10-17.	0.4	13
1971	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 93-97.	0.4	19
1973	Short- and long-term outcomes in Middle Eastern diabetic patients after percutaneous coronary intervention: results from The First Jordanian PCI Registry (JoPCR1). Diabetology International, 2017, 8, 30-38.	0.7	5
1974	Editor's Choice-Rule-in of acute myocardial infarction: Focus on troponin. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 212-217.	0.4	32
1975	Prospective assessment of a palliative care tool to predict one-year mortality in patients with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 272-279.	0.4	10
1976	Excess mortality and guideline-indicated care following non-ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 412-420.	0.4	37
1977	Editor's Choice-Acute versus subacute angiography in patients with non-ST-elevation myocardial infarction – the NONSTEMI trial phase I. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 490-499.	0.4	14
1978	The HEART score with high-sensitive troponin T at presentation: ruling out patients with chest pain in the emergency room. Internal and Emergency Medicine, 2017, 12, 357-364.	1.0	29
1979	Gender difference in the use of coronary interventions for patients with acute coronary syndrome: Experience from a major metropolitan hospital in Melbourne, Australia. Australian Critical Care, 2017, 30, 3-10.	0.6	12
1980	Cardiac Rehabilitation. Journal of Cardiovascular Nursing, 2017, 32, 236-243.	0.6	18
1981	Copeptin improves the sensitivity of cardiac troponin in patients 70 years or older, but not enough to rule out myocardial infarction at emergency department presentation. European Journal of Emergency Medicine, 2017, 24, 142-148.	0.5	2
1982	Telemetry-assisted early detection of STEMI in patients with atypical symptoms by paramedic-performed 12-lead ECG with subsequent cardiological analysis. European Journal of Emergency Medicine, 2017, 24, 272-276.	0.5	4
1983	ECG interpretation in Emergency Department residents: an update and e-learning as a resource to improve skills. European Journal of Emergency Medicine, 2017, 24, 149-156.	0.5	26
1984	Simultaneous determination of atorvastatin and its metabolites in human plasma by UPLC-MS/MS. Analytical Methods, 2017, 9, 1038-1045.	1.3	15
1986	Antiplatelet therapies in patients withÂanÂindication for anticoagulation. Clinical Hemorheology and Microcirculation, 2017, 64, 273-278.	0.9	4
1987	Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. European Journal of Internal Medicine, 2017, 40, 1-7.	1.0	5
1988	Oral antiplatelet agents for the management of acute coronary syndromes. Journal of the American Association of Nurse Practitioners, 2017, 29, 104-115.	0.5	2

#	Article	IF	CITATIONS
1989	Fractional flow reserve and resting indices for coronary physiologic assessment: Practical guide, tips, and tricks. Catheterization and Cardiovascular Interventions, 2017, 90, 598-611.	0.7	4
1991	Predictors of Nonuse of a Highâ€Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladibâ€Thrombolysis in Myocardial Infarction 52 (SOLIDâ€TIMI 52) Trial. Journal of the American Heart Association, 2017, 6, .	1.6	8
1992	Anemia in the elderly: a consequence of aging?. Expert Review of Hematology, 2017, 10, 327-335.	1.0	57
1994	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non–ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	1.5	26
1995	Hypertension is associated with increased mortality in patients with ischaemic heart disease after revascularization with percutaneous coronary intervention – a report from SCAAR. Blood Pressure, 2017, 26, 166-173.	0.7	11
1996	Reintroduction of antiâ€thrombotic therapy after a gastrointestinal haemorrhage: if and when?. British Journal of Haematology, 2017, 177, 185-197.	1.2	22
1997	Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I. Circulation, 2017, 135, 1597-1611.	1.6	138
1998	Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. Journal of International Medical Research, 2017, 45, 134-146.	0.4	19
1999	Gender differences in early invasive strategy after cardiac arrest: Insights from the PROCAT registry. Resuscitation, $2017, 114, 7-13$.	1.3	29
2000	Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. Platelets, 2017, 28, 706-711.	1.1	5
2001	Bleeding associated with the management of acute coronary syndromes. Heart, 2017, 103, 546-562.	1.2	5
2002	Coronary revascularisation in the elderly. Heart, 2017, 103, 316-324.	1.2	14
2003	Selecting patients with non-ST-elevation acute coronary syndrome for coronary angiography: a nationwide clinical vignette study in the Netherlands. BMJ Open, 2017, 7, e011213.	0.8	4
2004	Diagnostic and prognostic values of the V-index, a novel ECG marker quantifying spatial heterogeneity of ventricular repolarization, in patients with symptoms suggestive of non-ST-elevation myocardial infarction. International Journal of Cardiology, 2017, 236, 23-29.	0.8	16
2005	International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart, 2017, 103, 132-138.	1,2	43
2006	Improving the diagnostic accuracy of acute myocardial infarction with the use of high-sensitive cardiac troponin T in different chronic kidney disease stages. Scientific Reports, 2017, 7, 41350.	1.6	20
2007	Longitudinal 2D strain can help diagnose coronary artery disease in patients with suspected non-ST-elevation acute coronary syndrome but apparent normal global and segmental systolic function. International Journal of Cardiology, 2017, 236, 91-94.	0.8	31
2008	Association between Lp-PLA2 and coronary heart disease in Chinese patients. Journal of International Medical Research, 2017, 45, 159-169.	0.4	26

#	Article	IF	Citations
2009	Multiple pulmonary emboli as a result of renal cell carcinoma: A case report. Oncology Letters, 2017, 13, 267-270.	0.8	8
2010	Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Internal and Emergency Medicine, 2017, 12, 147-155.	1.0	186
2011	Proposal of quality indicators for cardiac rehabilitation after acute coronary syndrome in Japan: a modified Delphi method and practice test. BMJ Open, 2017, 7, e013036.	0.8	9
2012	Cardio-Oncology., 2017, , .		1
2013	The Role of Biomarkers in Detection of Cardio-toxicity. Current Oncology Reports, 2017, 19, 42.	1.8	19
2014	Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC Cardiovascular Disorders, 2017, 17, 97.	0.7	23
2015	Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome in Russia: an observational study (EPICOR-RUS study). Current Medical Research and Opinion, 2017, 33, 1269-1276.	0.9	2
2016	Trends in admissions for chest pain after the introduction of high-sensitivity cardiac troponin T. International Journal of Cardiology, 2017, 240, 1-7.	0.8	18
2017	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. European Heart Journal, 2017, 38, 2264-2276.	1.0	94
2018	Clinical and Economic Impact of a Multisciplinary Intervention to Reduce Bleeding Risk in Patients With Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 825-831.	0.4	5
2019	Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia., 2017, , 175-214.		0
2020	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. American Heart Journal, 2017, 188, 127-135.	1.2	5
2021	Impact of sleepâ€disordered breathing in patients with acute myocardial infarction: a retrospective analysis. Journal of Sleep Research, 2017, 26, 657-664.	1.7	15
2022	Prognosis of spontaneous coronary artery dissection treated by percutaneous coronary intervention with optical coherence tomography. Journal of Cardiology, 2017, 70, 524-529.	0.8	14
2023	Coronary computed tomography angiography derived risk score in predicting cardiac events. Journal of Cardiovascular Computed Tomography, 2017, 11, 274-280.	0.7	8
2024	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 143-172.	2.7	51
2025	Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, pvw043.	1.4	12
2026	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	0.6	39

#	Article	IF	CITATIONS
2027	Impact of Routine Fractional Flow Reserve on Management Decision and 1-Year Clinical Outcome of Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	44
2028	Prognostic Value of Coronary CT Angiography With Selective PET Perfusion Imaging in Coronary Artery Disease. JACC: Cardiovascular Imaging, 2017, 10, 1361-1370.	2.3	63
2029	Early Versus Delayed Invasive Strategies in High-Risk Non-ST Elevation Acute Coronary Syndrome Patients – A Systematic Literature Review and Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2017, 26, 1142-1159.	0.2	5
2030	CBT for Managing Non-cardiac Chest Pain., 0, , .		O
2031	Fractional flow reserve: a clinical perspective. International Journal of Cardiovascular Imaging, 2017, 33, 961-974.	0.7	19
2032	Optical coherence tomography compared with fractional flow reserve guided approach in acute coronary syndromes: A propensity matched analysis. International Journal of Cardiology, 2017, 244, 54-58.	0.8	11
2033	Diagnostic validity of hand gestures in chest pain of coronary origin. Revista Clínica Espanõla, 2017, 217, 252-259.	0.3	7
2034	Identification of High-Risk Patients After ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, e005841.	1.3	35
2035	Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–STâ€segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	0.7	16
2036	Assessment of peak skin dose in interventional cardiology: A comparison between Gafchromic film and dosimetric software em.dose. Physica Medica, 2017, 38, 16-22.	0.4	29
2037	Head-to-head comparison of cardiac troponin T and troponin I in patients without acute coronary syndrome: a systematic review. Biomarkers, 2017, 22, 701-708.	0.9	21
2038	Circulating HtrA2 as a novel biomarker for mitochondrial induced cardiomyocyte apoptosis and ischemia-reperfusion injury in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2017, 243, 485-491.	0.8	9
2039	² -Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. Journal of the American College of Cardiology, 2017, 69, 2710-2720.	1.2	174
2040	Prognostic value of ejection fraction in patients admitted with acute coronary syndrome. Medicine (United States), 2017, 96, e6226.	0.4	50
2041	The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. Pharmacogenomics, 2017, 18, 969-979.	0.6	16
2042	Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance. Cardiology, 2017, 138, 16-25.	0.6	1
2043	Diagnostic Accuracy of 3.0‶ Magnetic Resonance T1 and T2 Mapping and T2â€Weighted Darkâ€Blood Imaging for the Infarctâ€Related Coronary Artery in Non–STâ€Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	15
2044	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	1.4	18

#	Article	IF	CITATIONS
2045	The frequency and nature of medication errors in hospitalized patients with acute coronary syndrome. International Journal of Clinical Pharmacy, 2017, 39, 542-550.	1.0	13
2046	Pre-hospital and hospital delay in patients with non-ST elevation acute coronary syndromes in tertiary care. Egyptian Heart Journal, 2017, 69, 177-181.	0.4	9
2047	Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. Preventive Medicine Reports, 2017, 6, 203-209.	0.8	31
2049	ProACS risk score: An early and simple score for risk stratification of patients with acute coronary syndromes. Revista Portuguesa De Cardiologia, 2017, 36, 77-83.	0.2	23
2050	ProACS risk score: An early and simple score for risk stratification of patients with acute coronary syndromes. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 77-83.	0.2	15
2052	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American Heart Journal, 2017, 188, 147-155.	1.2	2
2053	High-sensitivity assays for troponin in patients with cardiac disease. Nature Reviews Cardiology, 2017, 14, 472-483.	6.1	144
2054	Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate. Anesthesia and Analgesia, 2017, 124, 1091-1098.	1.1	11
2055	Fast track protocols using highly sensitive troponin assays for ruling out and ruling in non-ST elevation acute coronary syndrome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1683-1689.	1.4	12
2056	Sex-Related 30-Day and Long-Term Mortality in Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention. Journal of Women's Health, 2017, 26, 374-379.	1.5	13
2057	Head-to-head comparison of the diagnostic performance of coronary computed tomography angiography and dobutamine-stress echocardiography in the evaluation of acute chest pain with normal ECG findings and negative troponin tests: A prospective multicenter study. International Journal of Cardiology, 2017, 241, 463-469.	0.8	8
2058	Safety and efficacy of drug eluting stents in patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2017, 238, 105-109.	0.8	22
2059	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. Annals of Pharmacotherapy, 2017, 51, 529-542.	0.9	5
2060	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal, 2017, 187, 19-28.	1.2	14
2061	Effect of Atrial Fibrillation on Contrast-Induced Nephropathy Development in Patients With Non-ST-Segment Elevation Myocardial Infarction. Angiology, 2017, 68, 871-876.	0.8	4
2062	P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. International Journal of Cardiology, 2017, 230, 204-208.	0.8	13
2063	Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE ARDIOGROUP IV and USZ registry. Catheterization and Cardiovascular Interventions, 2017, 90, E46-E52.	0.7	26
2064	Role of 2D speckle tracking echocardiography in predicting acute coronary occlusion in patients with non ST-segment elevation myocardial infarction. Egyptian Heart Journal, 2017, 69, 103-110.	0.4	9

#	Article	IF	CITATIONS
2065	Reflections on Cultural Preferences and Internal Medicine: The Case of Jehovah's Witnesses and the Changing Thresholds for Blood Transfusions. Journal of Religion and Health, 2017, 56, 732-738.	0.8	7
2066	Numeracy Predicts Risk of Pre-Hospital Decision Delay: a Retrospective Study of Acute Coronary Syndrome Survival. Annals of Behavioral Medicine, 2017, 51, 292-306.	1.7	30
2067	2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal, 2017, 25, 181-185.	0.3	49
2068	Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the <scp>CAPS</scp> study. Cardiovascular Therapeutics, 2017, 35, e12240.	1.1	12
2069	Editorial: Navigating the rough seas of anemia; caught between the devil and the deep blue sea. Journal of Interventional Cardiology, 2017, 30, 500-501.	0.5	0
2070	Effect of ticagrelor versus prasugrel on platelet reactivity. Coronary Artery Disease, 2017, 28, 597-604.	0.3	8
2071	Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. Circulation, 2017, 136, 1495-1508.	1.6	63
2072	Cardiac Rehabilitation for Patients With Coronary Artery Disease: A Practical Guide to Enhance Patient Outcomes Through Continuity of Care. Clinical Medicine Insights: Cardiology, 2017, 11, 117954681771002.	0.6	32
2073	Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1059-1067.	1.1	8
2075	Using High-Sensitivity Cardiac Troponin T for Acute Cardiac Care. American Journal of Medicine, 2017, 130, 1358-1365.e1.	0.6	47
2076	The impact of CYP2C19 *2, CYP4F2 * 3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy. Blood Coagulation and Fibrinolysis, 2017, 28, 658-664.	0.5	5
2077	Safety of Antiplatelet Agents: Analysis of â€ [*] Real-Worldâ€ [™] Data from the Italian National Pharmacovigilance Network. Clinical Drug Investigation, 2017, 37, 1067-1081.	1.1	7
2078	CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome. Medicina ClÃnica (English Edition), 2017, 149, 235-239.	0.1	2
2079	Impaired fibrinolysis and lower levels of plasma $\hat{l}\pm 2$ -macroglobulin are associated with an increased risk of severe asthma exacerbations. Scientific Reports, 2017, 7, 11014.	1.6	11
2080	Proposal of a novel clinical score to predict heart failure incidence in long-term survivors of acute coronary syndromes. International Journal of Cardiology, 2017, 249, 301-307.	0.8	7
2081	Validez diagn $ ilde{A}^3$ stica del lenguaje de las manos en el dolor tor $ ilde{A}_i$ cico de origen coronario. Revista Clinica Espanola, 2017, 217, 252-259.	0.2	7
2082	Age is not a bar to PCI: Insights from the longâ€term outcomes from offâ€site PCI in a realâ€world setting. Journal of Interventional Cardiology, 2017, 30, 347-355.	0.5	14
2083	The influence of treatment modality on illness perception and secondary prevention outcomes among patients with acute myocardial infarction. International Journal of Nursing Sciences, 2017, 4, 271-277.	0.5	6

#	ARTICLE	IF	Citations
2084	Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con sÃndrome coronario agudo. Medicina ClÃnica, 2017, 149, 235-239.	0.3	3
2085	Tratamiento de la angina estable. Medicine, 2017, 12, 2163-2173.	0.0	0
2087	Coronary Computed Tomographic Angiography-Derived Fractional Flow Reserve Based on Machine Learning for Risk Stratification of Non-Culprit Coronary Narrowings in Patients with Acute Coronary Syndrome. American Journal of Cardiology, 2017, 120, 1260-1266.	0.7	37
2088	Management and Prevention of Saphenous Vein Graft Failure: A Review. Cardiology and Therapy, 2017, 6, 203-223.	1.1	69
2089	The preference of the physicians in diagnosis and treatment of cardiovascular diseases. International Journal of the Cardiovascular Academy, 2017, 3, 11-15.	0.1	1
2090	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients TreatedÂWith Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	1.1	29
2091	Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography. Coronary Artery Disease, 2017, 28, 23-32.	0.3	18
2092	Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients. Shock, 2017, 47, 165-174.	1.0	38
2093	Trends in mortality risks among 94,328 patients surviving 30 days after a first isolated coronary artery bypass graft procedure from 1987 to 2006: A population-based study. International Journal of Cardiology, 2017, 244, 316-321.	0.8	17
2094	Discrimination of patients with type 2 myocardial infarction. European Heart Journal, 2017, 38, 3514-3520.	1.0	96
2095	Role of fractional flow reserve in the evaluation and management of patients with acute coronary syndrome. Current Opinion in Cardiology, 2017, 32, 767-775.	0.8	7
2096	Long-term outcomes after acute myocardial infarction in countries with different socioeconomic environments: an international prospective cohort study. BMJ Open, 2017, 7, e012715.	0.8	10
2097	Safety of a 1-hour Rule-out High-sensitive Troponin T Protocol in Patients With Chest Pain at the Emergency Department. Critical Pathways in Cardiology, 2017, 16, 129-134.	0.2	3
2098	Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. International Journal of Cardiology, 2017, 249, 18-24.	0.8	20
2099	Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. International Journal of Cardiology, 2017, 249, 66-72.	0.8	21
2100	Sexâ€Based Differences in the Performance of the HEART Score in Patients Presenting to the Emergency Department With Acute Chest Pain. Journal of the American Heart Association, 2017, 6, .	1.6	27
2101	APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. International Journal of Cardiology, 2017, 244, 13-16.	0.8	6
2102	Novel Risk Stratification Assays for Acute Coronary Syndrome. Current Cardiology Reports, 2017, 19, 69.	1.3	4

#	ARTICLE	IF	CITATIONS
2104	Association Between Helicobacter Pylori Infection and Long-term Outcome in Patients with Drug-eluting Stent Implantation. Scientific Reports, 2017, 7, 44954.	1.6	3
2105	The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: early invasive strategy for all?. Netherlands Heart Journal, 2017, 25, 170-172.	0.3	4
2106	Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres. Netherlands Heart Journal, 2017, 25, 482-489.	0.3	7
2107	Use of generic and essential medicines for prevention and treatment of cardiovascular diseases in Portugal. BMC Health Services Research, 2017, 17, 449.	0.9	8
2108	C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction. BMC Nephrology, 2017, 18, 202.	0.8	8
2109	Latin American Clinical Epidemiology Network Series – Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile. Journal of Clinical Epidemiology, 2017, 86, 117-124.	2.4	1
2110	Antiplatelet Therapy for Non–ST-Segment Elevation Myocardial Infarction in Complex "Real―Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group― Angiology, 2017, 68, 598-607.	0.8	1
2111	Second-generation drug-eluting stents in the elderly patients with acute coronary syndrome: the in-hospital and 12-month follow-up of the all-comer registry. Aging Clinical and Experimental Research, 2017, 29, 885-893.	1.4	1
2112	Analytical evaluation of a new point of care system for measuring cardiac Troponin I. Clinical Biochemistry, 2017, 50, 174-180.	0.8	28
2113	Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials. International Journal of Cardiology, 2017, 227, 617-624.	0.8	16
2114	Medium platelet volume as a noninvasive predictor of chronic total occlusion in non-infarct artery in patients with non-ST-segment elevation myocardial infarction and multivessel coronary artery disease. International Journal of Cardiology, 2017, 228, 594-598.	0.8	3
2115	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney International, 2017, 91, 216-226.	2.6	16
2116	Risk Scores After Acute Coronary Syndrome. Angiology, 2017, 68, 185-188.	0.8	7
2117	Gender differences and bleeding complications after PCI on first and second generation DES. Scandinavian Cardiovascular Journal, 2017, 51, 53-60.	0.4	6
2118	Real-World Use of Novel P2Y12 Inhibitors in Patients with Acute Myocardial Infarction: A Treatment Paradox. Cardiology, 2017, 136, 21-28.	0.6	22
2119	Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Acute Kidney Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology, 2017, 68, 419-427.	0.8	28
2120	Flow analysis of individual blood extracellular vesicles in acute coronary syndrome. Platelets, 2017, 28, 165-173.	1.1	12
2121	Safety and efficacy of Ilb/Illa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. Platelets, 2017, 28, 174-181.	1.1	10

#	Article	IF	CITATIONS
2122	Percutaneous Treatment of Cardiovascular Diseases in Women., 2017,,.		0
2123	Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 259-265.	1.7	14
2124	Outcome after coronary bypass grafting for coronary complications following coronary angiography. Journal of Surgical Research, 2017, 210, 69-77.	0.8	7
2125	Effects of radial versus femoral artery access in patients with acute myocardial infarction: AÂlarge centre prospective registry. Netherlands Heart Journal, 2017, 25, 33-39.	0.3	8
2126	Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thrombosis and Haemostasis, 2017, 117, 625-635.	1.8	33
2128	Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial. Scientific Reports, 2017, 7, 17451.	1.6	36
2129	The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform. Expert Review of Proteomics, 2017, 14, 973-986.	1.3	29
2130	High-sensitivity cardiac troponins I sandwich assay by immunomagnetic microparticle and quantum dots. Frontiers in Laboratory Medicine, 2017, 1, 107-113.	1.7	5
2131	Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. Thrombosis and Haemostasis, 2017, 117, 727-733.	1.8	27
2132	Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry. Journal of the American Heart Association, 2017, 6, .	1.6	134
2133	EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. European Heart Journal Cardiovascular Imaging, 2017, 18, 1191-1204.	0.5	63
2134	Cardiac magnetic resonance assessment of diastolic dysfunction in acute coronary syndrome. Journal of International Medical Research, 2017, 45, 1680-1692.	0.4	5
2135	Optimal timing of invasive management of NSTE-ACS. British Journal of Cardiac Nursing, 2017, 12, 24-30.	0.0	0
2136	Acute coronary syndromes: early diagnosis, management, and risk prediction. European Heart Journal, 2017, 38, 3037-3040.	1.0	1
2138	Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry. Cardiology Research, 2017, 8, 105-110.	0.5	16
2139	Gender differences in risk profile and outcome of Middle Eastern patients undergoing percutaneous coronary intervention. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 149-155.	0.5	5
2140	Evaluation of applying chest pain guidelines in coronary care patients on their health outcome. International Journal of Advanced Nursing Studies, 2017, 6, 99.	0.1	0
2141	Immediate/Early vs. Delayed Invasive Strategy for Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 2017, 8, 952.	1.3	11

#	ARTICLE	IF	CITATIONS
2142	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. European Heart Journal Supplements, 2017, 19, D151-D162.	0.0	1
2143	Perioperative red blood cell transfusion in orofacial surgery. Journal of Dental Anesthesia and Pain Medicine, 2017, 17, 163.	0.4	6
2144	Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. Annals of Laboratory Medicine, 2017, 37, 137-146.	1.2	20
2145	Clinical Implications of Electrocardiograms for Patients With Type A Acute Aortic Dissection. Circulation Journal, 2017, 81, 1254-1260.	0.7	12
2146	Advances in Cardiac Biomarkers of Acute Coronary Syndrome. Advances in Clinical Chemistry, 2017, 78, 1-58.	1.8	9
2147	Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?. Current Drug Targets, 2017, 18, 1722-1732.	1.0	6
2148	High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study. Vascular Health and Risk Management, 2017, Volume 13, 127-137.	1.0	12
2149	Ventricular Arrhythmia after Acute Myocardial Infarction: †The Perfect Storm'. Arrhythmia and Electrophysiology Review, 2017, 6, 134.	1.3	81
2150	Early diagnosis of acute myocardial infarction using high-sensitivity troponin I. PLoS ONE, 2017, 12, e0174288.	1.1	29
2151	Diagnostic performance of point-of-care and central laboratory cardiac troponin assays in an emergency department. PLoS ONE, 2017, 12, e0188706.	1.1	9
2152	Long-term prognosis of patients with non-ST-segment elevation myocardial infarction according to coronary arteries atherosclerosis extent on coronary angiography: a historical cohort study. BMC Cardiovascular Disorders, 2017, 17, 279.	0.7	9
2153	Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?. Israel Journal of Health Policy Research, 2017, 6, 49.	1.4	11
2154	Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacology & Emp; Toxicology, 2017, 18, 80.	1.0	15
2155	CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2017, 13, 771-775.	0.3	O
2156	Gender, Clinical Presentation And Risk Factors in Acute Coronary Syndrome under 45 years A Comparison Study. KYAMC Journal, 2017, 6, 620-622.	0.1	0
2157	Preoperative cardiac risks in noncardiac surgery: The role of coronary angiography. Monaldi Archives for Chest Disease, 2017, 87, 863.	0.3	9
2158	Postoperative Assessment of Myocardial Function and Microcirculation in Patients with Acute Coronary Syndrome by Myocardial Contrast Echocardiography. Medical Science Monitor, 2017, 23, 2324-2332.	0.5	4
2159	Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e523-e557.	1.6	763

#	Article	IF	CITATIONS
2160	Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome. Turkish Journal of Emergency Medicine, 2018, 18, 62-66.	0.3	6
2161	Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome. Thrombosis and Haemostasis, 2018, 118, 415-426.	1.8	5
2162	Diagnostic value of the cardiac electrical biomarker, a novel ⟨scp⟩ECG⟨/scp⟩ marker indicating myocardial injury, in patients with symptoms suggestive of nonâ€⟨scp⟩ST⟨/scp⟩â€elevation myocardial infarction. Annals of Noninvasive Electrocardiology, 2018, 23, e12538.	0.5	9
2163	Polymerâ€free drugâ€eluting stents for coronary artery disease. Journal of Interventional Cardiology, 2018, 31, 330-337.	0.5	21
2164	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591.	1.3	149
2165	Change in Left Ventricular EjectionÂFraction Following First Myocardial InfarctionÂandÂOutcome. JACC: Clinical Electrophysiology, 2018, 4, 672-682.	1.3	49
2166	Experiences of a One-hour Algorithm in Chest Pain Patients With a Nonelevated Troponin T at Presentation. Critical Pathways in Cardiology, 2018, 17, 6-12.	0.2	5
2167	The Existence of Obesity Paradox and Effect of Obesity on In-Hospital-Outcomes on Elderly Patients Treated with Primary Percutaneous Coronary Intervention. International Journal of Gerontology, 2018, 12, 17-21.	0.7	4
2168	Dual antiplatelet therapy after coronary artery bypass surgery: is there an increase in bleeding risk? A meta-analysis. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 573-582.	0.5	5
2169	<i>CETP</i> and <i>LCAT</i> Gene Polymorphisms Are Associated with Highâ€Density Lipoprotein Subclasses and Acute Coronary Syndrome. Lipids, 2018, 53, 157-166.	0.7	10
2170	Proposed clinical scale for the diagnosis of acute coronary syndrome in patients with an inconclusive electrocardiogram and myocardial injury biomarkers. Revista Clínica Espanõla, 2018, 218, 49-57.	0.3	0
2171	Acute coronary syndrome: Relationship between genetic variants and TIMI risk. Cytokine, 2018, 110, 344-349.	1.4	0
2173	Impact of Routine Invasive Physiology atÂTime of Angiography in Patients WithÂMultivessel Coronary Artery DiseaseÂon Reclassification of Revascularization Strategy. JACC: Cardiovascular Interventions, 2018, 11, 354-365.	1.1	24
2174	Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 102-110.	1.4	26
2175	Escalas clÃnicas: una herramienta para el diagnóstico de angina inestable. Revista Clinica Espanola, 2018, 218, 72-73.	0.2	0
2177	Understanding cardiac troponin part 2: early rule out of acute coronary syndrome. Emergency Medicine Journal, 2018, 35, 192-197.	0.4	2
2178	Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. International Journal of Cardiology, 2018, 255, 8-14.	0.8	1
2179	Efecto del tratamiento con calcifediol, sobre los episodios cardiovasculares en pacientes revascularizados tras sÃndrome coronario agudo. Medicina ClÃnica, 2018, 151, 345-352.	0.3	1

#	ARTICLE	IF	CITATIONS
2180	Propuesta de una escala clÃnica para el diagnóstico de sÃndrome coronario agudo en pacientes con electrocardiograma y biomarcadores de lesión miocárdica no concluyentes. Revista Clinica Espanola, 2018, 218, 49-57.	0.2	2
2181	Changes in global longitudinal strain and left ventricular ejection fraction during the first year after myocardial infarction: results from a large consecutive cohort. European Heart Journal Cardiovascular Imaging, 2018, 19, 1165-1173.	0.5	13
2182	Anemia and Patient Blood Management in Cardiac Surgeryâ€"Literature Review and Current Evidence. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2726-2742.	0.6	33
2183	Rural-Urban Disparity in Emergency Care for Acute Myocardial Infarction in Japan. Circulation Journal, 2018, 82, 1666-1674.	0.7	31
2184	Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders, 2018, 18, 44.	0.7	11
2185	Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2018, 19, 917-922.	0.3	0
2186	Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency. Thrombosis Journal, 2018, 16, 6.	0.9	8
2187	Long term outcome of patients suffering from cancer and Takotsubo syndrome or myocardial infarction. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 473-481.	0.2	8
2188	Optimal treatment of patients with NSTE-ACS in the Dutch health care system. Netherlands Heart Journal, 2018, 26, 289-295.	0.3	1
2189	<i>CYP2C19</i> or <i>CYP3A5</i> Genotyping Does Not Predict Clinical Response to Clopidogrel. Journal of Clinical Pharmacology, 2018, 58, 1274-1283.	1.0	3
2190	Impaired renal function is associated with adverse outcomes in patients with chest pain discharged from internal medicine wards. European Journal of Internal Medicine, 2018, 53, 57-61.	1.0	5
2191	Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan. Circulation Journal, 2018, 82, 747-756.	0.7	41
2192	Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?. Expert Review of Cardiovascular Therapy, 2018, 16, 369-377.	0.6	15
2193	First 24 h in the management of non-ST segment elevation myocardial infarction. European Heart Journal Supplements, 2018, 20, B29-B38.	0.0	1
2194	Value of three dimensional-speckle tracking imaging for predicting left ventricular function after non-ST-segment elevation myocardial infarction with percutaneous coronary intervention. Journal of X-Ray Science and Technology, 2018, 26, 331-339.	0.7	4
2195	Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. European Journal of Clinical Pharmacology, 2018, 74, 819-832.	0.8	48
2196	Gender-Related Differences in Heart Rate Variability of Epileptic Patients. American Journal of Men's Health, 2018, 12, 117-125.	0.7	14
2197	Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non–ST elevation myocardial infarction patients. Journal of Evaluation in Clinical Practice, 2018, 24, 31-41.	0.9	15

#	ARTICLE	IF	Citations
2198	Heart rate at admission is a predictor of in-hospital mortality in patients with acute coronary syndromes: Results from 58 European hospitals: The European Hospital Benchmarking by Outcomes in acute coronary syndrome Processes study. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 149-157.	0.4	21
2200	Implant of permanent pacemaker during acute coronary syndrome: Mortality and associated factors in the ARIAM registry. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 224-229.	0.4	2
2201	Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. Cardiovascular Intervention and Therapeutics, 2018, 33, 239-246.	1.2	14
2202	Identification of Biomarkers for Early Diagnosis of Acute Myocardial Infarction. Journal of Cellular Biochemistry, 2018, 119, 650-658.	1.2	14
2203	Use of clinical guidelines in cardiology practice inSudan. Journal of Evaluation in Clinical Practice, 2018, 24, 127-134.	0.9	5
2204	Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 631-638.	0.4	82
2205	Clustering-making model for diagnosis of acute coronary syndrome using PCA based on K-MICA algorithms. American Journal of Emergency Medicine, 2018, 36, 160-161.	0.7	1
2206	Interventions to slow cardiovascular aging: Dietary restriction, drugs and novel molecules. Experimental Gerontology, 2018, 109, 108-118.	1.2	21
2207	Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial. Age and Ageing, 2018, 47, 42-47.	0.7	18
2208	Culprit plaque characteristics in younger versus older patients with acute coronary syndromes: An optical coherence tomography study from the FORMIDABLE registry. Catheterization and Cardiovascular Interventions, 2018, 92, E1-E8.	0.7	9
2209	Development and validation of a risk model for longâ€term mortality after percutaneous coronary intervention: The IDEAâ€BIO Study. Catheterization and Cardiovascular Interventions, 2018, 91, 686-695.	0.7	3
2210	Examination of the appropriate timing of reperfusion therapy for recent myocardial infarction: a Japanese single-center retrospective study. Indian Heart Journal, 2018, 70, 4-9.	0.2	1
2211	Trends in the treatment and outcomes of elderly patients with acute coronary syndrome: Results from the CZECH registries. Cor Et Vasa, 2018, 60, e66-e69.	0.1	1
2212	Morphological changes of the internal carotid artery: prevalence and characteristics. A clinical and ultrasonographic study in a series of 19 804 patients over 25 years old. European Journal of Neurology, 2018, 25, 171-177.	1.7	21
2213	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes and Vascular Disease Research, 2018, 15, 14-23.	0.9	18
2214	Management of acute coronary syndromes in older people. Age and Ageing, 2018, 47, 2-3.	0.7	5
2215	Multifactorial risk index for prediction of intraoperative blood transfusion in endovascular aneurysm repair. Journal of Vascular Surgery, 2018, 67, 778-784.	0.6	9
2216	High validity of cardiomyopathy diagnoses in western <scp>Sweden</scp> (1989–2009). ESC Heart Failure, 2018, 5, 233-240.	1.4	12

#	Article	IF	CITATIONS
2217	Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention. Coronary Artery Disease, 2018, 29, 53-59.	0.3	13
2218	Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Realâ€Life Setting. Clinical Pharmacology and Therapeutics, 2018, 103, 1038-1046.	2.3	6
2219	Case fatality of acute coronary events is improving even among elderly patients; the FINAMI study 1995–2012. Annals of Medicine, 2018, 50, 35-45.	1.5	3
2220	Clopidogrel in Critically III Patients. Clinical Pharmacology and Therapeutics, 2018, 103, 217-223.	2.3	22
2221	Validation of the RETRIEVE (REverse TRIage EVEnts) Criteria for Same Day Return of Non-ST Elevation Acute Coronary Syndrome Patients to Referring Non-PCI Centres. Heart Lung and Circulation, 2018, 27, 792-797.	0.2	2
2222	Cerium dioxide-doped carboxyl fullerene as novel nanoprobe and catalyst in electrochemical biosensor for amperometric detection of the CYP2C19*2 allele in human serum. Biosensors and Bioelectronics, 2018, 102, 94-100.	5.3	44
2223	The cardiovascular risk of patients with carotid artery stenosis. Cor Et Vasa, 2018, 60, e42-e48.	0.1	8
2224	Non-ST-Elevation Acute Coronary Syndrome Prognosis. , 2018, , 502-521.		1
2225	Nocturnal respiratory rate as a predictor of mortality in patients with acute coronary syndrome. Open Heart, 2018, 5, e000887.	0.9	3
2226	Protocolo de atendimento odontol \tilde{A}^3 gico a pacientes usu \tilde{A}_i rios de terapia antitromb \tilde{A}^3 tica. Revista Da Faculdade De Odontologia (Universidade De Passo Fundo), 2018, 23, .	0.2	1
2227	Comparison of enoxaparin and unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Journal of Thoracic Disease, 2018, 10, 3308-3318.	0.6	5
2229	Long-Term Use of Antiplatelet Therapy in Real-World Patients with Acute Myocardial Infarction: Insights from the PIPER Study. TH Open, 2018, 02, e437-e444.	0.7	5
2230	All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study. Vascular Health and Risk Management, 2018, Volume 14, 383-392.	1.0	3
2231	Absence of chest pain and long-term mortality in patients with acute myocardial infarction. Open Heart, 2018, 5, e000909.	0.9	18
2232	Association between the reported intensity of an acute symptom at first prehospital assessment and the subsequent outcome: a study on patients with acute chest pain and presumed acute coronary syndrome. BMC Cardiovascular Disorders, 2018, 18, 216.	0.7	10
2233	OBSOLETE: Biomarkers in Ischemic Heart Disease. , 2018, , .		0
2234	Characteristics, Treatment and In-hospital Outcomes of Unselected Patients with Non-ST-Elevation Myocardial Infarction in Daily Clinical Practice at An Interventional Centre over a Period of Ten Years: Results from the MIRLU-Registry. Journal of Clinical & Experimental Cardiology, 2018, 9, .	0.0	O
2235	OBSOLETE: Non-ST-Elevation Acute Coronary Syndrome Prognosis. , 2018, , .		0

#	Article	IF	CITATIONS
2236	A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity. Chinese Medical Journal, 2018, 131, 508-515.	0.9	10
2237	Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 764-769.	0.9	1
2238	Outcomes Following Percutaneous Coronary Intervention in Non–ST-Segment–Elevation Myocardial Infarction Patients With Coronary Artery Bypass Grafts. Circulation: Cardiovascular Interventions, 2018, 11, e006824.	1.4	19
2239	Is There Any Relationship between TSH Levels and Prognosis in Acute Coronary Syndrome?. Arquivos Brasileiros De Cardiologia, 2018, 110, 113-118.	0.3	7
2240	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—The METAMORPHOSIS Trial. Thrombosis and Haemostasis, 2018, 118, 2126-2133.	1.8	39
2242	The objective CORE score allows early rule out in acute chest pain patients. Scandinavian Cardiovascular Journal, 2018, 52, 308-314.	0.4	9
2243	Immediate non-culprit vessel percutaneous coronary intervention (PCI) in patients with acute myocardial infarction and cardiogenic shock: a swinging pendulum. Journal of Thoracic Disease, 2018, 10, 661-666.	0.6	6
2244	Red Blood Cell Transfusions Following Resection of Skull Base Meningiomas: Risk Factors and Clinical Outcomes. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 599-605.	0.4	7
2245	Management of acute coronary syndrome in emergency departments: a cross sectional multicenter study (Tunisia). BMC Emergency Medicine, 2018, 18, 50.	0.7	9
2246	Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics, 2018, 8, 4710-4732.	4.6	110
2247	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. European Heart Journal, 2018, 39, 3766-3776.	1.0	112
2248	Recent progress and market analysis of anticoagulant drugs. Journal of Thoracic Disease, 2018, 10, 2011-2025.	0.6	29
2249	GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Scientific Reports, 2018, 8, 14529.	1.6	5
2250	Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease. Journal of the American Heart Association, 2018, 7, e008032.	1.6	45
2252	Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients. Cellular Physiology and Biochemistry, 2018, 50, 1164-1177.	1.1	3
2253	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circulation: Cardiovascular Interventions, 2018, 11, e007331.	1.4	23
2254	Association between perioperative \hat{I}^2 -blocker use and clinical outcome of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure. PLoS ONE, 2018, 13, e0201311.	1.1	10
2255	The Role of Oxygen Therapy in Normoxemic Acute Coronary Syndrome. Journal of Cardiovascular Nursing, 2018, 33, 559-567.	0.6	1

#	Article	IF	CITATIONS
2256	Rationale, design and preliminary results of the GALIPEMIAS study (prevalence and lipid control of) Tj ETQq 000 re 13243 .	gBT /Over 0.8	lock 10 Tf 50 2
2257	Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective. Journal of the American Heart Association, 2018, 7, e009949.	1.6	61
2258	Effect of calcifediol treatment on cardiovascular outcomes in patients with acute coronary syndrome and percutaneous revascularization. Medicina ClÃnica (English Edition), 2018, 151, 345-352.	0.1	0
2259	Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?. Wiener Klinische Wochenschrift, 2018, 130, 707-715.	1.0	4
2260	Combination of Aminoâ€Terminal Proâ€BNP, Estimated GFR, and Highâ€Sensitivity CRP for Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. Journal of the American Heart Association, 2018, 7, e009162.	1.6	12
2261	High-Sensitivity Cardiac Troponin I and Clinical Risk Scores in Patients With Suspected Acute Coronary Syndrome. Circulation, 2018, 138, 1654-1665.	1.6	92
2262	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. European Heart Journal, 2018, 39, 3798-3806.	1.0	62
2263	An mHealth intervention to improve medication adherence among patients with coronary heart disease in China: Development of an intervention. International Journal of Nursing Sciences, 2018, 5, 322-330.	0.5	36
2264	Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention. Thrombosis Research, 2018, 170, 142-147.	0.8	7
2265	Clinical laboratory practice recommendations for high-sensitivity cardiac troponin testing. Journal of Laboratory and Precision Medicine, 2018, 3, 30-30.	1.1	2
2266	NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology, 2018, 14, 47-52.	0.3	0
2267	Percutaneous coronary intervention versus conservative treatment for non ST-segment elevation myocardial infarction in patients above 80†years of age. International Journal of Cardiology, 2018, 267, 57-61.	0.8	8
2268	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis, 2018, 274, 182-190.	0.4	12
2269	Biomarkers in Ischemic Heart Disease. , 2018, , 303-314.		0
2270	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. International Journal of Cardiology, 2018, 270, 160-166.	0.8	24
2271	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP- $1\hat{1}^2$ in non-ST-elevation myocardial infarction. International Journal of Cardiology, 2018, 271, 1-7.	0.8	22
2272	Regional to tertiary inter-hospital transfer versus in-house percutaneous coronary intervention in acute coronary syndrome. PLoS ONE, 2018, 13, e0198272.	1.1	6
2273	High-Sensitivity Cardiac Troponin-Based Strategies for the Assessment of Chest Pain Patients—A Review of Validation and Clinical Implementation Studies. Clinical Chemistry, 2018, 64, 1572-1585.	1.5	22

#	ARTICLE	IF	CITATIONS
2274	Atrioventricular block after acute myocardial infarction and its association with other clinical parameters in Pakistani patients: an institutional perspective. BMC Research Notes, 2018, 11, 329.	0.6	5
2275	Beware of early drug intolerance in secondary prevention of cardiovascular disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 202-204.	1.4	0
2276	Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability. Methods in Molecular Biology, 2018, 1824, 371-385.	0.4	4
2277	Déterminants de l'insuffisance cardiaque aiguë au cours de l'infarctus du myocarde. Pan African Medical Journal, 2018, 29, .	0.3	1
2278	Early and long-term outcomes of complete revascularization with percutaneous coronary intervention in patients with multivessel coronary artery disease presenting with non-ST-segment elevation acute coronary syndromes. Postepy W Kardiologii Interwencyjnej, 2018, 14, 32-41.	0.1	3
2279	Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0200379.	1.1	13
2280	Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1255-1273.	0.9	5
2281	Blood Products and Transfusion Therapy in the ICU. , 2018, , 321-336.		0
2282	No-Reflow Phenomenon. , 2018, , 1007-1015.		0
2283	Association between brain-derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease. BMC Cardiovascular Disorders, 2018, 18, 23.	0.7	43
2284	Pre-hospital transthoracic echocardiography for early identification of non-ST-elevation myocardial infarction in patients with acute coronary syndrome. Critical Care, 2018, 22, 29.	2.5	13
2285	Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit. European Journal of Medical Research, 2018, 23, 6.	0.9	3
2286	High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet, The, 2018, 392, 919-928.	6.3	263
2287	Serum gamma-glutamyl transferase is a predictor of mortality in patients with acute myocardial infarction. Medicine (United States), 2018, 97, e11393.	0.4	13
2288	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
2289	Evaluation of relationship between common carotid artery intima-media thickness and coronary in-stent restenosis: A case-control study. Interventional Medicine & Applied Science, 2018, 10, 38-44.	0.2	2
2290	The high cost of critical care unit over-utilization for patients with NSTE ACS. American Heart Journal, 2018, 202, 84-88.	1.2	19
2291	Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 205-210.	1.4	29

#	Article	IF	CITATIONS
2292	Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction. Medicine (United States), 2018, 97, e11093.	0.4	14
2293	Guideline adherence in acute coronary syndromes between telemedically supported paramedics and conventional on-scene physician care: A longitudinal pre–post intervention cohort study. Health Informatics Journal, 2019, 25, 1528-1537.	1.1	8
2294	Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 127-138.	1.4	14
2295	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction. Circulation, 2019, 139, 448-457.	1.6	54
2296	Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 2019, 20, 309.	0.8	14
2297	Fast 0/1-h algorithm for detection of NSTEMI: are current high-sensitivity cardiac troponin assays fit for purpose? An EQA-based evaluation. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1999-2007.	1.4	5
2298	Coronary angiography and percutaneous coronary intervention in cardiac arrest survivors with non-shockable rhythms and no STEMI: A systematic review. Resuscitation, 2019, 143, 106-113.	1.3	5
2299	Medical care of acute myocardial infarction patients in a resource limiting country, Trinidad: a cross-sectional retrospective study. BMC Health Services Research, 2019, 19, 501.	0.9	5
2300	Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I. Journal of the American College of Cardiology, 2019, 74, 271-282.	1.2	75
2301	Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. BioMed Research International, 2019, 2019, 1-6.	0.9	10
2302	Cardiac CT for Coronary Imaging. , 2019, , 327-344.		0
2303	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2019, 12, e007830.	1.4	17
2304	A Machine Learning-Based Approach for the Prediction of Acute Coronary Syndrome Requiring Revascularization. Journal of Medical Systems, 2019, 43, 253.	2.2	13
2305	Does vessel length impact transluminal attenuation gradient in 320-slice coronary CT angiography? Correlation with invasive angiography. European Radiology, 2019, 29, 6837-6845.	2.3	2
2306	Trends in Death Rate 2009 to 2018 Following Percutaneous Coronary Intervention Stratified by Acuteness of Presentation. American Journal of Cardiology, 2019, 124, 1349-1356.	0.7	7
2307	CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions. Kidney Diseases (Basel,) Tj ETQq1 1 0.7843	81 4.2 gBT /0	Oværlock 10
2308	Cardiac CT, PET & Cardiac CT,		2
2309	Experimental evaluation of a radiation dose management system-integrated 3D skin dose map by comparison with XR-RV3 Gafchromic® films. Physica Medica, 2019, 66, 77-87.	0.4	16

#	Article	IF	CITATIONS
2310	Novel Techniques in Histologic Research: Morphometry and Mass Spectrometry Imaging. , 2019, , .		O
2311	Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 2032-2043.	1.2	84
2312	Higher in-hospital mortality during weekend admission for acute coronary syndrome: a large-scale cross-sectional Italian study. Journal of Cardiovascular Medicine, 2019, 20, 74-80.	0.6	8
2313	Usefulness of Haemoglobin Level Combined with CAMI-STEMI Score for Predicting MACCE in Patients with Acute ST-Elevation Myocardial Infarction after PCI. BioMed Research International, 2019, 2019, 1-8.	0.9	4
2314	High-Sensitivity Troponin and the Application of Risk Stratification Thresholds in Patients With Suspected Acute Coronary Syndrome. Circulation, 2019, 140, 1557-1568.	1.6	79
2315	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. New England Journal of Medicine, 2019, 381, 1621-1631.	13.9	431
2316	SREBF1c and SREBF2 gene polymorphisms are associated with acute coronary syndrome and blood lipid levels in Mexican population. PLoS ONE, 2019, 14, e0222017.	1.1	5
2317	Treatments and Mortality Trends in Cases With and Without Dialysis Who Have an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005879.	0.9	17
2318	Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization. Annals of Vascular Surgery, 2019, 59, 173-183.	0.4	5
2319	Effects of complete revascularization on long-term treatment outcomes in patients with multivessel coronary artery disease over 80 years of age admitted for acute coronary syndrome. Cardiovascular Diagnosis and Therapy, 2019, 9, 301-309.	0.7	5
2320	Associations of SNPs of the ADIPOQ Gene with Serum Adiponectin Levels, Unstable Angina, and Coronary Artery Disease. Biomolecules, 2019, 9, 537.	1.8	14
2321	Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study. Frontiers in Pharmacology, 2019, 10, 1112.	1.6	12
2322	Aortic dissection patients mimic acute coronary syndrome with preoperative antiplatelet therapy. Journal of Thoracic Disease, 2019, 11, 3385-3390.	0.6	6
2323	A Rule-Out Strategy Based on High-Sensitivity Troponin and HEART Score Reduces Hospital Admissions. Annals of Emergency Medicine, 2019, 73, 491-499.	0.3	38
2324	Treatment patterns of non-ST-elevation acute coronary syndrome patients presenting at non-PCI centres in the Netherlands and possible logistical consequences of adopting same-day transfer to PCI centres: aÂregistry-based evaluation. Netherlands Heart Journal, 2019, 27, 191-199.	0.3	10
2325	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PLoS ONE, 2019, 14, e0210821.	1.1	5
2326	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. American Journal of Medicine, 2019, 132, 749-757.e5.	0.6	48
2327	Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland. BMC Cardiovascular Disorders, 2019, 19, 123.	0.7	17

#	Article	IF	CITATIONS
2328	<p>The relationship between frailty syndrome and quality of life in older patients following acute coronary syndrome</p> . Clinical Interventions in Aging, 2019, Volume 14, 805-816.	1.3	15
2329	Antiplatelet Therapy and Coronary Artery Bypass Grafting: Analysis of Current Evidence With a Focus on Acute Coronary Syndrome. Canadian Journal of Cardiology, 2019, 35, 1030-1038.	0.8	8
2330	GDF-15 as a risk stratification biomarker for cardiovascular disease. International Journal of Cardiology, 2019, 292, 246-247.	0.8	10
2331	Association of CHA2DS2-VASc-HS Score with Adverse In-hospital Outcomes in Patients with Non-ST Segment Elevation Myocardial Infarction. Cardiovascular Journal, 2019, 11, 159-166.	0.0	0
2332	The impact of <i>CYP2C19</i> and <i>CYP4F2</i> variants and clinical factors on treatment outcomes during antiplatelet therapy. Pharmacogenomics, 2019, 20, 483-492.	0.6	10
2333	Type-II myocardial infarction and chronic myocardial injury rates, invasive management, and 4-year mortality among consecutive patients undergoing high-sensitivity troponin T testing in the emergency department. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 6, 41-48.	1.8	7
2334	A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRICâ€ACS study. Catheterization and Cardiovascular Interventions, 2019, 93, 1194-1204.	0.7	10
2335	Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. Clinical Research in Cardiology, 2019, 108, 1386-1393.	1.5	10
2336	Extensive phenotype data and machine learning in prediction of mortality in acute coronary syndrome $\hat{a}\in$ the MADDEC study. Annals of Medicine, 2019, 51, 156-163.	1.5	44
2337	Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review. Angiology, 2019, 70, 802-818.	0.8	114
2338	No time to delay reperfusion: A crossâ€sectional study of primary percutaneous coronary intervention times. Journal of Clinical Nursing, 2019, 28, 3233-3241.	1.4	0
2339	Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?. American Journal of Cardiovascular Drugs, 2019, 19, 377-379.	1.0	1
2340	Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome. IJC Heart and Vasculature, 2019, 22, 174-176.	0.6	12
2341	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine, 2019, 380, 1825-1833.	13.9	96
2342	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS ONE, 2019, 14, e0211464.	1.1	6
2343	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Postâ€Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACSâ€TIMI 46 and ATLAS ACS 2â€TIMI 51. Journal of the American Heart Association, 2019, 8, .	1.6	10
2344	Scavenger receptor Class B type I as a potential risk stratification biomarker and therapeutic target in cardiovascular disease. Journal of Cellular Physiology, 2019, 234, 16925-16932.	2.0	17
2345	Trial design for assessing analytical and clinical performance of high-sensitivity cardiac troponin I assays in the United States: The HIGH-US study. Contemporary Clinical Trials Communications, 2019, 14, 100337.	0.5	13

#	Article	IF	CITATIONS
2346	Impact of Normal Weight Central Obesity on Clinical Outcomes in Male Patients With Premature Acute Coronary Syndrome. Angiology, 2019, 70, 960-968.	0.8	9
2347	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1069.	3.8	144
2348	Spontaneous coronary artery dissection: a review of complications and management strategies. Expert Review of Cardiovascular Therapy, 2019, 17, 275-291.	0.6	37
2349	De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Chinese Medical Journal, 2019, 132, 197-210.	0.9	11
2350	Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry. American Journal of Cardiovascular Drugs, 2019, 19, 403-414.	1.0	4
2351	Risk stratification and timing for invasive approach in patients with non-STEMI. American Journal of Emergency Medicine, 2019, 37, 1792-1793.	0.7	O
2352	Predictive value of global and territorial longitudinal strain imaging in detecting significant coronary artery disease in patients with myocardial infarction without persistent ⟨scp⟩ST⟨/scp⟩â€segment elevation. Echocardiography, 2019, 36, 512-520.	0.3	18
2353	Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open, 2019, 9, e023337.	0.8	13
2354	Adherence to NSTEMI Guidelines in the Emergency Department. Critical Pathways in Cardiology, 2019, 18, 40-46.	0.2	10
2355	Intraoperative infusion of noradrenaline improves platelet aggregation in patients undergoing coronary artery bypass grafting: a randomized controlled trial. Journal of Thrombosis and Haemostasis, 2019, 17, 657-665.	1.9	4
2356	Cost-minimisation analysis alongside a pilot study of early Tissue Doppler Evaluation of Diastolic Dysfunction in Emergency Department Non-ST Elevation Acute Coronary Syndromes (TEDDy-NSTEACS). BMJ Open, 2019, 9, e023920.	0.8	5
2357	Pharmaceutical use and costs in patients with coronary artery disease, using Australian observational data. BMJ Open, 2019, 9, e029360.	0.8	1
2358	Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A post hoc analysis performed in emergency departments. BMJ Open, 2019, 9, e023994.	0.8	9
2359	Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China: a prospective observational study. BMJ Open, 2019, 9, e028211.	0.8	13
2360	Relationship between Particulate Matter Pollution and Acute Coronary Syndrome Incidence. Atmosphere, 2019, 10, 103.	1.0	1
2361	Initial evaluation of a brief pharmacy-led intervention to modify beliefs about medicines and facilitate adherence among patients hospitalised with acute coronary syndrome. European Journal of Hospital Pharmacy, 2019, 29, ejhpharm-2019-002041.	0.5	3
2362	Association between high-sensitivity cardiac troponin I measured at emergency department and complications of emergency coronary artery bypass grafting. Scientific Reports, 2019, 9, 16933.	1.6	1
2363	8. Grundlagen der Therapie mit einem internen Kardioverter-Defibrillator (ICD), der kardialen Resynchronisationstherapie (CRT) und der kardialen Kontraktilit Atsmodulation (CCM)., 2019,, 132-153.		0

#	Article	IF	CITATIONS
2364	Plasma levels of receptor interacting protein kinase-3 correlated with coronary artery disease. Chinese Medical Journal, 2019, 132, 1400-1405.	0.9	14
2365	Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014. Coronary Artery Disease, 2019, 30, 326-331.	0.3	3
2366	Do patients with non-ST-elevation myocardial infarction without chest pain suffer a poor prognosis?. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 788-792.	0.5	3
2367	Accuracy of left ventricular ejection fraction determined by automated analysis of handheld echocardiograms: A comparison of experienced and novice examiners. Echocardiography, 2019, 36, 2145-2151.	0.3	18
2368	Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion. Frontiers in Pharmacology, 2019, 10, 1158.	1.6	6
2369	Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay. Journal of Cardiovascular Pharmacology, 2019, 73, 40-47.	0.8	14
2370	The Association Between Modified Intracoronary Thrombus Grade and Cardiovascular Risk Factors and Initial Laboratory Findings in Patients Undergoing Primary Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2019, 18, 135-138.	0.2	2
2371	The predictive value of PRECISE-DAPT score for arrhythmic complications in patients with ST-elevation myocardial infarction. Coronary Artery Disease, 2019, 30, 499-504.	0.3	7
2372	The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology, 2019, 15, 277-281.	0.3	0
2373	A risk score model for predicting cardiac rupture after acute myocardial infarction. Chinese Medical Journal, 2019, 132, 1037-1044.	0.9	7
2374	Temperament and Depression After a First Acute Coronary Syndrome. Journal of Nervous and Mental Disease, 2019, 207, 277-283.	0.5	3
2375	Spontaneous coronary artery dissection. Current Opinion in Cardiology, 2019, 34, 594-602.	0.8	33
2376	Early surgical myocardial revascularization in non-ST-segment elevation acute coronary syndrome. Journal of Thoracic Disease, 2019, 11, 4444-4452.	0.6	8
2377	Association of the blood urea nitrogen-to-left ventricular ejection fraction ratio with contrast-induced nephropathy in patients with acute coronary syndrome who underwent percutaneous coronary intervention. International Urology and Nephrology, 2019, 51, 475-481.	0.6	5
2378	Derivation and validation of a simple inflammation-based risk score system for predicting in-hospital mortality in acute coronary syndrome patients. Journal of Cardiology, 2019, 73, 416-424.	0.8	16
2379	High-sensitivity cardiac troponin assays: finally ready for prime time?. Nature Reviews Cardiology, 2019, 16, 135-136.	6.1	4
2380	Social support buffers the negative effects of stress in cardiac patients: a cross-sectional study with acute coronary syndrome patients. Journal of Behavioral Medicine, 2019, 42, 469-479.	1,1	10
2381	Cardiorenal Syndrome Type 1., 2019, , 216-222.e3.		0

#	Article	IF	CITATIONS
2382	Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1069-1075.	0.7	3
2383	Early diagnostic value of circulating microRNAs in patients with suspected acute myocardial infarction. Journal of Cellular Physiology, 2019, 234, 13649-13658.	2.0	34
2384	Long-Term Follow-Up After Treatment of Drug-Eluting Stent Restenosis and De Novo Lesions Using SeQuent Please Paclitaxel-Coated Balloons. Angiology, 2019, 70, 414-422.	0.8	1
2385	Comparison of fourteen rule-out strategies for acute myocardial infarction. International Journal of Cardiology, 2019, 283, 41-47.	0.8	45
2386	Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. International Journal of Cardiology, 2019, 283, 35-40.	0.8	19
2387	Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 93, 241-247.	0.7	6
2388	Surgery and Hemostasis., 2019,, 696-720.		0
2389	Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 727-737.	0.4	33
2390	Assessment of acute myocarditis by cardiac magnetic resonance imaging: Comparison of qualitative and quantitative analysis methods. Journal of Nuclear Cardiology, 2019, 26, 857-865.	1.4	12
2391	Differences in symptoms, first medical contact and pre-hospital delay times between patients with ST-and non-ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 201-207.	0.4	19
2392	The search for water: Is it so easy to diagnose acute myocarditis?. Journal of Nuclear Cardiology, 2019, 26, 866-868.	1.4	1
2393	Superiority of wall motion score index over left ventricle ejection fraction in predicting cardiovascular events after an acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 78-85.	0.4	31
2394	Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 52-61.	0.4	14
2395	Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?. Acta Cardiologica, 2020, 75, 149-155.	0.3	0
2396	Revascularisation in older adult patients with non-ST-segment elevation acute coronary syndrome: effect and impact on 6-month mortality. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 358-366.	0.4	6
2397	Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis. Chinese Journal of Integrative Medicine, 2020, 26, 227-234.	0.7	6
2398	Coronary Embolism: A Systematic Review. Cardiovascular Revascularization Medicine, 2020, 21, 367-374.	0.3	27
2399	A machine learning–based 1-year mortality prediction model after hospital discharge for clinical patients with acute coronary syndrome. Health Informatics Journal, 2020, 26, 1289-1304.	1.1	32

#	ARTICLE	IF	CITATIONS
2400	Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Internal Medicine, 2020, 59, 311-321.	0.3	25
2401	Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 14-21.	1.4	4
2402	Management and outcomes of patients with unstable angina with undetectable, normal, or intermediate hsTnT levels. Clinical Research in Cardiology, 2020, 109, 476-487.	1.5	17
2403	Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. American Journal of Cardiovascular Drugs, 2020, 20, 105-115.	1.0	10
2404	Evolution of renal function and predictive value of serial renal assessments among patients with acute coronary syndrome: BIOMArCS study. International Journal of Cardiology, 2020, 299, 12-19.	0.8	3
2405	A Review of Signal Processing Techniques for Non-Invasive Fetal Electrocardiography. IEEE Reviews in Biomedical Engineering, 2020, 13, 51-73.	13.1	67
2406	HEART score improves efficiency of coronary computed tomography angiography in patients suspected of acute coronary syndrome in the emergency department. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 23-29.	0.4	6
2407	The thromboelastography G parameter as a potential biomarker of acute coronary syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 196-201.	0.6	2
2408	High-sensitivity-cardiac troponin for accelerated diagnosis of acute myocardial infarction: A systematic review and meta-analysis. American Journal of Emergency Medicine, 2020, 38, 1402-1407.	0.7	27
2409	Sex-differential effect of frailty on long-term mortality in elderly patients after an acute coronary syndrome. International Journal of Cardiology, 2020, 302, 30-33.	0.8	3
2410	Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: †The Ottawa Troponin Pathway'. PLoS ONE, 2020, 15, e0226892.	1.1	4
2411	Hemoglobin threshold and clinical predictors for perioperative blood transfusion in elective surgery: Systemic review. Trends in Anaesthesia and Critical Care, 2020, 31, 8-15.	0.4	4
2412	Long-term clinical outcomes in patients with unstable angina undergoing percutaneous coronary interventions in a contemporary registry data from Poland. Coronary Artery Disease, 2020, 31, 215-221.	0.3	9
2413	Diagnostic accuracy of troponin T measured ≥6h after symptom onset for ruling out myocardial infarction. Scandinavian Cardiovascular Journal, 2020, 54, 153-161.	0.4	6
2414	Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain; data from the Akershus cardiac Examination (ACE) 3 study. Clinical Biochemistry, 2020, 78, 10-17.	0.8	15
2415	A study on modified accelerated diagnostic protocol to safely discharge low-risk chest pain patients in emergency department. Hong Kong Journal of Emergency Medicine, 2020, 27, 134-145.	0.4	0
2416	The c.*52 A/G and c.*773 A/G Genetic Variants in the UTRâ€23 of the LDLR Gene Are Associated with the Risk of Acute Coronary Syndrome and Lower Plasma HDL-Cholesterol Concentration. Biomolecules, 2020, 10, 1381.	1.8	2
2417	The progress in outcomes of the management of patients with non-ST-segment elevation myocardial infarction between 2005 and 2014 in Poland – a propensity score matching analysis from the PL-ACS registry. Postepy W Kardiologii Interwencyjnej, 2020, 16, 41-48.	0.1	0

#	Article	IF	CITATIONS
2418	Two genetic variants in the promoter region of the CCL5 gene are associated with the risk of acute coronary syndrome and with a lower plasma CCL5 concentration. Immunology Letters, 2020, 228, 86-92.	1.1	0
2419	Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes. JAMA Network Open, 2020, 3, e2018735.	2.8	48
2421	Neutrophil-to-lymphocyte ratio for predictor of in-hospital mortality in ST-segment elevation myocardial infarction: a meta-analysis. Medical Journal of Indonesia, 2020, 29, 172-82.	0.2	0
2422	Changes in treatment for NSTEMI in women and the elderly over the past 16†years in a large real-world population. International Journal of Cardiology, 2020, 316, 7-12.	0.8	4
2423	Predictive Value of Serial ECGs in Patients with Suspected Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 2303.	1.0	10
2424	Stroke chameleons: acute central pain mimicking acute coronary syndrome. European Journal of Neurology, 2020, 27, 2312-2317.	1.7	4
2425	Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis. JAMA Cardiology, 2020, 5, 1286.	3.0	1
2426	Management of Acute Mesenteric Venous Thrombosis: A Systematic Review of Contemporary Studies. Scandinavian Journal of Surgery, 2021, 110, 145749692096908.	1.3	19
2427	Do age, period or cohort effects explain circulatory disease mortality trends, Scotland 1974–2015?. Heart, 2020, 106, 584-589.	1.2	4
2429	Effectiveness and Safety of the European Society of Cardiology 0-/1-h Troponin Rule-Out Protocol: The Design of the ESC-TROP Multicenter Implementation Study. Cardiology, 2020, 145, 685-692.	0.6	5
2430	Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction. Scientific Reports, 2020, 10, 21114.	1.6	8
2431	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Scientific Reports, 2020, 10, 22121.	1.6	9
2432	Exploring Patient Experience of Chest Pain BeforeÂand After Implementation of an Early Rule-Out Pathway for Myocardial Infarction: AÂQualitative Study. Annals of Emergency Medicine, 2020, 75, 502-513.	0.3	10
2433	Percutaneous coronary intervention in octogenarians: A risk scoring system to predict 30â€day outcomes in the elderly. Catheterization and Cardiovascular Interventions, 2020, 98, 1300-1307.	0.7	6
2434	Going beyond the mean: economic benefits of myocardial infarction secondary prevention. BMC Health Services Research, 2020, 20, 1125.	0.9	1
2435	Blood group A: a risk factor for heart rupture after acute myocardial infarction. BMC Cardiovascular Disorders, 2020, 20, 471.	0.7	4
2436	Coronary Artery Disease and The Evolution of Angioplasty Devices. SpringerBriefs in Materials, 2020, , .	0.1	0
2437	A Prospective, Randomized, Open-Label Trial of Atorvastatin versus Rosuvastatin in the Prevention of Contrast-Induced Acute Kidney Injury, Worsened Renal Function at 30 Days, and Clinical Events After Acute Coronary Angiography: the PRATO-ACS-2 Study. CardioRenal Medicine, 2020, 10, 288-301.	0.7	4

#	Article	IF	CITATIONS
2438	Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction. Cardiovascular Endocrinology and Metabolism, 2020, 9, 24-29.	0.5	6
2439	Correlation between overweightness and the extent of coronary atherosclerosis among the South Caspian population. BMC Cardiovascular Disorders, 2020, 20, 257.	0.7	6
2440	Imaging Cardiovascular Emergencies. Heart Failure Clinics, 2020, 16, 331-346.	1.0	4
2441	The GRACE Scale in the Prognosis of Patients with Takotsubo Syndrome. Journal of Interventional Cardiology, 2020, 2020, 1-7.	0.5	4
2442	The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Frontiers in Pharmacology, 2020, 11, 681.	1.6	6
2443	Value of Repeated Troponin Measurements to Improve the Safety of the HEART Score for Chest Pain Patients at the Emergency Department. Critical Pathways in Cardiology, 2020, 19, 62-68.	0.2	2
2444	Residual SYNTAX Score Is Associated With Contrast-Induced Nephropathy in Patients With Non-ST Segment Elevation Myocardial Infarction With Preserved LVEF. Angiology, 2020, 71, 799-803.	0.8	0
2445	Diagnostic and prognostic value of circulating miRNAâ€499 and miRNAâ€22 in acute myocardial infarction. Journal of Clinical Laboratory Analysis, 2020, 34, 2410-2417.	0.9	21
2446	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. International Journal of Cardiology, 2020, 318, 67-73.	0.8	11
2447	Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. Biomarkers in Medicine, 2020, 14, 775-784.	0.6	5
2448	Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS. Platelets, 2021, 32, 498-506.	1.1	3
2449	Comparison of O/3-Hour Rapid Rule-Out Strategies Using High-Sensitivity Cardiac Troponin I in a US Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006565.	0.9	7
2450	Identification of high-risk non-ST elevation myocardial infarction at presentation to emergency department. A prospective observational cohort study in North West England. BMJ Open, 2020, 10, e030128.	0.8	4
2451	Antiplatelet therapies in diabetes. Diabetic Medicine, 2020, 37, 726-734.	1.2	2
2452	Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1773-1783.	1.4	11
2453	Point-of-care troponin testing and management of patients with acute coronary syndrome: a systematic review. British Journal of Cardiac Nursing, 2020, 15, 1-16.	0.0	0
2454	Identifying low-risk chest pain in the emergency department: Obstructive coronary artery disease and major adverse cardiac events. American Journal of Emergency Medicine, 2020, 38, 1737-1742.	0.7	4
2455	Fibrinolysis for Acute STEMI in an Emergency Department Cardiac Care Unit in a Humanitarian Setting: Operational Experiences and Patient Outcomes. SN Comprehensive Clinical Medicine, 2020, 2, 587-595.	0.3	O

#	Article	IF	CITATIONS
2456	A comparison of cardiovascular risk scores in native and migrant South Asian populations. SSM - Population Health, 2020, 11, 100594.	1.3	15
2457	Gender-related disparities in the treatment and outcomes in patients with non-ST-segment elevation myocardial infarction: results from the Polish Registry of Acute Coronary Syndromes (PL-ACS) in the years 2012–2014. Archives of Medical Science, 2020, 16, 781-788.	0.4	6
2458	Fibrinogen and Low-Density Lipoprotein (LDL) Cholesterol Levels with the Occurrence of Acute Myocardial Infarction: Is it Correlated?. IOP Conference Series: Earth and Environmental Science, 2020, 441, 012183.	0.2	0
2459	The Ser290Asn and Thr715Pro Polymorphisms of the SELP Gene Are Associated with A Lower Risk of Developing Acute Coronary Syndrome and Low Soluble P-Selectin Levels in A Mexican Population. Biomolecules, 2020, 10, 270.	1.8	4
2460	Female sex impact on culprit plaque at optical coherence tomography analysis in the setting of acute coronary syndrome in OCT-FORMIDABLE registry. Future Cardiology, 2020, 16, 123-131.	0.5	3
2461	Frequency and Predictors of Radial Artery Occlusion after Coronary Procedure through Transradial Approach: A Vascular Doppler-guided Study. Bangladesh Heart Journal, 2020, 34, 111-117.	0.1	0
2462	Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. European Heart Journal, 2020, 41, 3153-3155.	1.0	1
2463	Activation of the Nitric Oxide Pathway and Acute Myocardial Infarction Complicated by Acute Kidney Injury. CardioRenal Medicine, 2020, 10, 85-96.	0.7	9
2464	Incidence, clinical features and outcome of Takotsubo syndrome in the intensive care unit. Archives of Cardiovascular Diseases, 2020, 113, 176-188.	0.7	9
2465	Assessing platelet reactivity after drug eluting stent implantation: state of the art. Expert Review of Cardiovascular Therapy, 2020, 18, 17-24.	0.6	1
2466	Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score. Catheterization and Cardiovascular Interventions, 2020, 95, 665-673.	0.7	5
2467	A LASSO-derived risk model for long-term mortality in Chinese patients with acute coronary syndrome. Journal of Translational Medicine, 2020, 18, 157.	1.8	19
2468	Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. Journal of Clinical Medicine, 2020, 9, 928.	1.0	9
2469	Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC European Heart Journal: Acute Cardiovascular Care, 2020, 9, 59-81.	0.4	51
2470	Embracing Dissemination and Implementation Research in Cardiac Critical Care. Global Heart, 2014, 9, 363.	0.9	12
2471	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. Global Heart, 2020, 9, 457.	0.9	34
2472	How Do Type of Preoperative P2Y12 Receptor Inhibitor and Withdrawal Time Affect Bleeding?. Annals of Thoracic Surgery, 2021, 111, 77-84.	0.7	8
2473	Percutaneous coronary intervention of unprotected left main and bifurcation in octogenarians: Subanalysis from RAIN (veRy thin stents for patients with left mAIn or bifurcatioN in real life). Catheterization and Cardiovascular Interventions, 2021, 97, 755-763.	0.7	0

#	Article	IF	CITATIONS
2474	Prognostic usefulness of residual SYNTAX score combined with clinical factors for patients with acute coronary syndrome who underwent percutaneous coronary intervention from the SHINANO Registry. Heart and Vessels, 2021, 36, 170-179.	0.5	4
2475	Comment on: Changes in treatment for NSTEMI in women and the elderly over the past 16Âyears in a large real-world population. International Journal of Cardiology, 2021, 322, 56.	0.8	0
2476	Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. International Journal of Cardiology, 2021, 327, 19-24.	0.8	1
2477	Right bundle brunch block in patients with acute myocardial infarction is associated with a higher in-hospital arrhythmic risk and mortality, and a worse prognosis after discharge. Journal of Electrocardiology, 2021, 64, 3-8.	0.4	2
2478	Acute Myocardial Infarction Biosensor: A Review From Bottom Up. Current Problems in Cardiology, 2021, 46, 100739.	1.1	20
2479	Assessment of serum phenylalanine and tyrosine isomers in patients with STâ€segment elevation vs nonâ€sTâ€segment elevation myocardial infarction. Journal of Clinical Laboratory Analysis, 2021, 35, e23613.	0.9	3
2480	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table. Cardiovascular Research, 2021, 117, 1248-1256.	1.8	11
2481	Diagnosis and Management of Coronary Artery Disease in Athletes. , 2021, , 211-225.		0
2482	Effect of Baseline Thrombocytopenia on Long-Term Outcomes in Patients With Acute ST-Segment Elevated Myocardial Infarction ― A Large Propensity Score-Matching Analysis From the China Acute Myocardial Infarction (CAMI) Registry ―. Circulation Journal, 2021, 85, 150-158.	0.7	2
2483	Performance of a Novel Research-Use-Only Secretoneurin ELISA in Patients with Suspected Acute Coronary Syndrome: Comparison with an Established Secretoneurin Radioimmunoassay. Cardiology, 2021, 146, 566-574.	0.6	3
2484	Liberal vs. Conservative Blood Strategies. , 2021, , 269-278.		0
2485	Drugs in Myocardial Infarction. , 2021, , 115-124.		0
2486	The prognostic impact of renal function decline during hospitalization for myocardial infarction. Journal of Comparative Effectiveness Research, 2021, 10, 219-228.	0.6	3
2487	Viscoelastic Haemostatic Assays in Cardiovascular Critical Care. Cardiac Failure Review, 2020, 7, e01.	1.2	5
2488	Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1353-1368.	1.5	8
2489	The relationship between corrected QT interval and neutrophil to lymphocyte ratio in patients with acute coronary syndrome. Journal of Surgery and Medicine, 2021, 5, 158-162.	0.0	0
2490	Pronóstico a largo plazo de pacientes con IAMSEST y coronarias sin lesiones obstructivas según los distintos subtipos angiográficos. Revista Espanola De Cardiologia, 2021, 74, 919-919.	0.6	3
2491	Relationship between thiol, disulphide volume and contrast-induced nephropathy in acute coronary syndrome patients treated with percutaneous coronary intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 173-180.	0.6	2

#	Article	IF	Citations
2492	Sex Differences in the Effects of COPD on Incidence and Outcomes of Patients Hospitalized with ST and Non-ST Elevation Myocardial Infarction: A Population-Based Matched-Pair Analysis in Spain (2016–2018). Journal of Clinical Medicine, 2021, 10, 652.	1.0	2
2493	Raccomandazioni del GdS MM SIPMeL per l'uso dei biomarcatori cardiaci in NSTEMI. Parte seconda: evidenze nella diagnosi. Rivista Italiana Della Medicina Di Laboratorio, 2021, 16, .	0.2	7
2494	Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study. Scientific Reports, 2021, 11, 4160.	1.6	2
2495	Impact of more conservative European Society of Cardiology guidelines on the management of patients with acute chest pain. International Journal of Clinical Practice, 2021, 75, e14133.	0.8	3
2496	On-board emergency medical equipment of European airlines. Travel Medicine and Infectious Disease, 2021, 40, 101982.	1.5	5
2497	Risk factors of the development of vascular and neuropathic complications in patients with type 2 diabetes mellitus and autoimmune thyroiditis. Klinicheskaia Meditsina, 2021, 98, 699-708.	0.2	0
2498	Management of Spontaneous Isolated Mesenteric Artery Dissection: A Systematic Review. Scandinavian Journal of Surgery, 2021, 110, 145749692110005.	1.3	22
2499	Percutaneous management of reperfusion arrhythmias during primary percutaneous coronary intervention: a case report. Egyptian Heart Journal, 2021, 73, 30.	0.4	4
2500	JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases. Circulation Journal, 2021, 85, 695-757.	0.7	16
2501	Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018. Implementation Science, 2021, 16, 42.	2.5	1
2502	The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study. BMC Cardiovascular Disorders, 2021, 21, 202.	0.7	4
2503	Estimation copeptinlevel and some biological criteria in induced male atherogenic rat. Materials Today: Proceedings, 2021, , .	0.9	0
2505	Ticagrelor Versus Clopidogrel in ST Segment Elevation Myocardial Infarction Patients Candidate for Primary Percutaneous Coronary Intervention. Indian Journal of Clinical Cardiology, 0, , 263246362110048.	0.3	0
2506	Clinical Impact of High-Sensitivity Cardiac Troponin T Implementation in theÂCommunity. Journal of the American College of Cardiology, 2021, 77, 3160-3170.	1.2	33
2507	Relationship Between Fasting Glucose, HbA1c Levels, and the SYNTAX Score 2 in Patients With Non-ST-Elevation Myocardial Infarction. Angiology, 2021, , 000331972110146.	0.8	4
2508	Use of historical high-sensitivity cardiac troponin T levels to rule out myocardial infarction. Open Heart, 2021, 8, e001682.	0.9	4
2509	The change in high-sensitivity troponin-T as a risk factor for significant coronary stenosis in patients with acute coronary syndrome. Korean Journal of Internal Medicine, 2021, 36, 608-616.	0.7	1
2510	Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes. Journal of Cardiothoracic Surgery, 2021, 16, 139.	0.4	1

#	Article	IF	CITATIONS
2511	The predictive value of creatinine clearance for mortality in patients undergoing revascularization. Journal of Cardiothoracic Surgery, 2021, 16, 120.	0.4	1
2512	Time-Series Transcriptome Analysis Reveals the miR-27a-5p- <i>Ppm1l</i> Axis as a New Pathway Regulating Macrophage Alternative Polarization After Myocardial Infarction. Circulation Journal, 2021, 85, 929-938.	0.7	2
2513	Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock Model. Drugs in R and D, 2021, 21, 321-329.	1.1	0
2514	Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. Advances in Therapy, 2021, 38, 4026-4039.	1.3	3
2515	Readiness for Discharge from Hospital after Myocardial Infarction: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2021, 18, 6937.	1.2	14
2516	The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (PCSK7) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides. Cells, 2021, 10, 1444.	1.8	6
2517	Association Between Air Pollution and Acute Coronary Syndromes During Lockdown for COVID-19: Results From the Terni Hub Center. Frontiers in Public Health, 2021, 9, 683683.	1.3	3
2518	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation, 2021, 143, 2214-2224.	1.6	80
2519	Translational perspectives on cardiac reprogramming. Seminars in Cell and Developmental Biology, 2021, 122, 14-14.	2.3	3
2520	Mortality Outcomes of Single-staged versus Multi-staged Complete Coronary Revascularization in Multivessel Non-ST Elevation Myocardial Infarction Patients. Duzce Universitesi Tip Fak $\tilde{A}\frac{1}{4}$ ltesi Dergisi, 0, , .	0.3	1
2521	Decision Support System to Risk Stratification in the Acute Coronary Syndrome Using Fuzzy Logic. Scientific Programming, 2021, 2021, 1-9.	0.5	2
2522	Analytical characterization and clinical performance evaluation of a new point-of-care testing system for high-sensitivity cardiac troponin I assay. Annals of Clinical Biochemistry, 2021, 58, 579-585.	0.8	4
2523	Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 774-786.	0.4	2
2524	Washing-free chemiluminescence immunoassay for rapid detection of cardiac troponin I in whole blood samples. Chinese Chemical Letters, 2022, 33, 743-746.	4.8	49
2525	Management of Multivessel Disease and Physiology Testing in ST Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2021, 10, 333-343.	0.2	0
2526	Impact of cardiac rehabilitation on left ventricular diastolic function and exercise capacity in patients treated with percutaneous coronary intervention after acute coronary event. Acta Cardiologica, 2022, 77, 506-514.	0.3	2
2527	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 2022, 108, 613-618.	1.2	7
2528	Prognostic Implications of High-Sensitivity Troponin T Levels Among Patients Attending Emergency Departments and Evaluated for an Acute Coronary Syndrome. American Journal of Medicine, 2021, 134, 1019-1028.e1.	0.6	2

#	ARTICLE	IF	CITATIONS
2529	Coronary CT angiography for suspected acute coronary syndrome: sex-associated differences. Netherlands Heart Journal, 2021, 29, 518-524.	0.3	4
2530	Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction. Circulation, 2021, 144, 528-538.	1.6	39
2531	Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents. Journal of Clinical Medicine, 2021, 10, 3642.	1.0	5
2532	Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine, 2022, 38, 54-60.	0.3	3
2533	Tirofiban: A Rare Cause of Thrombocytopenia in a Patient Undergoing Percutaneous Coronary Intervention. Cureus, 2021, 13, e18217.	0.2	3
2534	Prognostic value of circulating microRNAs compared to high-sensitivity troponin T in patients presenting with suspected acute coronary syndrome to the emergency department. Clinical Biochemistry, 2022, 99, 9-16.	0.8	4
2535	Update: Gender differences in CABG outcomes—Have we bridged the gap?. PLoS ONE, 2021, 16, e0255170.	1.1	15
2536	Role of Gender on the Outcomes of ST-Elevation Myocardial Infarction Patients Following Primary Coronary Angioplasty. Cureus, 2021, 13, e17892.	0.2	1
2537	Prevalence and prognosis of isolated posterior ST-segment elevation acute myocardial infarction using synthesized-V7–9 lead. Cardiovascular Intervention and Therapeutics, 2021, , 1.	1.2	2
2538	Prognostic value of oxidative stress in patients with acute myocardial infarction complicated by cardiogenic shock: A prospective cohort study. Free Radical Biology and Medicine, 2021, 174, 66-72.	1.3	13
2539	Biomarkers of Diseases: Their Role in Emergency Medicine. , 0, , .		0
2540	The value of admission Troponin I to predict outcomes in suspected infections in elderly patients admitted in Internal Medicine: results from the SOFA-T collaboration, a multi-center study. Internal and Emergency Medicine, 2021, 16, 981-988.	1.0	9
2541	National registry of Myocardial Infarction: Strategies for a developing country. Informatics in Medicine Unlocked, 2021, 23, 100527.	1.9	4
2542	A 13-Year-Old Boy from Thailand with Hutchinson-Gilford Progeria Syndrome with Coronary Artery and Aortic Calcification and Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). American Journal of Case Reports, 2021, 22, e928969.	0.3	2
2543	Diagnostic value of copeptin combined with hypersensitive cardiac troponin T detection in early acute myocardial infarction. Medicine (United States), 2021, 100, e23949.	0.4	3
2544	Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis. Mediators of Inflammation, 2021, 2021, 1-17.	1.4	10
2545	Sensible Use of High-Sensitivity Troponin Assays. Methods in Molecular Biology, 2013, 963, 385-406.	0.4	6
2546	Artificial Neural Networks in Acute Coronary Syndrome Screening. Lecture Notes in Computer Science, 2015, , 108-119.	1.0	3

#	Article	IF	Citations
2550	Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. International Journal of Cardiology, 2019, 283, 48-54.	0.8	27
2551	miR-134-5p inhibition reduces infarct-induced cardiomyocyte apoptosis via Creb1 upregulation. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104850.	0.7	11
2552	Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. European Heart Journal, 2016, 37, 3324-3332.	1.0	132
2553	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. Current Opinion in Cardiology, 2015, 30, 325-332.	0.8	8
2554	Influence of previous coronary artery bypass grafting in the difficulty of acute coronary syndrome diagnosis. European Journal of Emergency Medicine, 2021, 28, 125-135.	0.5	2
2555	Use of transthoracic echocardiography in the evaluation of chest pain: illustrative cases and review of recent guidelines. BMJ Case Reports, 2014, 2014, bcr2014205438-bcr2014205438.	0.2	2
2556	Cardioprotective medication adherence among patients with coronary heart disease in China: a systematic review. Heart Asia, 2019, 11, e011173.	1.1	22
2557	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging "Real-World―Questions. Thrombosis, 2012, 2012, 1-10.	1.4	4
2558	Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2015, 114, .	1.8	1
2559	Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome. Biochemia Medica, 2012, 22, 225-236.	1.2	25
2560	Circulating resistin protein and mRNA concentrations and clinical severity of coronary artery disease. Biochemia Medica, 2015, 25, 242-251.	1.2	13
2561	Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. Singapore Medical Journal, 2013, 54, 169-175.	0.3	18
2562	Acute coronary syndrome in the older adults. Journal of Geriatric Cardiology, 2016, 13, 101-8.	0.2	61
2563	Prognostic value of low and moderately elevated C-reactive protein in acute coronary syndrome: A 2-year follow-up study. Medical Science Monitor, 2013, 19, 777-786.	0.5	10
2564	Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. Medical Science Monitor, 2019, 25, 7138-7148.	0.5	13
2565	In Vivo Detection of Activated Platelets Allows Characterizing Rupture of Atherosclerotic Plaques with Molecular Magnetic Resonance Imaging in Mice. PLoS ONE, 2012, 7, e45008.	1.1	17
2566	Mortality Trends in Women and Men Presenting with Acute Coronary Syndrome: Insights from a 20-Year Registry. PLoS ONE, 2013, 8, e70066.	1.1	20
2567	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. PLoS ONE, 2013, 8, e71150.	1.1	32

#	Article	IF	CITATIONS
2568	Imbalanced Frequencies of Th17 and Treg Cells in Acute Coronary Syndromes Are Mediated by IL-6-STAT3 Signaling. PLoS ONE, 2013, 8, e72804.	1.1	20
2569	New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition. PLoS ONE, 2014, 9, e87843.	1.1	23
2570	New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human. PLoS ONE, 2014, 9, e87844.	1.1	39
2571	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. PLoS ONE, 2014, 9, e111816.	1.1	39
2572	The Diagnostic Value of Clinical Symptoms in Women and Men Presenting with Chest Pain at the Emergency Department, a Prospective Cohort Study. PLoS ONE, 2015, 10, e0116431.	1.1	17
2573	Plasma miR-122 and miR-3149 Potentially Novel Biomarkers for Acute Coronary Syndrome. PLoS ONE, 2015, 10, e0125430.	1.1	37
2574	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS ONE, 2015, 10, e0135037.	1.1	12
2575	Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry. PLoS ONE, 2015, 10, e0140101.	1.1	10
2576	Nucleated Red Blood Cells as Predictors of All-Cause Mortality in Cardiac Intensive Care Unit Patients: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0144259.	1.1	24
2577	Revascularization Treatment of Emergency Patients with Acute ST-Segment Elevation Myocardial Infarction in Switzerland: Results from a Nationwide, Cross-Sectional Study in Switzerland for 2010-2011. PLoS ONE, 2016, 11, e0153326.	1.1	5
2578	Impact of an Early Invasive Strategy versus Conservative Strategy for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome in Patients with Chronic Kidney Disease: A Systematic Review. PLoS ONE, 2016, 11, e0153478.	1.1	31
2579	Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events. PLoS ONE, 2016, 11, e0158355.	1.1	37
2580	Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. PLoS ONE, 2017, 12, e0179349.	1.1	8
2581	GDF-15 predicts cardiovascular events in acute chest pain patients. PLoS ONE, 2017, 12, e0182314.	1.1	27
2582	Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early period of acute coronary syndrome are derived from peripheral blood mononuclear cells. PLoS ONE, 2017, 12, e0184256.	1.1	25
2583	Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. PLoS ONE, 2017, 12, e0187662.	1.1	48
2584	Myocardial revascularization in patients with coronary heart disease and type 2 diabetes. Diabetes Mellitus, 2016, 19, 471-478.	0.5	5
2585	Neurocognitive impairment after acute coronary syndrome: Prevalence and characterization in a hospital-based cardiac rehabilitation program sample. Journal of Cardiovascular and Thoracic Research, 2018, 10, 70-75.	0.3	8

#	Article	IF	CITATIONS
2586	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation $\hat{a} \in A$ Brief Summary. Arrhythmia and Electrophysiology Review, 2013, 2, 115.	1.3	2
2587	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. Interventional Cardiology Review, 2011, 9, 94.	0.7	3
2588	Current Concepts in the Clinical Utility of Platelet Reactivity Testing. Interventional Cardiology Review, 2013, 8, 100.	0.7	4
2589	Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interventional Cardiology Review, 2014, 9, 164.	0.7	1
2590	Twelve Months Dual Antiplatelet Therapy after Drug-eluting Stents – Too Long, too Short or Just Right?. Interventional Cardiology Review, 2015, 10, 136.	0.7	2
2591	Multicenter observational study on the reliability of the HEART score. Clinical and Experimental Emergency Medicine, 2019, 6, 212-217.	0.5	9
2592	Cardiovascular risk in type 2 diabetes patients. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgB	3T /Overloo	ck ₃ 10 Tf 50 5
2594	Radial artery intima-media thickness regresses after secondary prevention interventions in patients' post-acute coronary syndrome and is associated with cardiac and kidney biomarkers. Oncotarget, 2017, 8, 53419-53431.	0.8	3
2595	High-sensitivity cardiac troponin testing in routine practice: economic and organizational advantages. Annals of Translational Medicine, 2016, 4, 257-257.	0.7	11
2596	Vitamin D Deficiency in Acute Coronary Syndrome - Clinically Relevant or Incidental Finding?. Central European Journal of Public Health, 2017, 25, 185-190.	0.4	5
2597	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	1.0	7
2598	Can Lipoprotein-associated Phospholipase A ₂ be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?. Current Cardiology Reviews, 2014, 9, 310-315.	0.6	5
2599	Acute Coronary Syndrome in the Young: Clinical Characteristics, Risk Factors and Prognosis. Open Cardiovascular Medicine Journal, 2014, 8, 61-67.	0.6	30
2600	Treatment of Acute Coronary Syndrome by Telemedically Supported Paramedics Compared With Physician-Based Treatment: A Prospective, Interventional, Multicenter Trial. Journal of Medical Internet Research, 2016, 18, e314.	2.1	28
2601	Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatient setting. Minerva Medica, 2019, 110, 139-156.	0.3	5
2602	Red blood cell transfusion policy: a critical literature review. Blood Transfusion, 2017, 15, 307-317.	0.3	57
2603	Is Troponin really a reliable marker in patients with acute ischemic stroke?. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2018, 56, 250-256.	0.3	2
2604	The Diagnosis of Chronic Coronary Heart Disease. Deutsches A& #x0308; rzteblatt International, 2017, 114, 712-719.	0.6	21

#	Article	IF	CITATIONS
2605	Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae, 2016, 8, 102-107.	1.7	9
2606	Prasugrel (Efient $\hat{A}^{@}$) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
2607	The prognostic utility of tests of platelet function for the detection of †aspirin resistance†in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-366.	1.3	22
2608	High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-234.	1.3	39
2609	Using nationwide †big data†from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the ClinicAl disease research using Linked Bespoke studies and Electronic health Records (CALIBER) programme. Programme Grants for Applied Research, 2017, 5, 1-330.	0.4	17
2611	Endothelial Nitric Oxide Synthase T-786C Mutation, Prothrombin Gene Mutation (G-20210-A) and Protein S Deficiency Could Lead to Myocardial Infarction in a Very Young Male Adult. Open Access Macedonian Journal of Medical Sciences, 2016, 4, 142-145.	0.1	6
2612	Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease. Experimental and Therapeutic Medicine, 2020, 19, 3411-3418.	0.8	3
2613	Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. Korean Journal of Internal Medicine, 2013, 28, 165.	0.7	17
2614	A pharmacodynamic study of the optimal P2Y ₁₂ inhibitor regimen for East Asian patients with acute coronary syndrome. Korean Journal of Internal Medicine, 2015, 30, 620-628.	0.7	21
2615	High-sensitive cardiac troponin T. Journal of Geriatric Cardiology, 2013, 10, 102-9.	0.2	68
2616	microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts. Cardiovascular Diagnosis and Therapy, 2015, 5, 17-36.	0.7	99
2617	Preventative Measures of Stroke in Patients With Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 399.	0.5	2
2618	Hjerteinfarkt i Norge i 2013. Tidsskrift for Den Norske Laegeforening, 2014, 134, 1841-1846.	0.2	26
2619	The impact of clinical pharmacist support on patients receiving multi-drug therapy for coronary heart disease in China. Indian Journal of Pharmaceutical Sciences, 2015, 77, 306.	1.0	17
2620	Assessment of no-reflow phenomenon by myocardial blush grade and pulsed wave tissue doppler imaging in patients with acute coronary syndrome. Journal of Cardiovascular Echography, 2014, 24, 52.	0.1	1
2621	Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?. Indian Journal of Medical Research, 2017, 146, 722.	0.4	2
2622	Plasma reference value of heart-type fatty acid-binding protein, the earliest available plasma biomarker of acute myocardial infarction. Health, 2013, 05, 1206-1209.	0.1	9
2623	Coronary Angiography in Patients with and without STEMI Following Out-of-Hospital Cardiac Arrest. Open Journal of Internal Medicine, 2014, 04, 115-122.	0.1	1

#	Article	IF	CITATIONS
2624	ROTational AThErectomy in acute coronary syndrome: early and midterm outcomes from a multicentre registry. EuroIntervention, 2016, 12, 1457-1464.	1.4	43
2625	Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial. EuroIntervention, 2014, 10, 58-64.	1.4	10
2626	Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. EuroIntervention, 2014, 10, 31-37.	1.4	221
2627	Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention, 2014, 10, 38-46.	1.4	119
2628	Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. EuroIntervention, 2014, 10, T55-T63.	1.4	28
2629	A comparison of multivessel and culprit vessel percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients with multivessel disease: a meta-analysis. EuroIntervention, 2015, 11, 525-532.	1.4	7
2630	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention, 2016, 12, 312-318.	1.4	27
2631	Predictors of high-sensitivity cardiac troponin in stable patients undergoing coronary angiography. EuroIntervention, 2016, 12, 329-336.	1.4	4
2632	Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention, 2013, 8, 1207-1216.	1.4	52
2633	Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention, 2013, 8, 1242-1251.	1.4	336
2634	ACS and STEMI treatment: gender-related issues. EuroIntervention, 2012, 8, P27-P35.	1.4	19
2635	Transcatheter aortic valve implantation and cerebrovascular accidents. EuroIntervention, 2012, 8, Q60-Q69.	1.4	17
2636	Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis. EuroIntervention, 2014, 9, 1333-1341.	1.4	6
2637	Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial. EuroIntervention, 2013, 9, 54-61.	1.4	80
2638	One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention, 2013, 9, 430-436.	1.4	21
2639	The role of the emergency services in the optimisation of primary angioplasty: experience from London and the Heart Attack Team. EuroIntervention, 2013, 9, 517-523.	1.4	5
2640	Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study. EuroIntervention, 2014, 10, 953-960.	1.4	21
2641	Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-Cypher registries. EuroIntervention, 2015, 11, 533-540.	1.4	24

#	Article	IF	CITATIONS
2642	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention, 2015, 10, 1095-1108.	1.4	29
2643	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
2644	Does access to invasive examination and treatment influence socioeconomic differences in case fatality for patients admitted for the first time with non-ST-elevation myocardial infarction or unstable angina?. EuroIntervention, 2016, 11, 1495-1502.	1.4	6
2645	High-sensitivity cardiac troponins in everyday clinical practice. World Journal of Cardiology, 2014, 6, 175.	0.5	25
2646	Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2013, 143, w13851.	0.8	8
2647	Pharmacogenomic Testing and Antithrombotic Therapy: Ready for Prime Time?. Rambam Maimonides Medical Journal, 2013, 4, e0005.	0.4	5
2648	Trends in evidence-based treatment and mortality for ST elevation myocardial infarction in Malaysia from 2006 to 2013: time for real change. Annals of Saudi Medicine, 2016, 36, 184-189.	0.5	8
2649	SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery. Anatolian Journal of Cardiology, 2015, 16, 655-61.	0.5	19
2650	Prevalence and predictors of frailty in a high-income developing country: A cross-sectional study. Qatar Medical Journal, 2020, 2019, 20.	0.2	4
2651	Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Hamostaseologie, 2013, 33, 9-15.	0.9	7
2652	Platelet function testing to time surgery in patients on dual antiplatelet therapy?. Hamostaseologie, 2014, 34, 40-45.	0.9	5
2653	Long-term outcomes of patients with multivessel coronary artery disease presenting non-ST-segment elevation acute coronary syndromes. Cardiology Journal, 2019, 26, 157-168.	0.5	12
2655	Increased carotid intima-media thickness associated with high hs-CRP levels is a predictor of unstable coronary artery disease: cardiovascular topic. Cardiovascular Journal of Africa, 2013, 24, 270-273.	0.2	11
2656	Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations. Arquivos Brasileiros De Cardiologia, 2015, 104, 337-46.	0.3	3
2657	The Relationship between GRACE Score and Epicardial Fat Thickness in non-STEMI Patients. Arquivos Brasileiros De Cardiologia, 2016, 106, 194-200.	0.3	13
2658	First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze) Tj $$ ETQq 1 1	0,784314	FrgBT/Over
2659	Epidemiological Profile and Quality Indicators in Patients with Acute Coronary Syndrome in Northern Minas Gerais - Minas Telecardio 2 Project. Arquivos Brasileiros De Cardiologia, 2016, 107, 106-15.	0.3	7
2660	Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. Arquivos Brasileiros De Cardiologia, 2018, 111, 345-353.	0.3	3

#	ARTICLE	IF	CITATIONS
2661	Integrated probability of coronary heart disease subject to the \hat{a} 308 tumor necrosis factor-alpha SNP: a Bayesian meta-analysis. PeerJ, 2015, 3, e1236.	0.9	1
2662	Low attenuation plaque volume on coronary computed tomography angiography is associated with plaque progression. Coronary Artery Disease, 2022, 33, 176-181.	0.3	2
2663	Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia. Life, 2021, 11, 1072.	1.1	6
2664	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high onâ€treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)â€2 Trial. British Journal of Haematology, 2021, , .	1.2	5
2665	Long-term outcome of patients with NSTEMI and nonobstructive coronary arteries by different angiographic subtypes. Revista Espanola De Cardiologia (English Ed), 2021, 74, 919-926.	0.4	1
2666	Antithrombotic therapy in secondary prevention. Srce I Krvni Sudovi, 2011, 30, 224-233.	0.1	0
2667	The importance of TIMI risk score in patients with acute myocardial infarction with ST segment elevation. Srce I Krvni Sudovi, 2012, 31, 151-155.	0.1	0
2671	Acute coronary syndromes: is there a place for a real pre-hospital treatment for patients "en route― to the coronary intensive care unit?. EuroIntervention, 2012, 8, P36-P43.	1.4	1
2672	Optimization of primary and secondary prevention ., 2012, , 259-277.		0
2673	Akutes Koronarsyndrom und Myokardinfarkt. , 2013, , 485-505.		0
2674	Kardiale Erkrankungen, Störungen des Herz-Kreislauf-Systems und GefÃßerkrankungen., 2013, , 245-277.		0
2675	Impact of routine invasive strategy on outcomes in patients with non-ST segment elevation myocardial infarction during 2005–2014: A report from the Polish Registry of Acute Coronary Syndromes (PL-ACS). Cardiology Journal, 2020, 27, 583-589.	0.5	3
2677	Acute Coronary Syndrome in Pre- and Post-partum Women – A Review. Interventional Cardiology Review, 2013, 8, 8.	0.7	3
2678	Smoking and the risk of acute coronary syndrome in young women treated in an emergency department. World Journal of Cardiovascular Diseases, 2013, 03, 9-12.	0.0	1
2679	Healthcare Utilization of Patients With Acute Coronary Syndrome in Germany. Cardiology Research, 2013, 4, 89-100.	0.5	0
2680	Kardiale NotfÃlle. , 2013, , 217-242.		0
2681	Common Clinical Indications for Anticoagulation. , 2013, , 7-31.		0
2682	Myocardial bridging as a suspected cause of acute coronary syndrome: a case report. Journal of the Japanese Coronary Association, 2013, 19, 133-137.	0.0	0

#	ARTICLE	IF	CITATIONS
2683	Diagnostic Algorithms in Patients with Suspected Coronary Artery Disease: Guidelines and Evidence-Based Behaviors., 2013,, 125-134.		0
2684	Kardiologische Therapie bei Hochbetagten. , 2013, , 433-446.		0
2687	Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?. EuroIntervention, 2013, 9, 299-301.	1.4	3
2688	American Versus European Guidelines: Critical Appraisal. , 2014, , 139-184.		0
2689	Triple Therapy: Risky but Sometimes Necessary. , 2014, , 185-212.		0
2691	Adjunctive Pharmacology for Coronary Intervention. , 2014, , 143-156.		0
2693	PERIOPERACINIS MIOKARDO INFARKTAS. Health Sciences, 2013, 23, 29-34.	0.0	0
2694	Análisis de un modelo de clases latentes en las escalas de clasificación diagnóstica del sÃndrome coronario agudo. Revista Universitas Medica, 2016, 55, 138-151.	0.0	0
2696	Re: FÃ, lges retningslinjene for behandling av hjerteinfarkt?. Tidsskrift for Den Norske Laegeforening, 2014, 134, 812-813.	0.2	0
2697	Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes., 2014,, 1-43.		0
2698	Leitsymptom Thoraxschmerz. , 2014, , 1-69.		0
2699	Impact of Different Obesity Assessment Methods after Acute Coronary Syndromes. Arquivos Brasileiros De Cardiologia, 2014, 103, 19-24.	0.3	5
2700	Diabetologie für die Pflege. , 2014, , 7-103.		0
2701	FÃ, lges retningslinjene for behandling av hjerteinfarkt?. Tidsskrift for Den Norske Laegeforening, 2014, 134, 412-416.	0.2	2
2704	Akute Herzinsuffizienz., 2014, , 1-11.		0
2705	L'infarctus du myocarde en France métropolitaine de 1995 à 2010 : évolution de la typologie des patients, de la prise en charge et du pronostic à court terme. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 85-100.	0.0	0
2707	Definitions of Common Terminologies Used in Nuclear Medicine. , 2014, , 117-154.		0
2708	Percutaneous Coronary Interventional Treatment for Coronary Artery Disease and the Role of Antiplaplatelets Therapy: A Review of the Literature. International Journal of Clinical Medicine, 2014, 05, 275-283.	0.1	O

#	Article	IF	CITATIONS
2709	Acute cardiac syndromes, investigations and interventions. , 2014, , 167-190.e4.		0
2710	Investigation of the vital status and nonfatal cardiovascular events in the prospective cohort study of the epidemiology of cardiovascular diseases and their risk factors in different regions of the Russian Federation (ESSE-RF). Profilakticheskaya Meditsina, 2014, 17, 26.	0.2	2
2711	FÃ, lges nye retningslinjer for hjerteinfarkt?. Tidsskrift for Den Norske Laegeforening, 2014, 134, 379-379.	0.2	0
2712	Chest pain with raised troponin, ECG changes but normal coronary arteries. BMJ Case Reports, 2014, 2014, bcr2013201975-bcr2013201975.	0.2	O
2713	An Independent and External Validation of the ACC NCDR Bleeding Risk Score among a National Multi-Site Community Hospital Registry of Cardiac Interventions. International Journal of Statistics in Medical Research, 2014, 3, 153-160.	0.5	1
2715	Patientensicherheit., 2015,, 81-96.		O
2717	Are There Age-Related Differences in the In-Hospital Treatment of Victims from Out-of-Hospital Cardiac Arrest?. International Journal of Clinical Medicine, 2015, 06, 431-438.	0.1	0
2720	Bare-Metal Stent., 2015, , 151-161.		O
2721	Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes., 2015,, 2071-2107.		0
2722	CT Angiography Versus Routine Stress Testing for Patients with Chest Pain Seen in the Emergency Room to Exclude Significant Coronary Artery Disease. , 2015, , 83-98.		0
2723	Department of invasive cardiology Zajecar: First results and experiences. Srce I Krvni Sudovi, 2015, 34, 68-71.	0.1	0
2724	Results of monitoring primary and secondary prevention of coronary heart disease in the North Caucasus. Profilakticheskaya Meditsina, 2015, 18, 19.	0.2	1
2725	Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)., 2015,, 17-26.		2
2726	Prognosis of Patients with Acute Coronary Syndromes and Bleedingâ€"The Importance of Routine Use of a Bleeding Risk Score. World Journal of Cardiovascular Diseases, 2015, 05, 327-334.	0.0	0
2727	Biomarkers of Myocardial Cell Damage: Heart-Type Fatty Acid Binding Protein (H-FABP) for the Early Evaluation of Suspected Acute Coronary Syndrome., 2015, , 1-31.		0
2728	No Reflow-phenomenon: from Current State of the Art to Future Perspectives. AIMS Medical Science, 2015, 2, 374-395.	0.2	0
2729	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?., 2015,, 255-269.		0
2730	A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory. Medical Science Monitor, 2015, 21, 338-344.	0.5	0

#	Article	IF	CITATIONS
2731	Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications., 2015, , 187-235.		0
2732	Patientensicherheit in der Intensivmedizin. , 2015, , 1-28.		0
2733	Results of clinical studies PLATO and place of ticagrelor in the treatment of acute coronary syndrome. Cardiosomatics, 2015, 6, 53-59.	0.2	1
2736	Eosinophil count is related with coronary thrombus in non ST-elevated acute coronary syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 266-271.	0.2	2
2737	No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome. PLoS ONE, 2015, 10, e0132000.	1.1	2
2738	What is the real predictive value of red cell distribution width for the mortality in non-ST elevation acute coronary syndrome?. Anatolian Journal of Cardiology, 2015, 15, 770-771.	0.5	0
2739	The correlation between traditional risk factors and the severity of acute coronary syndrome and long-term prognosis. Cardiosomatics, 2015, 6, 6-10.	0.2	0
2741	Difficult Heart. , 2016, , 181-186.		0
2742	Acute Shortness of Breath., 2016,, 221-234.		0
2743	Endoscopic resection of colorectal polyps in patients on antiplatelet therapy: an evidence-based guidance for clinicians. Revista Espanola De Enfermedades Digestivas, 2016, 108, 49-59.	0.1	3
2744	Pharmaka mit Wirkung auf die HÃmostase. Springer-Lehrbuch, 2016, , 445-472.	0.1	0
2745	Kardiologie. , 2016, , 277-355.		0
2746	Biomarkers of Myocardial Cell Damage: Heart-Type Fatty Acid Binding Protein (H-FABP) for the Early Evaluation of Suspected Acute Coronary Syndrome., 2016,, 235-265.		2
2747	Coronary CT Angiography: Native Vessels. , 2016, , 157-178.		1
2748	From lactate to soluble urokinase plasminogen activator receptor: The journey for ideal cardiac biomarker: Are we there in 2016?. Annals of Cardiac Anaesthesia, 2016, 19, 211.	0.3	0
2749	The role of statin therapy in general medical practice. Lìki Ukraìni, 2016, .	0.0	0
2750	Peri- and Post-procedural Antithrombotic Therapy in Women. , 2017, , 73-100.		1
2751	To Be or Not to Be … Acute Coronary Syndrome. Acta Marisiensis - Seria Medica, 2016, 62, 363-367.	0.3	0

#	Article	IF	CITATIONS
2752	Review of Antiplatelet Therapy for the Management of Acute Coronary Syndromes. Journal of Medical Sciences and Health, 2016, 02, 34-35.	0.1	O
2753	Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3318-3323.	1.0	1
2754	Urban Legend or Real Fact: Coronary artery size varies with demographics. İstanbul Kuzey Klinikleri, 2017, 5, 20-24.	0.1	0
2755	Hypertension as a risk for CAD and its management. Journal of the Japanese Coronary Association, 2017, 23, 103-107.	0.0	0
2757	Kardiale Umfelddiagnostik bei GefÃßoperationen und GefÃßinterventionen. , 2017, , 1-21.		0
2758	Pharmacology of Nitrovasodilators. , 2017, , 195-216.		0
2759	Management of Acute Coronary Syndrome. , 2017, , 111-120.		0
2760	Predictive Value of Estimated Glomerular Filtration Rate for the Prognosis of Elderly Patients With Acute Myocardial Infarction. Annals of Geriatric Medicine and Research, 2017, 21, 10-16.	0.7	0
2761	Inhibidores del receptor plaquetario P2Y12. Parte 2 de 2: etiolog \tilde{A} a, diagn \tilde{A}^3 stico y manejo de la resistencia. Medicina Y Laboratorio, 2017, 23, 313-348.	0.0	1
2763	Enfermedad coronaria basada en la evidencia. Carta Comunitaria, 2017, 25, 50-76.	0.0	0
2764	Optimal Medical Therapy for Stable Angina Pectoris. Cardiologia Croatica, 2017, 12, 226-230.	0.0	0
2765	Case Report: INTRAPROCEDURAL STENT THROMBOSIS IN PERCUTANEOUS CORONARY ANGIOPLASTY. Folia Medica Indonesiana, 2017, 52, 66.	0.1	0
2768	METABOLISM AND CHEMILUMINESCENT ACTIVITY OF NEUTROPHILIC GRANULOCYTES IN PATIENTS WITH DIFFERENT SENSITIVITY TO ACETYLSALICYLIC ACID IN ACUTE CORONARY SYNDROME. Journal of Clinical Practice, 2017, 8, 10-17.	0.2	0
2770	The Effects of Geography on Outcomes of Routine Early Versus Selective Late Revascularization Strategy in the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Transatlantic Randomized Controlled Trials. Journal of Clinical Medicine Research, 2018, 10, 868-876.	0.6	0
2771	Out-of-Hospital Cardiac Arrest. , 2018, , 327-340.		0
2772	Postoperative Bleeding Following Preoperative Clopidogrel Administration in Patients with Haemoglobin Level Above 110 g/L Undergoing Urgent CABG. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 59-63.	0.2	1
2773	Comparison of predictive value of five risk scores in patients with myocardial infarction treated with primary percutaneous coronary intervention. Medicinski Podmladak, 2018, 69, 28-35.	0.2	0
2774	Guideline for the management of patients with non-ST-elevation acute coronary syndromes (part 2). Kardiologicheskii Vestnik, 2018, 13, 59.	0.1	3

#	ARTICLE	IF	CITATIONS
2775	Rethoracotomy for early complications: A marker for increased morbidity and mortality. Turkish Journal of Thoracic and Cardiovascular Surgery, 2018, 26, 441-449.	0.2	1
2776	Women and men diagnosed with acute coronary syndrome – sex-related differences. Journal of Medical Science, 2018, 87, 92-98.	0.2	O
2777	The Diagnostic Value of Scube1 in Patients Presenting to the Emergency Department Due to Angina Pectoris. KÄ \pm rÄ \pm kkale Ã ∞ eniversitesi TÄ \pm p FakÃ $\frac{1}{4}$ ltesi Dergisi, 0, , .	0.0	3
2778	Investigation of cardiac markers cut off values in the diagnosis of acute coronary syndrome. Ortadoğu Tıp Dergisi, 2018, 10, 247-251.	0.1	O
2779	Results of qualitative test on fatty acid binding cardiac protein in suspected acute coronary syndrome and various kidney function level. Russian Journal of Cardiology, 2018, , 28-32.	0.4	0
2780	THE DIFFERENCES OF CORRELATION OF THE TIMI, GRACE, AND KILLIP RISK SCORES AS PREDICTOR PROGNOSIS PATIENTS WITH NON ST-ELEVATION MYOCARD INFARCTION ACUTE CORONARY SYNDROME IN ICCU RSUD DR.ISKAK TULUNGAGUNG. Jurnal Ilmu Keperawatan (Journal of Nursing Science), 2018, 6, 79-87.	0.0	O
2781	The adherence of doctors to clinical guidelines for the management of patients with acute coronary syndrome Klinicheskaia Meditsina, 2018, 96, 633-640.	0.2	0
2782	Incidence, Risk Factors and Prognosis of Contrast-Induced Acute Kidney Injury in Acute Heart Failure Patients Undergoing Coronary Angiography. International Journal of Heart Failure, 2019, 1, 72.	0.9	2
2783	Blood Transfusion Indications. , 2019, , 731-734.		0
2784	Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients. Current Vascular Pharmacology, 2019, 17, 191-203.	0.8	2
2785	Perioperative management of patients with chronic heart failure. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2019, , 5.	0.2	6
2786	Diagnostic accuracy of TIMI versus GRACE score for prediction of death in patients presenting with Acute Non-ST Elevation Myocardial Infarction (NSTEMI). Journal of Cardiology and Cardiovascular Medicine, 2019, 4, 001-005.	0.1	1
2787	A Pathognomonic Case of Isolated Acute Right Ventricular Infarction. International Cardiovascular Forum Journal, 0, 14, .	1.1	0
2788	Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice. Russian Journal of Cardiology, 2019, 24, 90-97.	0.4	1
2789	Akut Koroner Sendrom ile Başvuran Hastalarda Asetil Salisilik Asit Direncinin Araştırılması. SdÜ SaĞlik Bİlİmlerİ Dergİsİ, 0, , .	0.1	0
2790	Prognostic value of the cardiac fraction of fatty acid binding protein in patients with non-ST elevation acute coronary syndrome with concomitant type 2 diabetes. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 30-34.	0.4	2
2791	Evaluating possible acute coronary syndrome in primary care: the value of signs, symptoms, and plasma heart-type fatty acid-binding protein (H-FABP). A diagnostic study. BJGP Open, 2019, 3, bjgpopen19X101652.	0.9	3
2792	Akut anterior ST segment miyokard infarktüsü sonrası GRACE risk skorunun sol ventrikül ejeksiyon fraksiyonundaki prediktif değeri. Cukurova Medical Journal, 2019, 44, 819-828.	0.1	О

#	Article	IF	CITATIONS
2793	Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. Molecular Medicine Reports, 2019, 20, 4713-4722.	1.1	2
2795	of Care Testing, Cardiac Marker (Mainly Cardiac Troponin). The Journal of the Japanese Society of Internal Medicine, 2019, 108, 2467-2474.	0.0	O
2796	(In what extent we reached the standards of antiplatelet therapy in secondary prevention of) Tj ETQq0 0 0 rgBT /C	verlock 10 0.1	O Tf 50 662
2797	Comparison of Antiplatelet Effects and Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Chinese Patients With Acute Coronary Syndrome. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	O
2798	Calcium Channel Blockers. , 0, , .		2
2799	Isparta ve çevresinde klopidogrel direncinin araÅŸtırılması. SÃ⅓leyman Demirel Üniversitesi Tıp FakÃ⅓ Dergisi, 0, , .	ıltesi 0.0	0
2800	Effect of high-intensity statin preloading on TIMI flow in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Egyptian Heart Journal, 2020, 72, 40.	0.4	2
2801	Diagnosis of Myocardial Infarction in a Patient With Left Bundle Branch Block and Negative Sgarbossa Criteria. Journal of Osteopathic Medicine, 2020, 120, 655-659.	0.4	1
2802	Koroner anjiyografi uygulanan hastalarda serum endokan dýzeyleri ile kontrast kaynaklı nefropati varlığı arasındaki ilişki. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
2803	Perioperative management of patients with valvular heart disease. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2020, , 6.	0.2	1
2804	Coronary Microvascular Dysfunction (CMD). SpringerBriefs in Materials, 2020, , 11-14.	0.1	0
2805	Evaluation of the OÂh/1Âh high-sensitivity cardiac troponin T algorithm in diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) in Han population. Clinical Chemistry and Laboratory Medicine, 2021, 59, 757-764.	1.4	2
2806	Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Metabolites, 2021, 11, 25.	1.3	8
2807	The predictive value of HEART score for acute coronary syndrome and significant coronary artery stenosis. Clinical and Experimental Emergency Medicine, 2020, 7, 267-274.	0.5	1
2810	Pharmaka mit Wirkung auf die HÃmostase. , 2020, , 469-499.		0
2811	Antiplatelet Agent Choice and Platelet Function Testing in CKD. , 2020, , 103-118.		0
2812	Impact of Geriatric Nutritional Index in Contrast-Induced Nephropathy Developed in Patients with Non-ST Segment Elevation Myocardial Infarction who Underwent Percutaneous Coronary Intervention. Medeniyet Medical Journal, 2020, 35, 47-54.	0.4	0
2813	Kardiale Umfelddiagnostik bei GefÃßoperationen und GefÃßinterventionen. Springer Reference Medizin, 2020, , 209-229.	0.0	O

#	Article	IF	CITATIONS
2814	Genç akut miyokard infarktüslerinde metamfetamin ve kokain için idrar toksikoloji taramasının uygulanabilirliği. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
2815	Correlation between body mass index and in-hospital mortality in patients with ST-segment elevation myocardial infarction in Erbil city- Iraq. Diyala Journal of Medicine, 2021, 21, 35-43.	0.2	0
2816	P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention $\hat{a} \in \text{``Understanding the debate on Prasugrel or Ticagrelor., 2021,, 108029.}$		2
2817	Serum Level of Vitamin D Is Associated with Severity of Coronary Atherosclerosis in Postmenopausal Women. Biology, 2021, 10, 1139.	1.3	5
2819	<p>Diagnostic Performance of Point-of-Care Troponin I and Laboratory Troponin T in Patients Presenting to the ED with Chest Pain: A Comparative Study</p> . Open Access Emergency Medicine, 2020, Volume 12, 247-254.	0.6	2
2820	Cardiac Assessment in Noncardiac Surgery. , 2021, , 251-267.		0
2821	Effect of oxygen supply on mortality in acute ST-elevation myocardial infarction: systematic review and meta-analysis. European Journal of Emergency Medicine, 2021, 28, 11-18.	0.5	0
2822	The Evolution and Future Direction of The Cardiac Biomarker. EMJ Cardiology, 0, , .	0.0	2
2823	Frequência e Motivos para a não Administração e Suspensão de Medicamentos durante um Evento de SÃndrome Coronariana Aguda. Estudo ERICO. Arquivos Brasileiros De Cardiologia, 2020, 115, 830-839.	0.3	1
2825	Clinical presentation of patients with prior coronary artery bypass grafting and suspected acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 746-755.	0.4	2
2826	Fractional flow reserve measurements to identify justified targets for PCI in patients with stable angina: FAME 2 and beyond. Cardiovascular Diagnosis and Therapy, 2012, 2, 261-3.	0.7	0
2827	Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes. Cardiovascular Diagnosis and Therapy, 2014, 4, 13-20.	0.7	3
2828	New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments?. , 2014, 8, 124-6.		0
2829	Impact of invasive treatment strategy on health-related quality of life six months after non-ST-elevation acute coronary syndrome. Journal of Geriatric Cardiology, 2014, 11, 206-11.	0.2	7
2830	Relation of the aortic stiffness with the GRACE risk score in patients with the non ST-segment elevation myocardial infarction. International Journal of Clinical and Experimental Medicine, 2014, 7, 3030-6.	1.3	3
2831	Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. Translational Medicine @ UniSa, 2015, 11, 14-23.	0.8	0
2832	Mean platelet volume variability in young patients with non-ST elevation acute myocardial infarction. Journal of Medicine and Life, 2014, 7 Spec No. 3, 107-13.	0.4	3
2833	An analysis of patients receiving emergency CAG without PCI and the value of GRACE score in predicting PCI possibilities in NSTE-ACS patients. Journal of Geriatric Cardiology, 2015, 12, 246-50.	0.2	4

#	Article	IF	CITATIONS
2835	Transcatheter aortic valve implantation in very elderly patients: immediate results and medium term follow-up. Journal of Geriatric Cardiology, 2015, 12, 340-5.	0.2	7
2836	Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). International Journal of Clinical and Experimental Medicine, 2015, 8, 11360-9.	1.3	6
2837	Pre-analytic variability in cardiovascular biomarker testing. Journal of Thoracic Disease, 2015, 7, E395-401.	0.6	6
2838	Drug-Eluting Stents versus Bare-Metal Stents in Taiwanese Patients with Acute Coronary Syndrome: An Outcome Report of a Multicenter Registry. Acta Cardiologica Sinica, 2014, 30, 553-64.	0.1	16
2839	Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction. Heart Asia, 2015, 7, 46-51.	1.1	4
2840	Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives. Translational Medicine @ UniSa, 2016, 14, 54-63.	0.8	1
2841	Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae, 2016, 8, 102-7.	1.7	2
2842	Platelet Function Testing-Guided Antiplatelet Therapy. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 90-6.	0.7	9
2843	Successful Treatment of a Left Main Thrombus by Intracoronary Eptifibatide Infusion in a 36-Year-Old Patient. The Journal of Tehran Heart Center, 2016, 11, 143-148.	0.3	1
2844	Mortality Risk Associated with AF in Myocardial Infarction Patients. Journal of Atrial Fibrillation, 2012, 5, 554.	0.5	1
2845	Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel. American Journal of Cardiovascular Disease, 2017, 7, 1-8.	0.5	5
2846	Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. Acta Cardiologica Sinica, 2017, 33, 377-383.	0.1	11
2847	Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology, 2017, 29, 340-351.	0.4	2
2848	Contemporary Prescription Patterns of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndrome. P and T, 2018, 43, 667-674.	1.0	1
2849	Value of Manchester Acute Coronary Syndromes Decision Rule in the Detection of Acute Coronary Syndrome; a Systematic Review and Meta-Analysis. Emergency, 2018, 6, e61.	0.6	0
2850	Association of Epicardial Adipose Tissue Thickness with Extent and Complexity of Coronary Artery Disease in Patients with Acute Coronary Syndrome. Acta Cardiologica Sinica, 2019, 35, 459-467.	0.1	5
2851	Invasive versus conservative strategy in consecutive patients aged 80 years or older with non-ST-segment elevation myocardial infarction: a retrospective study in China. Journal of Geriatric Cardiology, 2019, 16, 741-748.	0.2	3
2852	Single Long Stents versus Overlapping Multiple Stents in the Management of Very Long Coronary Lesions: Comparisons of Procedures and Clinical Outcomes. The Journal of Tehran Heart Center, 2019, 14, 94-102.	0.3	3

#	ARTICLE	IF	CITATIONS
2853	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, .	0.9	1
2854	Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Single-Blind, Randomized Controlled Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 738496.	1.1	O
2855	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, e001453.	0.9	2
2856	Real-Life Outcomes of Coronary Bifurcation Stenting in Acute Myocardial Infarction (Zabrze–Opole) Tj ETQq1 1	0.784314 0.8	rgBT /Over
2857	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. Annals of Internal Medicine, 2022, 175, 101-113.	2.0	37
2858	Fractional flow reserve in patients with type 1 or type 2 non-ST elevation acute myocardial infarction. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, .	0.6	2
2859	The relationship between IL-6 levels and the angiographic severity of coronary artery disease following percutaneous coronary intervention in acute coronary syndrome patients. BMC Cardiovascular Disorders, 2021, 21, 578.	0.7	8
2860	Telomere Length and Oxidative Stress in Patients with ST-Segment Elevation and Non-ST-Segment Elevation Myocardial Infarction. Advances in Experimental Medicine and Biology, 2021, , 183-195.	0.8	1
2862	Acute Coronary Syndromes in the Elderly: Multicentric Study about 76 Cases in 3 Cardiology Departments in Dakar. World Journal of Cardiovascular Diseases, 2021, 11, 610-618.	0.0	0
2863	Akuter Myokardinfarkt ohne ST-Hebung (NSTEMI): Wie Algorithmen die Diagnose beschleunigen. , 0, , .		1
2864	Association of coronary angiographic lesions and mortality in patients over 80 years with NSTEMI. Open Heart, 2022, 9, e001811.	0.9	1
2865	Diagnostic Accuracy of High-Sensitive Troponin for the Identification of Myocardial Infarction in Patients Presenting with Acute Heart Failure. Journal of Emergency Medicine, 2022, 62, 359-367.	0.3	1
2866	Increased deformation of the left ventricle during exercise test measured by global longitudinal strain can rule out significant coronary artery disease in patients with suspected unstable angina pectoris. Echocardiography, 2022, 39, 233-239.	0.3	3
2867	A Novel Multiple Risk Score Model for Prediction of Long-Term Ischemic Risk in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Insights From the I-LOVE-IT 2 Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 756379.	1.1	2
2868	Accuracy of the European Society of Cardiology 0/1â€, 0/2â€, and 0/3â€hour algorithms for diagnosing acute myocardial infarction. Academic Emergency Medicine, 2022, 29, 512-514.	0.8	1
2869	Fasting Blood Glucose but not TMAO is Associated with In-Stent Restenosis in Patients with Acute Coronary Syndrome. Cardiovascular Innovations and Applications, 2022, 6, .	0.1	O
2870	Acute Coronary Syndromes in Subâ€Saharan Africa: A 10â€Year Systematic Review. Journal of the American Heart Association, 2022, 11, e021107.	1.6	13
2871	Improving the ACS Triageâ€"Using High Sensitivity TroponinI and Copeptin for Early †Rule-Out' of AMI. Indian Journal of Clinical Biochemistry, 2022, 37, 449-457.	0.9	2

#	ARTICLE	IF	CITATIONS
2872	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers, 2022, 27, 264-269.	0.9	3
2873	Machine learning-based in-hospital mortality prediction models for patients with acute coronary syndrome. American Journal of Emergency Medicine, 2022, 53, 127-134.	0.7	11
2874	The recent progress in the early diagnosis of acute myocardial infarction based on myoglobin biomarker: Nano-aptasensors approaches. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114624.	1.4	14
2877	Cardiovascular Comorbidity in Patients Scheduled for TKA. , 2022, , 139-150.		1
2878	NSTEMI with total left circumflex occlusion: how the N-wave might help (case report). Oxford Medical Case Reports, 2022, 2022, omac010.	0.2	1
2879	An mHealth Intervention to Improve Medication Adherence and Health Outcomes Among Patients With Coronary Heart Disease: Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e27202.	2.1	15
2880	Target Vessel Versus Complete Revascularization in Non-ST Elevation Myocardial Infarction Without Cardiogenic Shock. Cureus, 2022, 14, e23139.	0.2	0
2881	Association of serum cardiac troponin I and severity of coronary stenosis in patients with varied renal functions: a retrospective cohort study. BMJ Open, 2022, 12, e054722.	0.8	1
2883	Are P-glycoprotein (ABCB1/MDR1) and endothelial nitric oxide synthase (eNOS) polymorphisms related to severity of the coronary artery disease?. Journal of Surgery and Medicine, 2022, 6, 1-1.	0.0	0
2884	Platelet transmission electron microscopy for the assessment of poor biological response to antiplatelet agent: pilot descriptive and prospective study - ELECTROSTROKE. BMJ Open, 2022, 12, e050060.	0.8	0
2886	The influence of intra-aortic balloon counter pulsation on central venous blood oxygen saturation. Perfusion (United Kingdom), 2023, 38, 353-362.	0.5	0
2887	Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel—An observational cohort study in Sweden. Pharmacoepidemiology and Drug Safety, 2022, 31, 235-246.	0.9	1
2889	Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. Journal of International Medical Research, 2022, 50, 030006052210817.	0.4	0
2891	A Comparison Between Two-Dimensional and Three-Dimensional Regional and Global Longitudinal Strain Echocardiography to Evaluate Complex Coronary Lesions in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Cureus, 2022, 14, e24025.	0.2	1
2892	THE DIFFERENCES OF CORRELATION OF THE TIMI, GRACE, AND KILLIP RISK SCORES AS PREDICTOR PROGNOSIS PATIENTS WITH NON ST-ELEVATION MYOCARD INFARCTION ACUTE CORONARY SYNDROME IN ICCU RSUD DR.ISKAK TULUNGAGUNG. Jurnal Ilmu Keperawatan (Journal of Nursing Science), 2018, 6, 79-87.	0.0	1
2902	Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane	1.1	7
2908	Long-term predictors of death among Tunisian patients presenting for non ST-elevation acute coronary syndrome Tunisie Medicale, 2021, 99, 744-750.	0.2	0
2909	Early vs. Delayed Initiation of Treatment With P2Y12 Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2022, 9, 862452.	1.1	3

#	Article	IF	CITATIONS
2912	Health counseling support medication adherence to regular pulmonary tuberculosis patients. Clinical Epidemiology and Global Health, 2022, 15, 101055.	0.9	1
2913	Rapid diagnostic strategies using high sensitivity troponin assays: what is the evidence and how should they be implemented?. Annals of Clinical Biochemistry, 2023, 60, 37-45.	0.8	1
2914	Which therapy for which condition?., 2013,, 463-541.		1
2915	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants., 2013,, 332-397.		1
2916	Incidence, Current Guidelines and Management of Gastrointestinal Bleeding after Transcatheter Aortic Valve Replacement: A Systematic Review. Current Cardiology Reviews, 2022, 18, .	0.6	0
2917	The predictive value of five glomerular filtration rate formulas for longâ€term mortality in patients undergoing coronary artery bypass grafting. Journal of Cardiac Surgery, 0, , .	0.3	2
2918	P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis. Medicine (United States), 2022, 101, e29824.	0.4	0
2920	The Prognostic Value of Cardiac Troponin I in Patients with or without Three-Vessel Disease Undergoing Complete Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 3896.	1.0	O
2922	Neutrophil-to-lymphocyte ratio predicts coronary artery lesion severity and long-term cardiovascular mortality in patients with unstable angina pectoris. Acta Cardiologica, 2022, 77, 708-715.	0.3	5
2923	Time trends in incidence, treatment, and outcome in acute myocardial infarction in Norway 2013–19. European Heart Journal Open, 2022, 2, .	0.9	1
2924	Things We Do for No Reasonâ,,¢: Routine pretreatment with a P2Y12 receptor inhibitor before invasive coronary angiography for patients with a nonâ€ST elevation acute coronary syndrome. Journal of Hospital Medicine, 2023, 18, 177-180.	0.7	0
2925	High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain. Circulation, 2022, 146, 569-581.	1.6	37
2926	Addition of TyG index to the GRACE score improves prediction of adverse cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: A retrospective study. Frontiers in Cardiovascular Medicine, $0, 9, .$	1.1	3
2927	Incidence and Predictors of Adverse Events Among Initially Stable STâ€Elevation Myocardial Infarction Patients Following Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, .	1.6	4
2928	The role of 12-lead electrocardiogram in the risk stratification of non-ST elevation acute coronary syndrome and the correlation with coronary angiography - The CINCHONa study - A prospective cohort study in Northern India. Annals of African Medicine, 2022, 21, 173.	0.2	0
2929	A review on aptamers selection and application in heart diseases diagnosis. Current Topics in Medicinal Chemistry, 2022, 22, .	1.0	1
2930	Association of Nonalcoholic Fatty Liver Disease with Ventricular Tachycardia and Sinus Arrest in Patients with Non-ST-Segment Elevation Myocardial Infarction. International Heart Journal, 2022, 63, 814-820.	0.5	5
2931	Determinants of Arterial Pressure of Oxygen and Carbon Dioxide in Patients Supported by Veno-Arterial ECMO. Journal of Clinical Medicine, 2022, 11, 5228.	1.0	3

#	Article	IF	Citations
2932	Salivary biomarkers for diagnosis of acute myocardial infarction: A systematic review. International Journal of Cardiology, 2023, 371, 54-64.	0.8	2
2933	MiR-223 and MiR-186 Are Associated with Long-Term Mortality after Myocardial Infarction. Biomolecules, 2022, 12, 1243.	1.8	5
2934	Timing of angiography and outcomes in patients with non-ST-segment elevation myocardial infarction: Insights from the evaluation and management of patients with acute chest pain in China registry. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2935	JCS 2021 Guideline on the Clinical Application of Echocardiography. Circulation Journal, 2022, 86, 2045-2119.	0.7	16
2937	Optimal medical therapy after percutaneous coronary intervention in very elderly patients with coronary artery disease. International Journal of Cardiology Cardiovascular Risk and Prevention, 2023, 16, 200162.	0.4	0
2938	Serial high-sensitivity cardiac troponin testing for the diagnosis of myocardial infarction: a scoping review. BMJ Open, 2022, 12, e066429.	0.8	0
2939	The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease. BMC Cardiovascular Disorders, 2022, 22, .	0.7	1
2940	Prediction of significant coronary artery disease in acute chest pain without infarction in emergency department: MAPAC Cardio-PreTest model. European Journal of Emergency Medicine, 2023, 30, 40-46.	0.5	0
2941	Implementation of the ESC 0 h/1 h high-sensitivity troponin algorithm for decision-making in the emergency department. Revista Espanola De Cardiologia (English Ed), 2023, , .	0.4	0
2942	Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study. Archives of Medical Science, 2023, 19, 242-249.	0.4	0
2943	Relationship between the triglyceride-glucose index and the SYNTAX score 2 in patients with non-ST elevation myocardial infarction. Cardiovascular Endocrinology and Metabolism, 2023, 12, .	0.5	1
2944	Maternal Inheritance of Familial Hypercholesterolemia Gene Mutation Predisposes to Coronary Atherosclerosis as Assessed by Calcium Score in Adulthood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, .	1.1	4
2945	Comparison of the Success Rate of Treatment with Primary Percutaneous Coronary Intervention PCI versus Thrombolytic Treatment in Patients with ST-Elevation Myocardial Infarction in Local Hospitals in Iran. Majallah-i 'ilmi Pizhuhishi-i Danishgah-i 'Ulum-i Pizishki Va Khadamat-i Bihdashti-i Darmani-i Zanjan, 2023, 31, 32-39.	0.1	0
2946	Clinical Predictors and Prognosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) without ST-Segment Elevation in Older Adults. Journal of Clinical Medicine, 2023, 12, 1181.	1.0	3
2947	A double-blinded randomized controlled trial comparing eptifibatide bolus only versus bolus plus infusion in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2023, , .	0.3	1
2948	Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: A meta-analysis and systematic review. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	5
2949	Psychopathology, Personality and Depression after Acute Coronary Syndrome: A Network Analysis in an Italian Population. Diagnostics, 2023, 13, 915.	1.3	0
2951	Characteristics and treatment analysis of young acute coronary syndrome patients in a tertiary care hospital: A crossâ€sectional retrospective study. Health Science Reports, 2023, 6, .	0.6	0

#	Article	IF	CITATIONS
2952	The Relationship of Plasma Aterogenity Index and Mean Platelet Volume with the Risk of Development of 1-Year Total Major Adverse Cardiac Event in Patients with Non-ST Elevation Myocardial Infarction. International Journal of Angiology, $0, , .$	0.2	0
2953	Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen. Molecules, 2023, 28, 2311.	1.7	1
2954	Machine learning for prediction of bleeding in acute myocardial infarction patients after percutaneous coronary intervention. Therapeutic Advances in Chronic Disease, 2023, 14, 204062232311585.	1.1	1
2955	Plaque volume, composition, and fraction versus ischemia and outcomes in patients with coronary artery disease. Journal of Cardiovascular Computed Tomography, 2023, 17, 177-184.	0.7	2
2956	Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study. European Journal of Preventive Cardiology, 2023, 30, 969-977.	0.8	3
2967	Akutes Koronarsyndrom und Myokardinfarkt. , 2023, , 599-622.		0
2982	Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
2986	Non-Coding RNA-Mediated Gene Regulation in Cardiovascular Disorders: Current Insights and Future Directions. Journal of Cardiovascular Translational Research, 0, , .	1.1	1
2988	Current Evidence for the Use of High-Sensitivity Troponin Assays in the Emergency Department. Current Emergency and Hospital Medicine Reports, 2024, 12, 13-21.	0.6	0